Well-established whitening alternative with longer-release profile (~10-16% carbamide peroxide ≈ ~3-5% H2O2); preferred for overnight tray use due to slower active release; identical efficacy outcomes vs equivalent H2O2 doses; equally safe at OTC concentrations. For this-archetype CONFIRMED-IN-USE if pursuing cosmetic whitening — choose carbamide peroxide for tray-based protocols, hydrogen peroxide for strip-based.

Already in this user's V stack daily stack at 500 mg Cognizin. Best-evidenced and cleanest-safety-profile chronic choline donor for a 20yo brain-priority MMA athlete with subconcussive impact exposure — A-tier replicated trials in healthy adults (attention, working memory, processing speed) plus a large stroke-recovery evidence base, no Korean-style cardiovascular signal, and the cytidine-uridine bonus citicoline uniquely delivers makes it the ideal chronic baseline cholinergic substrate. Verdict would only change if 23andMe shows something unexpected or if a major safety signal emerges.

Strong replicated A-tier evidence in osteoarthritis pain, depression adjunct, mild cognitive decline (PET-imaging-confirmed amyloid/tau reduction in Small 2018), and athletic recovery (DOMS, CK reduction). this user's V stack form (Doctor's Best Curcumin Phytosome / Meriva) has 27× bioavailability vs. unformulated curcumin — 500 mg daily ≈ ~13.5 g unformulated equivalent, in the dose range used in clinical trials. Mechanism perfectly matched to subconcussive impact + daily MMA inflammatory load. Dominant uncertainty is formulation choice (Meriva vs Theracurmin vs liposomal vs piperine), not whether to take it. Verdict would only weaken if a credible long-term safety signal emerged (none has) or if iron deficiency / gallstones developed (no current indication).

"Well-established and effective for teeth whitening at cosmetic concentrations (3-6% in OTC strips/trays, 15-40% in dental office). Safe topical antiseptic. **Internal/ingested use is dangerous and unsupported** — gastric injury, oxidative stress without therapeutic benefit, embolism risk if injected. For this-archetype: TOPICAL CONFIRMED-IN-USE for cosmetic teeth whitening at 3-6%; DO NOT INGEST."

"Multi-decade Japanese clinical experience + emerging RCTs in EU/US show non-inferiority to fluoride for early-cavity prevention + remineralization in healthy users; particularly relevant for users wanting fluoride-free alternative; safe (it IS what teeth are made of); slightly less established than fluoride for high-cavity-risk patients but sufficient for most preventive use. For this-archetype: OPTIONAL — modern toothpaste choice; not load-bearing for any priority."

Already locked in this user's V stack stack (Source Naturals Magtein, 3 caps/day = ~144 mg elemental Mg as L-threonate). The single magnesium form with credible evidence for raising CSF Mg in humans, with a B-tier human cognitive RCT (Liu 2016) showing memory and executive function improvement in older adults. For a 20yo brain-priority MMA athlete with chronic subconcussive impact exposure, the brain-penetrant Mg angle complements the systemic Mg from Mg glycinate (which this user also takes 4 tabs = 400 mg). Maintain current dosing.

Already in this user's V stack stack at 1200 mg/day (Swanson NAC, 2 caps). Massive A-tier evidence base — FDA-approved indication for paracetamol overdose, A-tier psychiatric (OCD, BFRB/trichotillomania), B-tier addiction + glutamate-toxicity rationale. Cheap, daily-safe, BBB-penetrant. For an MMA athlete with daily subconcussive impact, the glutamate-modulation + glutathione-precursor combination is mechanistically near-perfect — no other single supplement covers both lanes as well. Verdict would only weaken if a credible chronic-toxicity signal emerged at 1200-2400 mg/day (none currently exists after 30+ years of clinical use).

Already locked in this user's V stack stack (Nature's Way Rhodiola 250 mg, 1 cap/day). Best-evidenced adaptogen for fatigue resistance and mental performance under stress. Effect is modest but reliably positive for the endpoints this user cares about. Standard SHR-5 / Rosavin-Salidroside-standardized extracts are well-trialed. Maintain current dosing; consider bumping to 250 mg BID if morning effect not strong enough.

"Best evidence-backed brain-protection compound that maps cleanly onto combat-sport context-subconcussive-impact thesis (CAPTAIN TBI meta-analysis effect at moderate-severe TBI, multiple stroke RCTs). Confidence is MEDIUM not HIGH because (a) athlete-prophylaxis use is extrapolation from acute injury data, (b) industry-sponsored trial bias flagged in 2025 GRADE assessment, (c) no head-to-head vs other neurotrophic peptides for sub-clinical impact load. Would upgrade to HIGH if: a true subconcussive-prophylaxis trial reads out, or if this user's first cycle produces clear subjective neuro-recovery signal post-spar weeks."

"Massive evidence base; deficiency is widespread (especially in night-owls with limited UV exposure) and clearly impairs immune function, bone density, mood, and athletic performance/recovery. For a 20yo MMA athlete training indoors, supplementation is essentially mandatory. Pair with K2-MK7 and adequate magnesium. Test serum 25(OH)D first; target 40-60 ng/mL."

"Foundational mineral with broad upside for male athletes: testosterone preservation, immune function, wound healing, taste/appetite regulation. Marginal deficiency is common in heavy trainers (sweat losses) and those on plant-heavy diets (phytate binding). Use modest doses (15-30 mg/day) with copper to avoid induced copper deficiency on long-term use. Picolinate, bisglycinate, or citrate forms are well-absorbed."

Reasonable A/B-test candidate vs modafinil for users in this archetype but the longer late-day plasma tail and 3-4hr later Tmax make it riskier for a late chronotype migrating to midnight bedtime; modafinil 100 mg AM remains the safer daily-driver default. Verdict would shift to OPTIONAL-ADD if A/B test shows modafinil insufficient duration past 3 PM, or to SKIP-FOR-NOW if armodafinil pushes sleep onset past 1 AM in week 8-12 trial.

"For Dylan specifically — 20yo MMA athlete + business owner running a 50-60 hr/week training + work load — ashwagandha's HPA-axis cortisol blunting maps directly onto the recovery-limiting variable. Auddy 2008, Chandrasekhar 2012, and Lopresti 2019 give us reproducible cortisol reductions of 15-30% in stressed adults, with parallel improvements in sleep onset and subjective stress. Wankhede 2015 in young resistance-trained men (n=57, +96 vs +18 ng/dL testosterone) is the strongest athletic-population dataset and gives a modest but real T-signal that complements the recovery story rather than headlines it. KSM-66 600 mg/day is the consensus research dose. Hard blocks: pregnancy (abortifacient), thyroid disease (T3/T4 elevation), and any liver dysfunction (Björnsson 2020 + Philips 2023 case series document ~30+ DILI cases — rare but real). Cycle 8 weeks on / 4 weeks off to preserve adaptogen responsiveness."

"Multiple meta-analyses confirm meaningful HbA1c (-0.5%), fasting glucose, fasting insulin, and lipid improvements — comparable to metformin without prescription requirement. For an MMA athlete cycling weight or pursuing body recomposition, berberine is the most evidence-backed natural metabolic agent. Bioavailability is poor (~5%); take with fat and split doses. Cycle 8-12 weeks on / 4 weeks off to minimize gut-microbiome remodeling concerns."

"A-tier evidence for performance in the 60-240 second high-intensity exercise window via muscle carnosine elevation — meta-analyses (Hobson 2012, Saunders 2017) show consistent ~2-3% improvement in time-to-exhaustion and total work in this domain. This is the most direct fit imaginable for MMA: 3-5 minute rounds with bursts of maximal effort heavily tax this exact energy system. Cheap, well-tolerated (paresthesia aside), no meaningful safety concerns. Effectively a default supplement for any combat-sports athlete."

For peripheral nerve compression (cubital tunnel-type) — peripheral nerve regeneration is one of the most robust BPC-157 animal data sets (sciatic crush, transection, spinal cord), mechanism is aligned (VEGFR2 angiogenesis + Schwann-cell support + anti-inflammatory at compression site), peptide-vendor sourcing is solvable, side-effect profile in 20+ years of rat data is benign, and a 4-8 week localized-injection trial is reversible. Confidence is MEDIUM not HIGH because (a) ZERO Phase 3 human RCTs exist for any indication, (b) >80% of evidence base is from a single Croatian lab (Sikiric/Seiwerth, Zagreb) with open 2024-2025 academic dispute about confirmation bias and lack of independent replication, (c) FDA 2024 prohibition flags "potential safety concerns" without specifying them, and (d) no published protocol exists for cubital tunnel specifically — the typical protocol for this archetype would be extrapolated from sciatic-nerve rat data + biohacker community consensus. Would upgrade to HIGH if (a) an independent Phase 2 nerve-injury RCT replicates the Croatian results, (b) users in this archetype run a 4-week local-injection trial near both elbows and sees objective symptom reduction (tingling threshold, Tinel's sign at cubital tunnel), or (c) an orthopedic sports-medicine systematic review reports positive human data. Would downgrade to OPTIONAL-ADD if FDA issues specifics on the 2024 safety concerns or if cancer-angiogenesis signal emerges in any human cohort.

Best-evidenced cognitive enhancer + ergogenic on the planet, trivial sourcing, and this user's zero-baseline = maximum responder window. Cycle 2-4 days/week + theanine pairing + AM-only dosing preserves responsiveness and protects late-chronotype sleep migration. Confidence drops only if a user in this archetype is CYP1A2 CC (slow metabolizer) per pending 23andMe — would shift to once-or-twice-weekly PRN.

"Collagen peptides have the best evidence in the entire 'joint-support' supplement class for an athletic population, specifically via Shaw/Baar lab work showing 15g hydrolyzed collagen + 50mg vitamin C, 60 minutes before targeted connective-tissue loading, doubles collagen synthesis markers and improves tendon mechanical properties. For an MMA athlete with daily heavy tendon/ligament/cartilage stress (BJJ rolls, striking, takedowns), this is a high-leverage low-cost intervention. Also doubles as glycine source which has its own value (sleep onset, anti-inflammatory). Default-yes."

Foundational anti-inflammatory + cardiovascular + brain-membrane lipid with the strongest cumulative evidence base of any OTC supplement category. Reproducibly lowers triglycerides 20-30% at 2-4 g/day; pharmaceutical-grade EPA (Vascepa) cuts MACE 25% in high-risk patients (REDUCE-IT 2018); modest depression-adjunct signal; structural DHA support for synaptic membranes and retinal photoreceptors. Cheap ($10-20/mo), daily-safe up to ~3 g/day, no cycling, perfect pairing with astaxanthin (which protects DHA from peroxidation). Verdict would only weaken if a clean replication of REDUCE-IT fails or if AFib signal proves dose-bounded at the OTC range. Mild atrial fibrillation signal at >2 g/day warrants attention but does not displace the core verdict for users in this archetype.

For a 20yo MMA athlete + business owner accumulating tendon/ligament loading 5-7 days/week, gelatin is one of the highest-leverage cheap-and-safe interventions in the recovery toolkit. The Shaw 2017 trial (PMID 27852613) is a properly designed crossover with engineered-ligament collagen-content doubling — that's a mechanistic readout, not just a biomarker shift. Lis & Baar 2019, Lis 2022 (RFD), Clark 2008 (joint pain in 147 athletes) all replicate the broader thesis. Safety profile is essentially perfect — gelatin has been a food ingredient for centuries; no clinically meaningful interaction profile; cost is trivial ($15-30/mo). The MMA-specific use case (tendon/ligament durability under repeated loading) is exactly the Shaw mechanism. Confidence is MEDIUM-HIGH not HIGH because (a) Shaw 2017 has only n=8 healthy males, (b) the 2x collagen-content readout is from in-vitro engineered-ligament constructs cultured in subjects' serum — a clever proxy but not direct in-vivo tendon imaging, (c) full RCT in injury-prevention or tendinopathy-rehab populations remains pilot-stage (Lis & Baar 2019 is small), (d) collagen-peptide RCTs for skin/joint endpoints are largely industry-funded (Verisol, Bioactive Collagen Peptides). Verdict would shift to HIGH if a properly powered RCT confirmed in-vivo tendon CSA / mechanical property gains in athletes. Verdict would shift to OPTIONAL-ADD only if a credible safety signal emerged or if the engineered-ligament doubling failed to translate to in-vivo human outcomes in a follow-up trial (none indicated to date).

Gordji-Nejad 2024 (Sci Rep) is a clean RCT in 21-32 yo healthy adults showing a single 20 g dose produces measurable brain creatine increase via 31P-MRS AND cognitive performance rescue under 21 hr sleep deprivation. Mechanism is well-grounded (cerebral ATP buffering during metabolic stress). Effect size modest in absolute terms but the demographic + sleep-deprivation context maps directly to a delayed-sleep-phase chronotype + sparring + cognitive workload profile. PRN protocol (1-3×/month max) sits on top of his existing 5-10 g/day baseline without replacing it. Verdict downgrades only if (a) replication fails, or (b) chronic high-dose data emerges showing accumulation harm. Verdict upgrades to STRONG-CANDIDATE-DAILY if 10 g/day chronic brain-saturation data accumulates and a user in this archetype wants the steady-state version rather than acute pre-stress.

A-tier evidence for cleaner cognition when paired with caffeine; A-tier subjective sleep onset support; B-tier acute anxiolytic. Cheap, daily-safe, minimal tolerance, stack-clean with everything in V4. Already in V4 at Suntheanine 200 mg/day. Verdict would only change if a credible chronic-toxicity signal emerged (none does) or if the 2025 sleep meta-analysis "subjective-only, not objective" finding hardens into "placebo-equivalent on PSG" — at which point it stays A-tier for caffeine pairing but becomes B-tier (not A) for sleep onset.

A-tier evidence for sleep onset latency reduction at 1 g+ doses with the proper timing (empty stomach, 30-60 min pre-bed); cheap; clean side effect profile; pharmacologically more relevant than glycine for a late-chronotype migrating earlier (it actually feeds the melatonin pathway, glycine doesn't). Would shift to PRIMARY-PICK if this user's bloodwork shows low ferritin/B6/Mg (which would otherwise bottleneck conversion).

"Foundational mineral with A-tier evidence for sleep quality, BP modulation, migraine prophylaxis, CVD risk reduction, and glucose metabolism. Subclinical deficiency is widespread in Western diets (DiNicolantonio 2018 estimates ~50% of US adults below the EAR). For a 20-year-old MMA athlete with high training cardiovascular load, daily sweat Mg loss, and brain-protection priorities, a foundation of 200-400 mg elemental Mg as glycinate is one of the highest-confidence supplement decisions in the V4 stack. Already locked in V4 at 400 mg elemental as Doctor's Best Albion TRAACS glycinate (sleep + relaxation foundation), paired with Source Naturals Magtein (CNS-targeted) — this dual-form approach is correct: glycinate covers systemic repletion + sleep, threonate covers brain-specific Mg. Affordability (~$0.28/day) and safety profile push this firmly into STRONG-CANDIDATE / CONFIRMED-IN-USE territory. Form selection is the actionable variable, not whether to take it."

For this user's specific use case — late-chronotype migration from 2-3 AM toward midnight bedtime — low-dose (0.3-0.5 mg) early-evening melatonin is one of the few interventions with A-tier evidence directly on his actual problem (delayed sleep-wake phase disorder, DSWPD). The phase-advance application is mechanism-aligned, evidence-supported (Brzezinski/Zhdanova MIT physiological-dose meta-analyses, AASM 2015/2024 DSWPD clinical practice guideline), cheap ($5-15/mo), low-risk at correct dose/timing, and complementary to his V4 magnesium glycinate + magtein stack. The verdict is HIGH-confidence for phase-shift use AND explicitly NOT a sleep-onset hypnotic recommendation — high doses (3-10 mg) at bedtime are both unnecessary and counterproductive for his chronotype problem. Verdict would shift to PRIMARY-PICK only if behavioral phase-advance proves insufficient at week 4-6 and this user formally adds it; would shift toward WATCH-LIST only if he develops a measurable HPG-axis concern (theoretical, very unlikely at these doses) or finds it produces morning grogginess despite microdose protocol.

Plausibly a longer-acting, more convenient Semax; mechanism extrapolated from parent compound; PK numbers and "3-5x potency" claims are vendor-marketing not peer-reviewed; only meaningful if vendor identity/COA can be verified — otherwise it's just expensive Semax (or worse, regular Semax mislabeled). Promote to higher confidence if a verified COA + 4-week self-trial replicates Semax effects at lower mcg with longer duration.

"Clean stim-class racetam with measurable cognitive + physical performance benefit, well-fit to this user's high-cognitive-load business days and pre-MMA-training pulses. Verdict is PRN-only (not daily) because tolerance reliably builds in 1-2 weeks of daily use — this is the load-bearing limit. Confidence is MEDIUM-HIGH not HIGH because the entire human evidence base is single-source Russian (Savchenko 99-pt encephalopathy trial; ~400-pt stroke trial citation, but primary-source attribution is murky), zero independent Western RCTs exist, and the encyclopedia/secondary-source claim of \"400-patient double-blind stroke trial\" appears to conflate multiple smaller trials — see Open questions. What would change the verdict: independent Western RCT, better characterized tolerance kinetics in humans, or a clean this user A/B against pramiracetam at matched cost."

"PS has the cleanest RCT evidence of any supplement for blunting exercise-induced cortisol — two well-cited Starks/Fahey studies and a Monteleone series show 600-800mg PS reduces post-exercise cortisol by 20-30%. For an MMA athlete with very heavy training load + business stress (chronically elevated cortisol risk), this is one of the few sports-cortisol interventions with mechanistic + clinical support. Modest cognition / focus signal as a side benefit. Cost is the main friction — soy-PS at ~$0.30-0.50/g for the effective dose is fine; sunflower-PS is pricier but allergen-free."

Best-in-class non-sedating anxiolytic for users in this archetype's pre-sparring / pre-presentation / pre-call anxiety with no tolerance, no dependence, and benzodiazepine-comparable acute efficacy in Russian RCTs. Mechanism is well-characterized and multi-modal; safety record across 17+ years of Russian Rx use is exceptional. Confidence is MEDIUM-HIGH not HIGH because (a) all RCT-quality human data is Russian (Zozulya 2008 vs medazepam, Kost 2024 alcohol-withdrawal), (b) Western replication is thin, (c) effect size in already-low-anxiety baseline is uncertain. Verdict would upgrade to PRIMARY-PICK (PRN tier) only if this user's first 4-week PRN trial shows clear pre-event benefit; would downgrade only if nasal irritation persists past adaptation window or if the anxiolytic effect is sub-noticeable.

Verdict applies to LOW ORAL (1-2.5 mg) tier only — strong mechanistic + animal-longevity case + clean human safety at this dose, but direct healthy-young-adult cognitive evidence is thin. Emsam tiers separately verdicted in body. Would upgrade to PRIMARY-PICK if 23andMe shows DRD2 Taq1A A1 carrier or low-DA-tone genotype where preservation matters more; would downgrade to OPTIONAL-ADD if baseline mood + drive already strong without it.

Excellent fit for users in this archetype's brain-priority + MMA-subconcussive context (neurotrophic + dopaminergic without amphetamine-class downsides); main caveat is that Adamax appears to be the same mechanism with better duration and BBB profile, so Semax is the explicit tier-1 backup if Adamax sourcing slips. Verdict would upgrade to PRIMARY-PICK only if Adamax sourcing fails.

"Sulforaphane is the most validated dietary Nrf2 activator in the literature — robust mechanistic chain from cruciferous intake → phase II enzyme induction → durable antioxidant defense. Direct human data: blood pressure (Christiansen 2010), airway inflammation, post-exercise oxidative stress (Malaguti 2009), brain BDNF/HPA modulation (Yagishita 2019), autism (Singh 2014 Hopkins trial), and emerging cancer prevention data. Glucoraphanin + myrosinase = far better bioavailability than fresh sulforaphane (which degrades on shelf). 10-day-old broccoli sprouts are the highest-density food source. Cheap, low-toxicity, broad-spectrum protective. Strong fit for an MMA athlete generating high oxidative load."

Cheap, safe, broad mechanistic coverage relevant to MMA cardio + impact recovery + sleep. Verdict holds even if 2025 longevity reanalysis is correct — cardiovascular and exercise evidence stand independent of the contested aging-driver hypothesis. Would only downgrade if a credible chronic-toxicity signal emerges at 1-3g doses (none currently exists).

"Strong preclinical (rodent + equine) and mechanistic case for cubital tunnel + general MMA recovery, classic pairing with BPC-157 covers complementary repair pathways (BPC-157 = VEGFR2/NO/local; TB-500 = G-actin/cell-migration/systemic). Confidence is MEDIUM not HIGH because: (a) the human evidence is thin — RGN-259 ophthalmic Phase 3 (full TB-4 protein, not the LKKTETQ fragment) MISSED primary endpoint in 2024 SEER-3 European trial, RGN-352 cardiac was clinical-hold-stalled since 2011; (b) most \"TB-500\" community data is racehorse-derived; (c) March 2024 paper suggests the active wound-healing metabolite is Ac-LKKTE (5-AA), not the LKKTETQ heptapeptide vendors sell — opening a real possibility that injected TB-500 only works via metabolic conversion; (d) theoretical cancer-promotion concern (TB-4 overexpressed in pancreatic, NSCLC, RCC, colorectal cancers — causation unresolved) flags a non-zero risk for any user with cancer family history; (e) human data confidence would jump if RGN-259 US Phase 3 reads positive or any sport-medicine trial publishes. Verdict would downgrade to OPTIONAL-ADD if cancer-promotion causation gets confirmed, or upgrade to PRIMARY-PICK for cubital tunnel if a peripheral-nerve RCT reads positive in humans."

"K2 (MK-7) is the under-appreciated partner of vitamin D3 — D3 increases calcium absorption, K2 directs it to bone rather than arteries. For a young athlete on D3 supplementation, K2-MK7 at 90-180 mcg/day is a near-mandatory pairing. K1 from leafy greens is generally sufficient for clotting; K2 specifically is what most diets lack. Low risk, modest cost, strong mechanistic rationale; growing observational evidence for arterial and bone protection."

"For combat-sport context subconcussive prophylaxis use case, mechanism is highly aligned (oral analog of cerebrolysin's neurotrophic logic — multi-target neuroprotection, mitochondrial preservation, anti-neuroinflammatory) but evidence base is **acute ischemic stroke and post-stroke cognitive impairment in Chinese populations**, not subconcussive impact in young healthy athletes. TBI rodent data is positive but no human TBI RCT exists. Hepatotoxicity signal (ALT elevation 1.4-17.5% in trials) is real but manageable with monitoring + NAC (already in V4). Verdict would upgrade to STRONG-CANDIDATE if (a) any human TBI/concussion RCT reads out positive, (b) CSPC's US Phase 3 program publishes a non-Chinese cohort, or (c) a head-to-head against cerebrolysin shows non-inferiority. For now: cheaper oral adjunct to cerebrolysin worth a single 90-day cycle when the V5 stack is otherwise stable."

Strong rodent evidence for BDNF-pathway activation, neuroprotection, and TBI/depression models — but human data is essentially absent and oral bioavailability is poor (~5%). Speculative pick for users in this archetype's brain-protection thesis; 7,8-DHF prodrug R-13 may be the path forward.

Real but mild "cleaner caffeine" energy + mitochondrial insurance for a 20yo athlete; the TMAO/cardiovascular concern (>30-fold rise on 1.5 g/day) is the only thing keeping it out of STRONG-CANDIDATE — cycling or stacking with TMAO-mitigating fiber/probiotics restores the case.

Best risk/benefit retinoid for acne — OTC, well-tolerated, equivalent efficacy to tretinoin in head-to-head trials. For Dylan at 20: not a current need without active acne, but if acne ever appears, adapalene + benzoyl peroxide is the modern standard. OPTIONAL-ADD as the retinoid-first-choice for any future acne phase.

For this-archetype, the compound stacks safely with V4/V5 and offers a plausible 4-in-1 angle (mild calm, pre-workout pump, neuropathic-pain ceiling, stim-tolerance hedge) at low cost; verdict would upgrade to STRONG-CANDIDATE if a single mechanism (e.g., elbow neuropathic pain, modafinil tolerance prevention) becomes dominant in his use case, or downgrade to SKIP-FOR-NOW if pill burden becomes a problem and no subjective signal emerges in 4-6 week trial.

Among the first "next-gen probiotics" with mechanism-validated human RCT evidence. Cumulative case for adding gets stronger with: metabolic syndrome markers, NAFLD signals, gut barrier symptoms. For Dylan at 20 with healthy metabolism + presumed normal Akkermansia abundance, the marginal benefit is small but downside is essentially zero. OPTIONAL-ADD if microbiome testing shows low Akkermansia (commonly seen in Western diet patterns); SKIP otherwise. Pasteurized form (Pendulum) has better data than live form for the metabolic indications.

"Different mechanistic flavor from pramiracetam (mood-bright + creativity + mild anxiolysis vs cognitive sharpness) backed by a B-tier 1991 EU placebo-controlled SDAT trial (n=109, 1500 mg/day, 6 mo, 12-35% SCAG improvement vs 9-19% placebo decline) and Japan post-stroke depression/anxiety use through the 1990s — but healthy-adult cognitive enhancement evidence is thin (one Baylor crossover) and a confirmatory placebo-controlled trial in Japan failed, prompting market withdrawal there. For this-archetype: defensible PRN tool for mood/creativity-flavored sessions where pramiracetam isn't the right fit; requires fat for absorption, doesn't add value chronically given the ~30 min parent-compound half-life, and overlaps mechanistically with citicoline/V4 stack on the cholinergic side. Verdict would upgrade to STRONG-CANDIDATE only if a modern healthy-adult RCT replicated the EU SDAT cognitive signal in cognitively-intact subjects; would downgrade to SKIP-FOR-NOW if any signal of long-term receptor desensitization / cognitive blunting emerged or if this user reports paradoxical anxiety on trial dose."

Strong mechanistic story (CD38/NAD+, GABA, senomorphic) but bioavailability is ~30% with rapid clearance — most users at 50 mg likely under-dose for systemic effects. Cheap insurance bet; would upgrade to STRONG-CANDIDATE if liposomal form used + bloodwork shows estradiol baseline isn't already low.

KSM-66 is the best-trialed standardized ashwagandha extract for testosterone, cortisol, and athletic performance endpoints. For this user, low-priority add given V4 already includes rhodiola for adaptogenic coverage; STRONG-CANDIDATE for stress-prone, athletic, or T-focused archetypes. Verdict would upgrade to STRONG-CANDIDATE if this user's June bloodwork shows elevated cortisol or low-normal testosterone for age. See parent ashwagandha.md for full pharmacology.

Sensoril is the optimal ashwagandha extract for sleep-onset and anxiolytic endpoints due to its higher withanolide concentration and root + leaf composition. For this user, OPTIONAL-ADD low priority — V4 sleep stack (Magtein, glycine→tryptophan, magnesium glycinate) already addresses sleep architecture. STRONG-CANDIDATE for sleep-disordered, anxiety-prone archetypes. KSM-66 likely better choice for this user profile if any ashwagandha is added (more pro-energy, fits AM dosing).

One of the most underrated skincare actives. Works for acne + rosacea + post-inflammatory hyperpigmentation + melasma simultaneously, with very low irritation profile, safe in pregnancy. For Dylan with no specific indication, no current case. OPTIONAL-ADD for any future combined acne + post-inflammatory hyperpigmentation phase, especially in skin of color (where AHA/BHA can worsen PIH).

Best-studied sporebiotic — GanedenBC30 strain has RCT signal for IBS symptom improvement, post-exercise recovery (Jäger 2016 — improved protein utilization + reduced muscle damage markers), and respiratory infection prevention. Shelf-stable + acid-resistant makes it a more practical probiotic delivery for users skeptical of viability of typical Lactobacillus products. For Dylan: low-risk OPTIONAL-ADD especially around training blocks given the exercise-recovery data.

Dhaliwal 2019 head-to-head RCT (12 weeks) showed equivalence to 0.5% retinol on wrinkle depth + hyperpigmentation with significantly less irritation + dryness. Single RCT but the design was clean. For users who can't tolerate retinoids or who want a vitamin-C-compatible alternative, bakuchiol is the best-supported "natural retinol" option. OPTIONAL-ADD for skincare-curious.

Among the most interesting "dietary cannabinoid" molecules — gets the CB2 anti-inflammatory benefit without psychoactivity, sold as food-grade copaiba oil supplement. Small RCTs in fibromyalgia + IBD show signal. Anecdotally good for joint inflammation in training contexts. For Dylan with no specific indication, OPTIONAL-ADD as a low-risk anti-inflammatory adjunct, especially around injury recovery.

Class-level entry — Bifidobacterium genus is the most consistently age-depleted microbiome group + among the most-studied probiotic classes. Strain-specific benefits well-documented (B. longum 35624 for IBS, B. lactis BB-12 for cold/flu reduction). For Dylan at 20 with healthy gut: marginal benefit at baseline; reasonable add during antibiotic courses or symptom flares. OPTIONAL-ADD.

"Clean anti-inflammatory mechanism via 5-LOX inhibition makes boswellia genuinely useful for the joint-recovery niche, especially in athletes with mechanical wear. RCTs in OA show meaningful pain/function improvement at 7-90 days. Less effective than NSAIDs acutely but better long-term GI profile. Reasonable adjunct during heavy training blocks; not a daily core item but a 4-12 week course around grappling-heavy phases is defensible."

"Bromelain has B-tier evidence for post-surgical / post-traumatic edema and inflammation reduction (Rosenberg 2015 NexoBrid; Brien 2004 review). Acute use in sports injury (sprains, contusions, post-spar bruising) has plausible mechanism and small trial support. Less convincing as a chronic daily anti-inflammatory in a healthy athlete — better-evidenced options exist (omega-3, curcumin/meriva). PRN use after hard sparring, takedown sessions, or visible contusions is a reasonable acute anti-inflammatory add-on. Cheap, well-tolerated."

Solid evidence for mood/motivation/anhedonia in target populations and clean stim-like profile without amphetamine harshness — but this user's daily subconcussive head-impact exposure (10+ hr/wk MMA + sparring) is the exact pattern FDA labeling and TBI literature flag for elevated seizure-threshold risk. Worth holding until baseline (modafinil + bromantane + selegiline) lands; revisit only if anhedonia/motivation persists, and only via XL formulation at 150 mg max with prescriber knowing the head-impact context.

"A-tier preclinical neuroprotection across multiple labs and models (5xFAD AD, Parkinson's, ischemia, subarachnoid hemorrhage), elegant proelectrophilic mechanism that activates only in damaged tissue, FDA GRAS, very few side effects at supplement doses, cheap (~$15-30/mo), and stack-clean with V4 curcumin + V5 astaxanthin + NAC. **The catch: zero published human cognitive RCTs exist.** Lipton's 2025 diAcCA paper from Scripps is the highest-profile recent translational push, but human trials haven't started. For this user: cheap insurance compatible with the MMA subconcussive-impact thesis, but should be sized as a low-conviction additive layer behind astaxanthin/cerebrolysin/idebenone, not as a primary brain-protection move. Verdict would upgrade to STRONG-CANDIDATE if (a) diAcCA enters and clears Phase 1, (b) NRF2 wild-type genotype confirmed in this user, or (c) a clean human cognitive/oxidative-stress RCT lands positive. Would downgrade to SKIP-FOR-NOW if a meaningful hepatotoxicity signal emerges in healthy long-term users at >200 mg/day."

Solid pre-workout vasodilator with replicated meta-analysis support for reduced fatigue + reps; PRN before hard MMA sessions makes sense, daily dosing unnecessary.

Replicated B-tier evidence in the most relevant niche for this user — URTI reduction (Davison 2007 PMID 17446836; Brinkworth 2003 PMID 12923655; Crooks 2006 PMID 16676703) and attenuation of exercise- + NSAID-induced gut permeability (Marchbank 2011 PMID 21148400; Halasa 2017 PMID 28397754; March 2017 PMID 28316573) at 20g/day. Effect sizes modest but honest. Combat-sport context with heavy training load + frequent gut/respiratory exposures fits the Davison cohort well. Oral IGF-1 absorption is mostly degraded — systemic IGF-1 / "anabolic" claims are oversold (Davison 2021 review PMID 34073917 confirmed null for sustained IGF-1 elevation across dose ranges). Verdict is OPTIONAL-ADD not STRONG because (a) glutamine + BPC-157 already cover most of his gut barrier slot; (b) cost and protein-load are non-trivial at 20-40g/day; (c) a true milk allergy or significant lactose intolerance can flip benefit to harm. Would upgrade to STRONG-CANDIDATE if he develops a recurrent URTI pattern during fight camps, documents elevated zonulin or post-training endotoxin spillover, or runs a heavy NSAID block. Would downgrade if he tolerates V4 baseline + BPC-157 + glutamine without URTI/gut symptoms.

Mechanism is unique among racetams (HACU enhancement via CHT1 trafficking, not receptor modulation) and the visual-perception subjective effect is genuinely interesting and reproducibly reported, but human evidence is one mixed Phase 2a depression trial (BrainCells 2008-2010, BCI-540, missed primary endpoint with subgroup signal in MDD+GAD) and a single n=1 case study; cognitive enhancement evidence in healthy adults is anecdotal-only. Verdict would upgrade to STRONG-CANDIDATE PRN if a fresh trial replicated the MDD+GAD signal or if this user finds the visual/cognitive effect reproducible in a self-trial; downgrade to SKIP-FOR-NOW if pramiracetam already covers his cholinergic-racetam slot without redundancy.

"Standalone copper supplementation is rarely needed (deficiency is uncommon on a varied diet), but it is essentially mandatory as a copper-zinc balance counterweight for anyone supplementing 25+ mg zinc daily long-term. 1-2 mg copper per 15-30 mg zinc keeps the ratio safe and prevents copper-deficiency neuropathy/anemia (44%+ of zinc-induced copper-deficiency myelopathy cases never recover full neurologic function — Jaiser & Winston 2010 systematic review of 55 cases). For an MMA athlete on Dylan's V4 zinc 25mg/day stack, copper inclusion is a near-mandatory minor add. archetype reinforcement: at 20 with daily zinc supplementation, the copper counterweight is cheap insurance against an irreversible neurologic outcome."

"Modest but real ergogenic effect with chronic supplementation (3+ weeks) for time-to-exhaustion and VO2max — relevant to MMA conditioning. Effect sizes are small and require consistent dosing. Cordyceps militaris (cultivated mycelium) is the form with the better-evidenced trials, not wild C. sinensis. Low risk profile, but stop 2 weeks pre-fight due to mild antiplatelet activity."

"For a metabolically pristine 20yo MMA athlete, dihydroberberine is a convenience play not an evidence play — same drug as parent berberine systemically, marketed as 5× more bioavailable on the strength of a single 5-person crossover (Moon 2021). For pre-diabetic / T2D / NAFLD users wanting better GI tolerability than parent berberine, DHB is a defensible upgrade. For Dylan — NO metabolic indication = NO call to use either. The 5× claim is a reasonable pharmacokinetic extrapolation but rests on thin clinical data; the safety surface (CYP3A4/2D6/2C9 + P-gp inhibition, pregnancy contraindication, ~40% cost premium over parent berberine) is identical to the parent compound."

Among the safest pharmacological sleep options. At 3-6 mg the H1-only mechanism avoids the dependence, REM suppression, and morning grogginess of benzos and z-drugs. Particularly useful for the "wake at 3 AM and can't get back to sleep" phenotype (sleep maintenance vs initiation). For Dylan with no sleep complaint, no current case. OPTIONAL-ADD if maintenance insomnia ever appears — preferable to trazodone (which has α1 + 5-HT2A activity), benzos (tolerance, withdrawal), or z-drugs (parasomnias, abuse potential). Off-label 3-6 mg generic doxepin compounded is much cheaper than Silenor brand.

"Useful adjunct as part of a daily green-tea catechin intake or a focused metabolic-support stack (with L-theanine or caffeine), but high-dose extract supplementation carries real hepatotoxicity risk — especially when taken fasted, as a bolus, or in concentrated extract form. For a 20yo athlete with no caffeine baseline, drinking 2-3 cups of brewed green tea daily captures most of the benefit without the risk; EGCG capsule supplementation is only worth it for specific goals (fat-loss cut, metabolic support) and should be food-paired."

"Real adaptogenic + immune-modulation evidence with two specific clinical niches (Cicero 2004 elderly QoL; Williams 1995 HSV-2 outbreak reduction; Narimanian 2005 URTI combination), but the modern Western RCT evidence base is thin and mixed (Hartz 2004 null in full sample with subgroup signal; Schaffler 2013 null for stress-related asthenia; Goulet 2005 endurance review concluded no benefit). For this user — 20yo MMA athlete + business owner with rhodiola already in V4 — eleuthero is redundant for the adaptogen slot and weaker-evidenced than ashwagandha for athlete-stress endpoints. Patyra 2025 Frontiers review (PMID 41235111) confirms heterogeneity + standardization problems make modern clinical signal hard to extract. Verdict would upgrade to STRONG-CANDIDATE for: frequent-illness phenotype (immune + URTI combo evidence); recurrent HSV-2 outbreaks (Williams 1995); chronic fatigue with shift-work or asthenia context (Russian Rx tradition + EMA approval). Remains OPTIONAL-ADD low for cognitive optimization in healthy young adults — rhodiola covers the same target better. archetype-specific reinforcement: at 20 with high training load + nightly business workload, the case is for rhodiola + ashwagandha (already in V4); eleuthero is a redundant third adaptogen unless a specific immune or HSV trigger emerges."

Standard-of-care adjunct for upper respiratory infections + chronic bronchitis + sinusitis in much of Europe. Oral 200 mg TID or aromatherapy use both well-tolerated. For Dylan: useful to know as a low-risk respiratory tool for cold/flu seasons or training-camp respiratory infection contexts. OPTIONAL-ADD as needed; not a daily baseline.

Mechanism is genuinely interesting (slow-acting glutamate-system rebalancer rather than acute stimulant or GABA agonist), the Nippon Shinyaku safety record is long, and it has the only credible pediatric pivotal-track development of any racetam — but the clinical efficacy story is mixed (one positive open-label adolescent ADHD signal in mGluR-mutation carriers, one fully negative randomized Phase 2 in unselected ADHD, one underpowered signal-finding crossover in 22q11.2DS that missed p<0.05). For this-archetype with no mGluR mutation phenotype and no anxiety pathology, the upside ceiling is "subtle anxiolytic + mild cognitive smoothing on a long-acting GABA-B/mGluR axis," which does not displace anything in V4/V5. Verdict would upgrade to STRONG-CANDIDATE if Nobias Phase 2b/3 hits in 22q11.2DS AND independent biohacker corpus replicates an anxiolytic effect at 5–30 mg in non-mutation-carriers; would downgrade to SKIP-FOR-NOW if any further controlled trial fails or if the GABA-B upregulation rebound profile turns out to mirror phenibut withdrawal in chronic-dosing biohackers.

"Mansoori 2020 meta-analysis (PMID 32048383) and Smith 2023 anabolic review (PMID 37253363) confirm small-to-moderate testosterone, free-T, and lean-mass effects (SMD ~0.3) in male athletes — best evidence is for Testofen (50% fenusides) at 600 mg/day. Marginally useful for a 20yo athlete already at normal T baseline; effect sizes are noticeable but not transformative. Often paired with creatine in strength studies."

"Most promising senolytic small molecule with realistic safety profile and food-derived origin. Mayo Clinic 'hit-and-run' protocol (20 mg/kg/day for 2 consecutive days, once monthly or every 2 months) has good preclinical rationale and reasonable short-term safety. Active human trials (Mayo NCT03675724, NCT06133634, NCT06431932) are ongoing but no positive efficacy readouts yet. For a 20-year-old MMA athlete: senescent-cell burden is low at this age, so the longevity rationale is weak; however, single-pulse anti-inflammatory and recovery applications post-camp/post-fight are mechanistically plausible. OPTIONAL-ADD for intermittent low-key use (1-2 times/year hit-and-run) rather than daily."

"GHK-Cu is the rare compound where topical use has 50+ years of replicated mechanism + clinical evidence (A-tier for skin aging, hair growth, wound healing) while injectable systemic use is biohacker-extrapolation from topical mechanism with thin direct evidence and theoretical copper-accumulation concerns. For this user: topical use is a real option for nose dermatitis + as connective-tissue insurance; SC for cognition is wrong-tool (Cerebrolysin / Semax / NASA already cover that lane with stronger evidence). Verdict would upgrade for SC if (a) human RCT data on systemic GHK-Cu lands, (b) a user in this archetype develops a specific connective-tissue indication that GHK-Cu hits better than BPC-157 + TB-500."

"Robust evidence for anti-inflammatory effect (CRP, TNF-α, hs-CRP reduction across 16-RCT meta-analyses) and nausea relief (chemotherapy, pregnancy, post-operative, motion sickness — multiple meta-analyses). Cheap, food-grade safety, no meaningful sourcing barriers. Useful for an MMA athlete managing weight cuts, post-spar nausea, DOMS, and chronic low-grade inflammation. Best delivered as fresh ginger in cooking/tea + optional 1g standardized extract on heavy training days. Not stack-essential but high-value cheap baseline — falls into the 'free fix first' tier (food before supplement) until the use case demands the higher dose."

GLOW is a real, sensible 3-peptide combo for skin + soft-tissue regeneration with reasonable mechanistic cohesion (all three are upregulators of collagen/repair pathways). For this user, two of three components are already in pipeline for cubital tunnel — so GLOW-as-such is a packaging decision, not a new vector. Confidence is MEDIUM because (a) fixed-blend products often deliver components outside individual therapeutic ranges (pep-pedia explicitly flags this), (b) no human RCTs on the blend itself, (c) this user's primary skin issues (perioral dermatitis + tinea cruris) are better addressed by topical clotrimazole + GHK-Cu than by injectable blend. Verdict would upgrade to OPTIONAL-ADD if this user adds dedicated aesthetic/anti-aging cycle, or if skin issues persist after V4 topicals fail.

"Evidence in established knee OA is mixed-to-modest — GAIT 2006 (PMID 16495392) null overall for glucosamine HCl, modest combo effect in moderate-severe pain subgroup; Reginster 2001 Lancet (PMID 11214126) and Pavelká 2002 Arch Intern Med positive for prescription-grade crystalline glucosamine sulfate (Rotta formulation) on joint-space narrowing + symptoms; Wandel 2010 BMJ (PMID 20847017) network meta-analysis null; Rabade 2024 Inflammopharmacology (PMID 38581640) confirms GS-monotherapy benefit on JSN but null combo. The sulfate-vs-HCl distinction matters and is under-appreciated in US OTC market — only crystalline glucosamine sulfate (Rotta/Mylan Dona) has consistent positive RCT signal. OARSI 2019 recommends against; ACR 2019 strongly recommends against; ESCEO 2019 recommends prescription-grade crystalline GS as first-line SYSADOA — the field is genuinely split. For Dylan (20yo MMA, no diagnosed OA): prevention/cartilage-protection evidence in young athletes is thin (Eraslan 2015 PMID 25630243 null in ACL-rehab athletes; Momomura 2013 mixed) — no strong RCT support for asymptomatic prevention in his cohort. UK Biobank observational signals (Ma 2019 BMJ PMID 31088786 → 15% CVD reduction; Li 2020 ARD PMID 32253185 → 15% all-cause mortality reduction) are biologically interesting but residual confounding (healthy-user bias) likely dominates. Cheap (~$10-15/mo), low side-effect burden (notably benign vs almost any other intervention here), and joint stress of grappling is genuinely chronic — reasonable optional add as part of a joint-care stack (collagen peptides 15g pre-training + omega-3 2-3g + glucosamine sulfate 1500mg + chondroitin 1200mg) during heavy training blocks. Not a high-leverage pick on its own. Move to STRONG-CANDIDATE if Dylan develops persistent joint symptoms or hits late 20s with cumulative grappling mileage; verdict would tighten if any joint MRI shows early cartilage changes."

Sleep evidence at 3 g pre-bed is real but thin (two small Ajinomoto-funded trials, no independent replication, modest effect sizes on subjective metrics). NMDA glycine-site mechanism is well-established but generic — substrate is not rate-limiting in healthy adults. Cheap and safe enough that it's defensible as a daily-driver, but for users in this archetype specifically the V5 plan correctly flags it for replacement with l-tryptophan, which has stronger evidence and better mechanism-fit for late-chronotype melatonin pathway support. Verdict would shift to STRONG-CANDIDATE if (a) independent non-Ajinomoto replication of the 3 g sleep effect appeared, or (b) this user's bloodwork showed kynurenine-shunt reasons l-tryptophan won't work. Verdict would shift to SKIP if a credible safety signal emerged at 3 g (none currently exists).

Cheap, low-risk, mechanism-coherent. Sekhar's RCTs in older adults show consistent improvements across 30+ aging biomarkers. Single-group / small RCT design limits inference but the consistency across measures + the cheap mechanism-validated rationale (glutathione substrate restoration) make it a reasonable longevity add. For a 20yo with intact GSH synthesis, the marginal benefit is much smaller than for an aging cohort. OPTIONAL-ADD for general longevity hedging or in any context where glutathione load is unusually high (exposure to oxidative stress, alcohol metabolism, hard training blocks).

"Real anxiolytic + cognitive-mood signal in small Centella asiatica 500 mg b.i.d. trials (Jana 2010 GAD open-label, Wattanathorn 2008 healthy elderly), but the 2017 Puttarak meta-analysis found no significant cross-domain cognitive effect vs placebo. Skin/wound-healing + venous-insufficiency evidence is the strongest application (Pointel 1987, Incandela/Cesarone 2001) — peripherally rather than centrally useful. For a 20yo MMA athlete with anxiety, ashwagandha + L-theanine + selank already dominate the niche; gotu kola is at best a redundant rotation item. Worth a 4-week trial only if the athlete specifically wants venous-return support during heavy training blocks or topical scar-management — and the topical route is better-evidenced than oral for both. Hepatotoxicity case reports (Madecassol 2001 European cluster) impose a real cycling discipline (≤6 weeks on / ≥2 weeks off) and a liver-panel check before continuous use. Verdict would shift to STRONG-CANDIDATE only if a future trial replicates Wattanathorn's cognitive signal at the magnitude of bacopa/ashwagandha — current evidence does not support a foundation slot."

"Solid vascular-endothelial evidence (~3 mmHg systolic BP reduction in meta-analyses, eNOS upregulation), real antioxidant activity, very cheap (~$10/month). Functionally equivalent to pycnogenol for most use cases at one-fifth the cost. For a 20-year-old athlete with already-healthy BP and endothelium, the floor effect is real — the marginal benefit is small. But: high training load → oxidative stress, and the safety profile is essentially nil. Worth including as a cheap polyphenol baseline if the user wants antioxidant support without committing to pycnogenol's price tag. Optional-add at low priority."

Chinese AD trials (Xu 1995, Zhang 2002, Cochrane 2008 pooled) are robust at 200-400 mcg/day with replicated cognitive benefit on MMSE/ADAS-Cog/HDS; healthy adolescent Chinese trials (Sun 1999) showed memory benefit; healthy young adult Western data is thin. For a 20-year-old in this archetype with citicoline 500 mg already daily, stacking AChE inhibition on top of choline supply is mechanistically sound for *acute task booster* but risks chronic post-synaptic muscarinic/nicotinic downregulation if used daily — cycling 4 weeks on / 1-2 weeks off is non-negotiable. Verdict would shift to STRONG-CANDIDATE if APOE ε4+ on 23andMe (June 2026); would shift to SKIP-FOR-NOW if cholinergic dysphoria emerges in trial.

"Oral low-molecular-weight hyaluronic acid (80-200mg/day) has B-tier evidence for symptomatic knee OA (Tashiro 2012, Oe 2016 series, multiple meta-analyses converging on small-to-moderate WOMAC/VAS improvement) and B-tier evidence for skin hydration + elasticity in midlife/older adults (Oe 2017 PMID 28761365 — verified, plus Kawada 2014, Sato 2014). The mechanism for oral absorption + tissue redistribution is real (Balogh 2008, Kimura 2016 tracer studies) but effect sizes are modest and the strongest evidence base is in OA populations, not 20-year-old athletes with healthy joints. Intra-articular HA injection (Synvisc, Euflexxa, Orthovisc, Durolane) is a separate, stronger evidence-base modality reserved for moderate-severe knee OA + post-injury / post-surgical joint inflammation — irrelevant for the user unless a specific traumatic joint injury occurs in grappling. For Dylan: oral HA in a joint-resilience stack (collagen peptides + glucosamine + chondroitin + boswellia + omega-3) is a reasonable OPTIONAL-ADD during heavy training blocks; standalone benefit is middling. The compound is cheap, very safe, and has no meaningful downside other than opportunity cost on a finite supplement budget. The theoretical CD44-tumor concern has zero clinical signal at supplement doses across 20+ years of widespread use — not a real-world block. Verdict would upgrade to STRONG-ADD if specific joint pain emerges (knee, wrist, shoulder); downgrade to OPTIONAL only if budget pressure forces choosing between joint-stack components."

A-tier evidence in LHON only; B-tier in DMD respiratory function and Friedreich's cardiac hypertrophy reduction; C-tier in MCI/post-stroke cognitive impairment (recent 2024-2025 Chinese trials look real but are non-Western, often single-arm, and cognitive evidence in healthy young adults is essentially absent). Mechanism (BBB-crossing electron carrier + lipid-membrane antioxidant) is highly compatible with this user's brain-priority + MMA mitochondrial-load thesis, and stack-safe with V4/V5 (especially astaxanthin and ALCAR). But for users in this archetype's age/health bracket, ALCAR + astaxanthin already cover most of the same mitochondrial-protection ground at lower cost and with cleaner evidence. Verdict would upgrade to STRONG-CANDIDATE if (a) a clean young-adult cognitive RCT lands positive, (b) a contact-sport TBI/subconcussive-impact biomarker study reads out positive, or (c) NQO1-genotype data places this user in a likely-responder category. Verdict would downgrade to SKIP-FOR-NOW if a hepatotoxicity signal emerges in healthy long-term users or if cost stays >$60/mo for evidence this thin in his demographic.

"Iodine is essential but for the vast majority of users on a typical US/Western diet, baseline intake from iodized salt + dairy + seafood + bread + eggs is sufficient. Modest supplementation (100-200 mcg/day from a multivitamin or kelp tablet) is reasonable insurance for users who avoid iodized salt (Himalayan/sea/kosher), avoid dairy, and eat little seafood. High-dose Lugol's protocols (12.5-50 mg/day, Brownstein/Abraham-style) are NOT-RECOMMENDED outside specific physician-supervised indications — they precipitate Hashimoto's flares, autoimmune thyroiditis, iodine-induced hypothyroidism in susceptible individuals, and Jod-Basedow hyperthyroidism in those with autonomous nodules. Narrow therapeutic window: U-shaped curve where both deficiency and excess cause thyroid dysfunction. PRIMARY-PICK for pregnant/lactating users at 220-290 mcg/day. HARD BLOCK at high doses for Graves'/hyperthyroid. CAUTION for Hashimoto's (low end only, with endocrinologist). Selenium co-supplementation (100-200 mcg/day) mitigates some autoimmune risk."

Cheap, OTC, low-risk topical with three relevant mechanisms for the hair-loss stack: antifungal (Malassezia reduction → reduces inflammatory scalp environment), mild scalp anti-androgen, anti-inflammatory. Pierard-Franchimont 1998 showed 2% ketoconazole shampoo 2-3×/week produced hair density + shaft diameter increases comparable to 2% minoxidil over 6 months. For a 20yo without MPB it's still a reasonable scalp-health add (twice weekly, 5-min contact) — also doubles as dandruff/seborrhea control. Flips to STRONG (alongside minoxidil + topical fin) if MPB onset. No real downside besides occasional dryness; oral form is the hepatotoxic one and not in scope.

"KPV is the C-terminal tripeptide of α-MSH and one of the rare oral-bioavailable peptides (survives gut peptidases due to small size + Pro residue), with B-tier human evidence in ulcerative colitis (Pliva BCT-1 / PL-14736 Phase 2 in early 2000s) and consistent A-tier animal data across colitis, contact dermatitis, asthma, and arthritis models — all converging on NF-κB inhibition as the core mechanism. For this user specifically: useful where his V4 stack hasn't fully resolved nose dermatitis (perioral pattern) and tinea cruris co-inflammation, plus theoretical fit for post-sparring gut barrier stress and skin lesion healing on the same KLOW-stack lane as GHK-Cu. Verdict is OPTIONAL-ADD not STRONG because (a) no human RCT exists outside the IBD use case, (b) the perioral dermatitis + tinea cruris combo is more directly addressed by the V4 clotrimazole + behavioral fixes this user already has, and (c) BPC-157 already covers gut + tissue healing in this user's pipeline. Would upgrade to STRONG-CANDIDATE if (a) this user's skin issues persist past 8 weeks of clotrimazole + behavioral fixes, (b) a flare of post-sparring GI symptoms emerges, or (c) a combat-sport-relevant chronic-inflammation indication develops. Would downgrade if this user's skin clears on V4 baseline alone."

Well-characterized compound; effect-size honestly small in healthy adults. Strong evidence in catabolic/ICU/burn populations does not transfer to MMA athletes outside extreme overreaching states. Useful adjunct for gut/immune insurance during high training load; cognitive benefit weak. Cheap enough to try; not a primary lever. Would upgrade to STRONG-CANDIDATE if a user in this archetype develops persistent gut issues, frequent URTI, or enters a documented overtraining/illness window.

A-tier evidence for stress-condition cognitive rescue (military training, cold, sleep deprivation) and B-tier for sustained working-memory under cognitive load — but no meaningful effect at baseline in non-depleted neurons. For this-archetype, valid as PRN tool pre-sparring / pre-cognitive-load-day / pre-modafinil-washout-day; not a daily-core candidate. Cheap and safe. Verdict would upgrade to STRONG-CANDIDATE if this user moves to chronically sleep-deprived training blocks or if 23andMe shows COMT Val/Val (faster DA clearance, plausibly more responsive to substrate loading); would downgrade to SKIP-FOR-NOW only if subjective signal stays absent across ≥3 stressor exposures.

Best-studied probiotic strain — replicated efficacy for acute infectious diarrhea (Cochrane reviews), antibiotic-associated diarrhea prevention (modest), prevention of recurrent C. difficile. For chronic everyday use without specific indication, benefits are smaller + less replicated. For Dylan at 20: not a daily-baseline pick, but reasonable add during/after antibiotic courses, travel-diarrhea risk windows, or specific gut symptom flares.

"Lactoferrin is one of the few oral-bioavailable glycoproteins with measurable human RCT data — Paesano 2014 (IDA in pregnancy), multiple Italian H. pylori adjunct trials, Velliyagounder 2003-line oral health work, and the ARTEMIS C19 hypothesis-generating COVID trial. Mechanism is well-characterized (iron sequestration is biochemistry, not handwaving), it's GRAS / not WADA-banned, and side-effect profile is benign across decades of dietary and supplement exposure. For the user specifically (20yo MMA athlete + business owner, V4 stack locked, no anemia, no H. pylori, no recurrent UTI, no chronic gut symptoms): there is no specific clinical indication driving immediate use. It earns OPTIONAL-ADD rather than SKIP because (a) gut barrier stress from heavy combat-sport training is real and lactoferrin maps to that mechanism, (b) it stacks cleanly with his V4 fish oil + curcumin + NAC + Vit C for anti-inflammatory layering, and (c) when his June 2026 bloodwork lands, if ferritin is low-normal or hsCRP elevated, lactoferrin moves up the priority list. Verdict is MEDIUM not HIGH because the biggest evidence-supported wins (IDA in pregnancy, H. pylori adjunct) don't apply to him. Would upgrade to STRONG-CANDIDATE if (a) June 2026 ferritin <50 ng/mL, (b) post-training GI symptoms emerge, or (c) recurrent URI/sinus issues during heavy training blocks become a pattern. Would downgrade to SKIP if his bloodwork is unremarkable and no gut/immune indication develops."

"Mild GABA-modulating anxiolytic with reasonable RCT support (heart palpitations, anxiety, sleep). Safe, well-tolerated, stacks well with L-theanine for evening wind-down. Not a core stack item but a low-risk pre-sleep adjunct for a night-owl athlete who occasionally needs softer downregulation than melatonin."

"Leucine is the most-studied BCAA and the rate-limiting amino acid for mTORC1-driven muscle protein synthesis. BUT: in a 20yo MMA athlete eating 1.6-2.2 g protein/kg/day from whole foods (chicken, beef, eggs, fish, whey), each high-protein meal already provides 2.5-4 g leucine and mTORC1 is already saturated 4-5x daily. Supplemental leucine adds nothing on top of adequate protein. The leverage cases are narrow: (a) plant-based eaters / leucine-poor meals where rice/beans rescued by 2-3 g supplemental leucine matches whey for MPS (Lim 2024 PMID 38846451); (b) energy-restricted athletes during weight cuts where leucine-rich whey preserves LBM; (c) older adults with anabolic resistance (Devries 2018 PMID 29901760). For Dylan: SKIP standalone — V4 stack whey + omnivorous protein intake covers it 4-5x daily. Cost ~$0.05-0.10/serving if added; safety benign; the only real downsides are pill burden and redundancy. Would upgrade to ADD only if he transitions to plant-based macros, runs sustained weight cuts, or wants explicit leucine-content auditing during fight camp."

Real molecular mechanism (erinacine A NGF stimulation in vitro is well-replicated) but the gap between bench data and clinical effect in healthy young adults is significant. The single best human trial (Mori 2009) was Japanese MCI patients, not healthy 20yos. Cheap, safe, and has plausible upside for users in this archetype's brain-priority/MMA brief, but it's clearly second-tier next to the Russian peptide layer (Semax/NASA/Adamax/Bromantane) for actual NGF/BDNF effect. Verdict would upgrade to STRONG-CANDIDATE if (a) a healthy-adult RCT replicates the Mori signal, OR (b) a head-to-head vs. Semax shows comparable subjective benefit. Would downgrade to SKIP if this user reports the (anecdotal) genital-numbness side effect.

Real mechanistic and epidemiological signal for low-dose lithium as a brain-protective micronutrient (GSK-3β / BDNF / tau / hippocampal volume), with the only RCT-grade human cognitive data being Nunes 2013 (Alzheimer microdose) and Marshall-style microdose follow-ups. Direct evidence in healthy young adults is thin; the most relevant-to-archetype data is Pacholko 2024 (rat mTBI) plus the Schrauzer/Sugawara/Kessing population-water-lithium series. Verdict would upgrade to STRONG-CANDIDATE if (a) Pacholko-type findings replicate in a human concussion cohort, (b) a baseline-low serum lithium is documented for users in this archetype, or (c) longer-term hippocampal-volume preservation data emerges at OTC doses. Verdict would downgrade to SKIP-FOR-NOW if any unexpected thyroid/renal signal appears at 5-10 mg elemental Li in healthy young adults — which is not currently in the literature.

"Modest, durable upside for visual performance + long-term retinal protection — useful for an MMA athlete with high computer/screen exposure between training blocks. AREDS2 evidence is in AMD-risk older populations, but young-adult RCTs (Stringham 2017 high-screen-time; Renzi-Hammond 2017 cognitive; Lopresti 2025 dry eye/photostress) consistently show improved contrast sensitivity, glare recovery, visual processing speed, and macular pigment density at AREDS2 doses (10 mg L + 2 mg Z) over 3-6 months. Cost is trivial ($8-12/month) and safety is excellent (only side effect at supraphysiologic chronic intake is reversible carotenodermia). The reason this stays OPTIONAL-ADD rather than STRONG-CANDIDATE is that ≥2 daily servings of leafy greens + 2-3 egg yolks saturates dietary intake — Dylan should fork the decision off diet rather than buy first. If diet doesn't deliver consistently (likely during cutting/competition phases), supplement at 10/2 mg with a fat-containing meal."

"Lysine is essential and dietary intake is usually adequate in a meat-eating athlete (RDA 38mg/kg; combat athletes typically consume 4-5x RDA from protein-heavy diet). Supplemental L-lysine HCl 1-3g/day has B-tier evidence for reducing HSV-1 cold-sore frequency/severity. Outside that indication, marginal value for a healthy athlete with adequate protein. STRONG-CANDIDATE specifically for an MMA athlete with recurrent HSV-1 (very common in grappling sports — herpes gladiatorum is endemic in BJJ/wrestling). Otherwise OPTIONAL/skip."

"Multiple RCTs (Gonzales 2002, Zenico 2009, Dording 2008) show modest but real improvement in libido and sexual function in both sexes WITHOUT changes to serum testosterone — useful nutritional support for libido/sexual-function deficits, not a T-booster despite folkloric marketing. For a 20yo MMA athlete with normal T, normal libido, and high training drive, marginal benefit — V4 stack already addresses energy/cognition/mood more directly. Verdict would shift to STRONG-CANDIDATE for menopausal women, aging male 40+ with subjective libido decline, SSRI-induced sexual dysfunction, or sperm-quality concerns. SKIP for hypothyroid + iodine-deficient (theoretical goitrogenic concern with raw maca), or if expecting T elevation (won't happen). Food-grade safety means experimentation cost is low — 1-2 month trial at 1.5-3 g/day gelatinized black or red maca is reasonable if libido/energy ever subjectively dip."

"Excellent profile for pre-sleep anxiolysis in a high-stress athlete: shortens sleep latency, increases NREM/REM duration in animal models, and small human RCTs (postmenopausal women, healthy women on Relora) show meaningful anxiety reduction. Benzo-site GABA-A activity is real — flag for dependence risk theoretically, though no clinical evidence of withdrawal at supplement doses. Better for sleep than lemon balm at heavier-stress nights; pairs well in a wind-down stack."

Useful tool for users on a ketogenic / low-carb protocol who want rapid ketone elevation without strict dietary compliance, or for endurance contexts (small but real free-fatty-acid availability boost). Tolerated dose varies enormously by gut adaptation — start ≤5 g, build to 15-20 g. Not a weight-loss tool by itself; caloric load is real (~9 kcal/g). For Dylan in combat sport context: modest carb-sparing value pre-training, useful for cognitive sharpness in fasted-state work blocks. OPTIONAL-ADD.

For this-archetype, memantine is a tolerance-modulation hedge — useful only IF chronic stimulant tolerance becomes a real problem (which is unlikely on modafinil-only and unproven on bromantane). Brain-priority allows it because memantine is uniquely "physiology-sparing" among NMDA antagonists, but the human evidence for stim-tolerance prevention is anecdote + animal data, not clinical-grade. Verdict would upgrade to OPTIONAL-ADD if this user transitions to a classical stimulant (Vyvanse/Focalin/methamphetamine) where dopamine receptor downregulation is real, or if a TBI/concussion event from sparring creates an acute neuroprotection rationale. Verdict would drop to SKIP-FOR-NOW if this user reports cognitive blunting at 5-10 mg/day during a trial, or if dissociative threshold is reached at lower-than-expected doses suggesting individual hypersensitivity.

"Reasonable choice for liver support during gray-market PED cycles, alcohol use, or NAFLD-trending biomarkers (elevated ALT/AST). Meta-analyses confirm significant ALT/AST reductions in NAFLD/NASH and chronic liver disease, though clinical-outcome data is limited. Bioavailability is poor for plain silymarin — phytosome (Siliphos) forms are 5–10× better absorbed. For a 20yo MMA athlete on a clean stack, marginal preventive value; meaningful if cycling PEDs or heavy oral compounds."

"Genuinely interesting endogenous-peptide mechanism with strong rodent A-tier evidence (insulin sensitivity, exercise capacity 2× in 22-mo mice, healthspan + trend toward lifespan extension), but **zero published human RCT efficacy data on native MOTS-c as of May 2026**. The most advanced human trial — MOTS-c analog CB4211 Phase 1a/1b (CohBar, 2021) — completed safely with positive ALT/AST/glucose biomarker signals, but CohBar abandoned the program in 2023 (formulation issues, company merged into TuHURA). A **Phase 2a native-MOTS-c study (NCT07505745, \"MOTS-MET\", Hudson Biotech, 120 prediabetics, 12 weeks SC daily)** started recruiting Feb 2026 — readout est. May 2028. For this user: exercise-mimetic claim is interesting for MMA cardio/recovery but **(a) WADA-banned (would matter if he goes sanctioned), (b) evidence is preclinical, (c) higher-yield levers exist** (sleep, creatine, beta-alanine, actual training). Would upgrade to STRONG-CANDIDATE if MOTS-MET reads out positive on insulin sensitivity + safety, OR if this user's first 60-day cycle produces a clear cardio/recovery signal post-bloodwork (June 2026)."

"Modest, well-tolerated joint/recovery supplement with consistent (if small) evidence for reduced joint pain, decreased post-exercise muscle soreness, and reduced oxidative stress markers. Effects are real but small. Reasonable for an MMA athlete dealing with chronic joint stress from grappling/striking. 3 g/day for 4+ weeks; doesn't acutely affect a single workout."

Marketing claims of superior bioavailability are largely refuted by pharmacokinetic data showing low systemic tyrosine yield; plain L-tyrosine is cheaper and better-evidenced. Keep as minor option only if GI tolerance to L-tyrosine is poor.

"At 20yo this user's baseline NAD+ is already near-peak. The age-decline thesis itself is contested (Brenner: blood NAD+ doesn't clearly drop with age; tissue NAD+ varies). Human trials reliably raise blood NAD+ ~130-150% but functional endpoints (cognition, muscle, lifespan) remain mixed-to-null. For this user, apigenin (CD38 inhibition — preserves existing NAD+) is more cost-effective than precursor supplementation. Verdict would change to STRONG-CANDIDATE if (a) bloodwork shows low NAD+ at his age, (b) a definitive A-tier human cognitive/performance trial lands, or (c) this user crosses 35-40."

"For this-archetype (20yo, no autoimmune dx, no addiction, no chronic pain) LDN is interesting but not yet justified — the strong evidence is in fibromyalgia/MS/Crohn's/long COVID, not in healthy MMA athletes. Becomes OPTIONAL-ADD if a chronic inflammation signal emerges (persistent post-impact CNS inflammation, training-load fatigue not resolving with V4/V5 baseline, or any autoimmune flag in June bloodwork). Standard 50 mg dose is irrelevant to him (no AUD/OUD). What would change verdict to OPTIONAL-ADD: (a) bloodwork showing elevated hsCRP/IL-6 not resolving on V4 anti-inflammatory layer, (b) subjective brain-fog/recovery plateau after 8-12 weeks of V5, OR (c) any autoimmune marker in 23andMe → bloodwork pipeline."

"Mechanistically interesting \"anti-apathy + anxiolytic-flavored racetam\" with one positive Phase 2 apathy substudy (Robinson 2009, post-stroke depression cohort, n=70, 900mg arm) — but the headline post-stroke depression Phase 2 (Robinson 2008, n=159) MISSED its primary endpoint, the 2016 Starkstein replication for post-stroke apathy was underpowered (n=13) and negative, Daiichi withdrew its Japanese NDA in 2002 for insufficient efficacy, and there are zero healthy-young-adult cognitive-enhancement RCTs. For this-archetype: rarely the right call vs better-evidenced racetams (pramiracetam for memory/focus, aniracetam for mood-anxiolytic flavor); only consider if specifically chasing the apathy/motivation phenotype and other Russian dopaminergics (bromantane, sulbutiamine) under-deliver. Confidence would jump to MEDIUM only if a healthy-adult cognitive-enhancement RCT replicates the apathy-Scale signal in a non-stroke population."

Cheap, exceptionally safe, and a genuine NAD+ precursor — but at supplemental doses (50-500 mg) the systemic NAD+ effect is real but modest and largely overlaps with what NMN/NR deliver. The "high-dose nootropic" 500-1500 mg/day protocol has scattered cognitive and skin/longevity case data but no large RCT. For this user, a low-dose B3 inclusion (50-100 mg) is reasonable insurance; the 1500 mg high-dose protocol is not justified by current evidence.

"Strongest cardiometabolic evidence of any common culinary herb — 2025 GRADE-assessed meta-analysis (82 RCTs, n≈5026) shows replicated reductions in LDL, total cholesterol, triglycerides, SBP/DBP, fasting glucose, HbA1c, and BMI. Confirmed bronchodilator effect in asthma + allergic rhinitis RCTs (Boskabady 2010 lineage). Useful as a low-risk multi-target anti-inflammatory adjunct for someone managing seasonal allergies + cardiometabolic baseline optimization. Smaller glycemic effect than berberine; smaller lipid effect than red yeast rice; smaller BP effect than beetroot. The case for adding it to this archetype is weak (no metabolic indication, no allergic baseline, V4 already covers anti-inflammatory load with curcumin + omega-3) — hence OPTIONAL-ADD rather than PRIMARY-PICK. Verdict would upgrade for hypertensive, pre-diabetic, T2D, or seasonal-allergy users. Verdict downgrades for users on anticoagulants, pre-surgery, or pregnant."

Better cognitive evidence base than eleuthero; multiple A-tier human cognitive RCTs (Reay 2005/2006, Scholey 2010 Cereboost). Korean Red Ginseng in particular has solid evidence for attention and working memory in healthy adults. For this user, OPTIONAL-ADD — V4 covers cognitive ground but Panax is mechanistically distinct from rhodiola/citicoline; could add as PRN cognitive boost. STRONG-CANDIDATE for executive maintenance and 50+ archetypes. Modest stim-like effect requires AM dosing.

Small but converging RCT signal for caffeine-equivalent cognitive benefit with cleaner cardiovascular + sleep profile, plus shorter half-life that suits this user's late-chronotype migration. Confidence is MEDIUM (not HIGH) because long-term safety data is essentially absent (ingredient launched 2022), the RCT base is single-sponsor (Compound Solutions / Jagim/Kreider/Arent group), and caffeine + theanine likely matches paraxanthine's clean profile at a fraction of the cost. Would upgrade to STRONG-CANDIDATE if independent (non-Compound-Solutions-funded) RCTs replicate the cleaner-than-caffeine claim and 12-month safety data lands.

"Head-to-head equivalence with oxazepam in DSM-IV GAD (Akhondzadeh 2001) plus replicated preoperative anxiolysis (Movafegh 2008, Aslanargun 2012) and modest sleep-quality signal (Ngan 2011, Harit 2024) put passionflower in the most evidence-rich tier of OTC herbal anxiolytics — comparable to chamomile and lemon balm and ahead of valerian. Same risk-free niche as chamomile and lemon balm — pre-sleep tea or extract for mild anxiolysis. Functionally interchangeable with those alternatives at this risk tier — pick one for the stack, rotate, or skip entirely if chamomile/lemon balm already present. For Dylan: OPTIONAL evening anxiolytic for business-stress wind-down + occasional sleep onset support, lower priority than Selank (already lined up) and the V4-locked theanine/glycine/magnesium evening stack."

"Cheap, fast-acting, and the molecule that famously gives chocolate its trace stimulant signature — but the 5-15 min half-life means standalone PEA is essentially useless without a MAO-B inhibitor (selegiline) or a competitive MAO-B substrate (hordenine) to extend it. As a PRN tool stacked with hordenine it is mildly interesting; as a standalone supplement it is mostly placebo. CRITICAL: distinct from palmitoylethanolamide (also abbreviated PEA), which is the anti-inflammatory PEA-Ultra product."

Multiple A-tier indications (chronic venous insufficiency Cochrane meta, allergic rhinitis, ADHD adjunct Trebatická 2006, vascular endothelial function Liu 2013, ED Stanislavov 2003) with broad safety margin and clean mechanism. For this archetype (20yo MMA, brain + vascular + recovery focus), the mechanism is supportive — endothelial NO, anti-inflammatory, mild antiplatelet, collagen support — but the V4/V5 stack already has overlapping antioxidant + anti-inflammatory coverage from astaxanthin (membrane), curcumin (NF-κB/COX), NAC (glutathione), apigenin (flavonoid). Pine bark is a credible LATERAL move, not a missing pillar. Verdict would strengthen if a user in this archetype develops vascular complaints (cold extremities, ED, varicose tendency), allergic rhinitis, or wants ADHD-adjunct support — otherwise it sits in the "fine to add, not required" tier behind the V4/V5 antioxidant quartet.

Common dietary + aromatherapy terpene. Mild cognitive + bronchodilatory effects in small studies. Inhaling pine forest essential oils / rosemary essential oil produces measurable α-pinene exposure. Pharmacologic supplementation as isolated α-pinene capsules is uncommon. For Dylan: not a primary tool, but worth knowing as the principal "smell of pine forest" molecule with mild measurable cognitive effects. Forest-bathing literature attributes some of its cognitive benefits to α-pinene + other monoterpenes.

"Solo-use case is weak: piperine alone has thin evidence as a nootropic or thermogenic. The real value is as a bioavailability enhancer paired with otherwise poorly-absorbed compounds (curcumin, resveratrol, CoQ10). For this archetype, only worth supplementing in formulations that already include it (BioPerine-paired curcumin) — avoid stand-alone use because of CYP3A4 inhibition, which can elevate plasma levels of many prescription drugs unpredictably."

Parent racetam with strong A-tier evidence for cortical myoclonus, post-stroke aphasia, vascular cognitive impairment, and breath-holding spells in children — but **weak and inconsistent signal in cognitively-intact healthy adults**, the population that matters for users in this archetype. Newer racetams (pramiracetam ~10-30× more potent by weight, oxiracetam cleaner stim flavor, phenylpiracetam DA-flavored stim profile, aniracetam mood/creativity flavor) cover specific subjective use-cases more efficiently. Piracetam at 1.6-4.8 g/day is essentially the "baseline" racetam — the one that proves the family works clinically but doesn't dominate any specific relevant-to-archetype niche. **OPTIONAL-ADD** rather than SKIP-FOR-NOW because it's the cheapest, most-evidence-rich, longest-safety-track-record racetam, and a sensible first-touch for someone wanting to know whether the racetam class produces any noticeable effect for them at all (cleanest mechanistic baseline before paying premium for derivatives). Verdict would upgrade to STRONG-CANDIDATE only if a modern healthy-adult RCT replicated meaningful cognitive enhancement at clinical doses (which Malykh 2010 and the 2024-class meta-reviews do not show), or if this user ever develops vascular/cognitive-aging concerns. Would downgrade to SKIP-FOR-NOW if a head-to-head trial in healthy adults showed pramiracetam or phenylpiracetam clearly dominates on cognitive-output endpoints for the same dose-cost (which the user-corpus already strongly suggests, even without trial-grade data).

For this-archetype, propranolol is a near-ideal PRN tool for sales calls, public speaking, sparring nerves, and pitch-style high-stakes events — A-tier evidence for performance anxiety, no sedation, no cognitive blunting, ~$10-20/mo Rx, and stack-clean with V4. The verdict is OPTIONAL-ADD (not PRIMARY-PICK) only because this user's actual performance-anxiety load is unclear and many days don't need it; verdict would upgrade to STRONG-CANDIDATE PRN if he confirms 2-4× per week pitch/sales-call use, or downgrade to SKIP-FOR-NOW if a 4-week trial shows no perceptible delta vs L-theanine + breath protocol on similar events. AVOID for endurance/aerobic training days regardless.

"The most-trialed OPC extract (>100 RCTs) with strong evidence for endothelial function, mild BP reduction (~3 mmHg systolic in meta-analysis), erectile function, and chronic venous insufficiency. Genuine vascular and anti-inflammatory effects beyond placebo. The catch: ~5x more expensive than grape seed extract for substantially overlapping mechanism. For a 20-year-old MMA athlete with normal BP and endothelial function, the floor effect is real — payoff is small. Worth considering for venous health (training-induced varicosity) or recovery if budget allows; otherwise grape seed extract from this same batch is the budget-equivalent."

"Meaningful but modest BP reduction (>500 mg/day) and antihistamine effects make this useful for athletes with allergies or seasonal congestion affecting cardio performance. Poor oral bioavailability (~2%) is the major issue — phytosome/Sophora japonica forms perform better. Senolytic claims are speculative outside clinical research with dasatinib. Use as needed for allergies or as exercise-recovery adjunct, not as core stack."

"Reishi has the best traditional reputation as an evening adaptogen for sleep and stress modulation, but human RCT evidence is mostly limited to fatigue in clinical populations (cancer survivors, neurasthenia). For a healthy 20yo with no chronic disease, the evening sedation effect is real but mild. Look for dual-extract (water + ethanol) products standardized to beta-glucans and triterpenes. Marginal stack item — rotate with chamomile/magnesium for sleep if interested."

Strong evidence for fine-line / sun-damage / mild acne benefit with substantially less irritation than tretinoin. Among the easier ways to get retinoid benefit without the 6-week "retinization" period of tretinoin. For Dylan at 20: not a current cosmetic need but a reasonable add to skincare baseline if interested in long-term skin-aging prevention. OPTIONAL-ADD.

Panahi 2015 (Skinmed) ran a single 6-month RCT of rosemary oil vs 2% minoxidil in MPB and reported non-inferior hair count outcomes. Single trial, small N, methodological criticism — but the effect direction and the very low-risk profile justify OPTIONAL-ADD status. Useful for users who prefer a botanical approach or as adjunct to minoxidil. For Dylan with no MPB, no current case but it's a low-cost, low-risk scalp tonic to know about.

"Genuine antidepressant evidence in 2024 meta-analyses (Limveeraprajak: 23 trials, 2,183 participants; Peng: 14 trials, 1,522 participants — both show efficacy comparable to imipramine/escitalopram for major depression with better tolerability profile). MTHFR variant-relevant: people with C677T variants may benefit more (methylation cycle support). Expensive (~$30-60/month for adequate dose) and requires enteric coating. For a 20-year-old MMA athlete without depression or methylation symptoms, this is not a daily — but a real tool if mood/motivation falls or post-fight depression appears. MEDIUM confidence rather than HIGH because trials have heterogeneity and SAM-e plasma stability across products is variable."

Real adaptogenic and hepatoprotective evidence (well-established in Russian/Chinese pharmacopeia; Pittler 2003 review; Panossian 2008 mechanism), but most data is on non-Western trial populations and the CYP3A4 induction effect is a real stack-conflict risk for anyone on prescription medications. For this user (no Rx; cognitive endurance + liver support angle), low-priority OPTIONAL-ADD. Verdict would upgrade to STRONG-CANDIDATE for hepatoprotective indication if ALT/AST elevated on June bloodwork; SKIP-FOR-NOW if any Rx with CYP3A4 substrate enters this user's regimen.

"Selenium is essential but the therapeutic window is narrow and US soil/wheat content is generally adequate (200 mcg/day is achievable with 2 Brazil nuts). Most adults are sufficient. Supplementation is mainly worthwhile for: (1) thyroid health (T4→T3 conversion), (2) Hashimoto's autoimmunity, (3) regions with selenium-poor soil (parts of Europe, China). Don't exceed 200 mcg/day chronically — UL is 400 mcg/day. Brazil nuts (1-2/day) are the cleanest source."

"Pandit 2016 RCT (PrimaVie 500 mg, 90 days) showed ~20% total-T and 19% free-T increases in middle-aged men — industry-funded but methodologically sound. Effect size in young men with normal T is likely smaller. Use only purified, lab-tested products (PrimaVie or equivalent) to avoid heavy-metal contamination — raw Himalayan shilajit is high-risk. Reasonable T-supportive adjunct for the MMA athlete archetype."

Mechanism is unusually well-characterized for a longevity supplement (autophagy is the cleanest aging axis we know) and rodent + human-epidemiology data is consistent. Hofer 2024 (Nat Cell Biol) elevates spermidine from "adjunct" to obligate fasting effector — fasting's longevity payoff depends on endogenous spermidine flux. Human RCT base is still thin — the largest cognitive trial (SmartAge 2022, n=100) was null on mnemonic discrimination; the 2024 40 mg/day safety trial confirms a wide therapeutic margin but shows homeostatic control limits how much circulating polyamine rises on supplementation. POLYCAD (n=187, CAD, 24 mg/day, 48-week, NCT06186102) reads out mid-2026 — first adequately-powered CV trial. Cheap, exceptionally safe, daily-compatible. Would upgrade to STRONG-CANDIDATE if POLYCAD or a larger cognitive RCT lands positive or if this user's longevity priority moves up; would stay OPTIONAL for a 20yo brain-priority profile.

"Solid evidence for modest BP reduction (Serban 2016, 2024 GRADE meta-analyses), lipid improvement (Serban 2016 + Hatami 2023 dose-response), allergic rhinitis symptom relief (Cingi 2008), and ergogenic VO2/time-to-exhaustion gains in athletes (Kalafati 2010). Real food-grade nutritional value (protein, iron, GLA). Main caveats are: (1) heavy-metal/microcystin contamination risk from open-pond cultivation — sourcing from certified producers (Hawaiian Cyanotech, EU/Japanese third-party-tested) is non-negotiable; (2) cost-per-gram-protein vastly worse than whey/pea/soy; (3) modest effect sizes that may not justify cost over whole-food diet. For Dylan specifically — LOW priority: protein already covered by athlete-level diet, no allergic-rhinitis indication, no current BP or lipid issue, microcystin risk in non-tested product is real. Reasonable greens-substitute or rotational add but not a core stack item."

Real but transient PRN tool for low-energy days — clean motivation/drive lift in first 1-2 weeks then tolerance crashes the effect via D1 downregulation; cheap and low-risk so worth keeping in the PRN drawer for 2-3×/week max use, but tolerance permanently rules out daily slot. Stronger candidate for chronic asthenia / post-viral fatigue / MS fatigue archetypes than for a 20yo athlete with already-good baseline energy.

FDA-approved with 20+ years of safety data and a long half-life that makes daily 2.5-5mg cleanly steady-state; cognitive/dementia signal is real but observational-only and not enough to push it past OPTIONAL-ADD for a healthy 20yo. Verdict would upgrade to STRONG with cleaner cognitive RCTs OR a personal interest in the vascular/erectile/CV upside. Would downgrade only on intolerance (headache, back pain) or rare ophthalmologic event.

Plausible mast-cell-driven neuroinflammation thesis (relevant to MMA subconcussive impact context) and a genuine PK improvement over plain luteolin, but the entire human evidence base is preliminary and largely from one investigator group (Theoharides). For this user as PRN tool around heavy sparring blocks it is conceivable; as a daily core item it is not justified yet.

"Leisegang 2022 meta-analysis (PMID 36013514, 9 studies, 5 RCTs in pooled analysis) shows SMD 1.35 for total testosterone increase — but effect concentrates in hypogonadal / borderline-low-T men, not healthy young men with normal T. For a 20yo MMA athlete with intact HPG axis and peak endogenous T, expect modest free-T bumps via SHBG reduction (10-25% across trials) and cortisol blunting rather than dramatic T elevation. The libido evidence (Talbott 2013, Ismail 2012, George/Henkel 2014) is more consistent than the T-elevation evidence. Reasonable stress/recovery + libido adjunct IF Physta-standardized (skip unstandardized root powders — mercury contamination risk). For Dylan specifically: LOW-PRIORITY ADD — peak endogenous T at 20 means returns are smallest in this archetype; cortisol angle is more useful than T angle given high training load + entrepreneurial stress. Not a magic T-booster; not a skip either."

Massive replicated literature for acne and photoaging (gold-standard topical retinoid since 1971); but tretinoin is a documented trigger and aggravator of perioral/periorificial dermatitis — this user's primary current skin complaint. The right move is "zero-therapy" (stop topicals, eliminate triggers, possibly tetracycline-class oral antibiotic) for the POD first; add tretinoin later once skin is stable, if acne/aging-prevention is a goal. Verdict would upgrade to OPTIONAL-ADD or STRONG-CANDIDATE the moment POD is resolved and a user in this archetype wants to start a long-horizon photoaging-prevention layer.

"Real evidence for liver protection in cholestatic disease and ER stress reduction. Most relevant athletic use case is hepatoprotection during prescription drug or AAS cycles where ALT/AST commonly elevate — and this archetype is not running AAS cycles. Solid baseline tool to have in the toolbox: if the user ever runs an oral 17α-alkylated steroid, modafinil chronic dosing, or any hepatotoxic compound, TUDCA at 500-1,000 mg/day has reasonable preclinical/clinical support for ALT/AST normalization. Without a hepatic insult to address, it's a marginal-benefit daily supplement at ~$30/month. Keep on the shelf for situational use."

"Decades of clinical and mechanistic data; dose-response and bioavailability differences between ubiquinone and ubiquinol well characterized; benefit is age-stratified — endogenous synthesis declines after ~30 and supplementation rationale is strongest in older adults, statin users, and patients with mitochondrial-disease, CHF, or specific neurodegenerative conditions. **For this user (20yo, no statin, no mitochondrial disease, no cardiac pathology, healthy endogenous synthesis): supplementation is plausible-positive but low-impact;** the same mitochondrial-protection real estate is more efficiently covered by ALCAR, astaxanthin, NAC, and (if added) idebenone (which actually crosses the BBB). Verdict would upgrade to STRONG-CANDIDATE if (a) this user starts a statin, (b) bloodwork reveals abnormal cardiac biomarkers, (c) genetic data shows an NQO1 or COQ-pathway variant impairing endogenous CoQ10 cycling, or (d) he turns 30+ and wants a low-effort age-related mitochondrial maintenance lever. Verdict would downgrade to SKIP-FOR-NOW only if budget pressure forces choices and ALCAR/astaxanthin already on board."

Cheap, low-risk membrane-phosphatide substrate that supplements brain phospholipid synthesis when paired with choline + DHA. Strong mechanistic foundation (Wurtman MIT lab paradigm; LipiDiDiet trial signal in prodromal AD). Healthy-adult RCT evidence is thin — most human data sit inside multi-nutrient formulations (Souvenaid/Fortasyn) rather than isolated UMP. Carlezon 2005 rat antidepressant-like effect + community mood/cognition reports support a real but subtle phenotype. Reasonable add for users running citicoline + DHA stack who want full Kennedy-pathway substrate coverage; not a primary nootropic for acute cognitive enhancement.

"This is the most-evidenced \"longevity supplement\" available OTC as of May 2026 — three distinct human RCTs (Andreux 2019, Liu 2022, Singh 2022 ATLAS-derived) consistently show measurable improvements in mitochondrial gene expression, plasma C-acylcarnitine biomarkers, and modest muscle endurance gains in older adults at 500–1000 mg/day. **Effect size is real but modest, age-stratified (best signal in 50+), and chronic (4+ months for muscle endpoints).** For a 20-year-old in this archetype: low-priority because (a) endogenous mitochondrial quality is already near peak, (b) muscle endurance signal in young athletes is unstudied and likely below detection threshold against training-driven adaptation, (c) ~30–40% of Western adults are urolithin \"non-producers\" — this user's producer status is unknown until 23andMe + microbiome testing or direct urinary metabolite assay. Verdict moves to **STRONG-CANDIDATE at 30+** and STRONG-CANDIDATE today *if* microbiome non-producer status confirmed. **What would change verdict:** confirmed urinary non-producer status post-pomegranate-load test → upgrade to STRONG-CANDIDATE now (specific physiological gap to fill); positive young-athlete RCT readout → upgrade."

Cheap baseline insurance for a 20yo athlete with moderate-choline diet — covers B1/B2/B3/B5/B7 gaps not addressed by V4 (V4 already provides B6 indirectly via NAC-supported methylation, B9 via fish-oil-paired methylation context, and B12 indirectly via cobalamin-rich animal protein). The specific case for the *methylated* form depends on this user's pending MTHFR genotype (~June 5-15, 2026 23andMe) — if C677T heterozygous or homozygous (~30% and ~10% of population respectively), methylated B-complex is a genuine pharmacogenomic upgrade, not marketing. At ~$25-40/mo for Pure Encapsulations B-Complex Plus or Thorne Basic B, it's the cheapest possible "all your B-vitamin demands probably covered" insurance against subtle cofactor deficiency. Verdict moves to STRONG-CANDIDATE post-23andMe if MTHFR variant confirmed.

"Cheap, safe, broadly useful — but marginal benefit of supplementation in a young athlete with a varied diet is modest. Mainly worthwhile for: heavy training and sickness windows (immune support), pre/peri-workout (iron co-absorption with non-heme sources), connective-tissue recovery (collagen synthesis after injury). Don't mega-dose chronically — controversial evidence that very high doses may blunt training adaptations."

For peripheral nerve compression (cubital tunnel-type) context, the Wolverine Stack is the single most mechanism-aligned non-surgical intervention available — peripheral nerve regeneration is BPC-157's strongest preclinical data set (sciatic crush/transection/spinal cord rat models), and TB-500 supplies the cell-migration arm that BPC-157 alone doesn't fully cover. Verdict is OPTIONAL-ADD (not STRONG-CANDIDATE) because (a) it's a targeted recovery intervention, not a daily stack member, (b) a user in this archetype should run behavioral protocol (night splint, ergonomic pad, sleep position) for 2-4 weeks first since 50%+ of mild cubital tunnel resolves without peptides, (c) the cubital-tunnel-cycle protocol already exists as the archetype-specific implementation. Confidence is MEDIUM-HIGH because both component evidence bases are individually solid (BPC-157 = >180 Sikiric papers + 2025 Vasireddi systematic review of 36 articles; TB-500 = robust rodent + equine data + RegeneRx human ophthalmic/cardiac trials on full TB-4); the *combination* is supported by one published human study (Lee & Padgett 2021, n=16 knee pain, 87.5% improvement combined or BPC-only) and overwhelming biohacker community consensus. Would upgrade to STRONG-CANDIDATE post-positive this user N=1 trial. Would downgrade to WATCH-LIST if independent confirmation of BPC-157 effects fails to materialize OR if cancer-promotion signal emerges in any human cohort.

"Genuine eye-protection evidence in AMD risk reduction (AREDS2 trial — 4,203 participants over 5 years; 10-year follow-up in Report 28 confirmed durability) and increasingly supported in younger populations for digital eye strain and visual performance (Stringham 2017, n=48, 6-month placebo-controlled with high-screen-time young adults). The night-owl, screen-heavy framing of this user profile maps well — chronic blue-light exposure during late-night browsing/training prep is a real driver of accumulated retinal oxidative stress over decades. Combined with lutein, zeaxanthin is one of the very few eye-specific supplements with population-level outcome data. Daily AREDS2-style dose (10 mg lutein + 2 mg zeaxanthin) at $10-15/month is cheap insurance. Verdict optional rather than strong-candidate because the disease-prevention payoff is decades away and most of the visual-performance evidence is for the lutein+zeaxanthin pair rather than zeaxanthin in isolation."

"Genuinely interesting mechanism for a benzodiazepine-alternative anxiolytic — the dual GABA-A + TSPO-neurosteroid axis produces clinically meaningful anxiolysis (Nguyen 2006 RCT vs lorazepam: non-inferior on HAM-A, superior on post-treatment rebound, cleaner cognitive profile) without the cognitive impairment, motor incoordination, anterograde amnesia, or dependence/withdrawal liabilities that make benzodiazepines a bad fit for this archetype (20yo MMA athlete + business owner, brain-priority + reaction-time goals, no diagnosed anxiety disorder). However, three real frictions block STRONG-CANDIDATE: (1) sourcing requires EU pharmacy or gray-market import — the compound is not FDA-approved and US Rx pathways do not exist; legal status is 'personal-import allowance' gray zone, (2) idiosyncratic hepatotoxicity signal is rare-but-real per Cottin et al. 2016 French pharmacovigilance review of 99 cases over 1995-2015 — drove ANSM risk minimization measures; not dose-dependent, mechanism unclear, requires LFT monitoring at baseline and 4-8 weeks if used, (3) no current indication for this user — anxiety is not a presenting complaint and propranolol + L-theanine + behavioral baseline cover any plausible performance-anxiety use case at zero hepatotoxicity risk. Verdict shifts to OPTIONAL-ADD if (a) a documented anxiety indication emerges that is not adequately handled by behavioral + propranolol + theanine + buspirone, AND (b) baseline LFTs are clean, AND (c) an EU-prescriber relationship is established for genuine pharmacy supply (not gray-market). The mechanism remains scientifically interesting irrespective of personal-fit verdict — the same TSPO + neurosteroid axis underlies brexanolone and zuranolone for PPD and is an active research target for anxiety, depression, and PTSD, so etifoxine is worth tracking as the field evolves. Verdict-change conditions also include any future FDA approval (unlikely near-term given Sanofi/Biocodex commercial focus on EU markets) or ALT/AST signal in any of the user's bloodwork that would shift the hepatotoxicity risk-reward."

Same plasticity + therapeutic profile as psilocybin (see [[psilocybin]]) — the prodrug differs only in absorption pharmacokinetics. The research-chem supply has occasional adulteration with stronger analogs (e.g., 4-AcO-DET) so identity verification matters. For Dylan at 20 with no depression indication, same WATCH-LIST verdict as psilocybin applies.

"Mechanistically interesting — NNMT inhibition is a clean adipose/methylation/NAD-axis lever in rodents (Kraus 2014 onward), and the pep-pedia community is enthusiastic (n=1569 responses, 71% \"would recommend\" yes/probably-yes, 63% \"no side effects\" reported). **Zero human RCTs.** All published efficacy data is rodent or cell-culture. Sold strictly as research chemical with high vendor-quality variance and no COA standardization across the market. Chronic safety profile entirely unknown. **For this user (20yo MMA, brain priority, lean):** primary marketed effect (fat loss) is irrelevant; theoretical NAD/SAM-preservation angle exists but is better served by NMN/NR + methyl support already in play. **WATCH-LIST low priority — revisit only if a credible Phase 1/2 human trial reads out positive.** What would change verdict: any human RCT (positive or negative) at any endpoint; FDA IND filing; reproducible LC-MS purity data across the major vendors."

"Polanski lab body of work (2007-2020, multiple replicated rat + cell-culture papers) is genuinely substantial preclinical evidence for a multimodal dopaminergic neurorestorative profile rare in the nootropic literature — TH upregulation, hippocampal dopamine elevation, dendritic outgrowth, BDNF/artemin induction, anti-inflammatory microglial effects, MPP+ neuron rescue. BUT: zero human trials of any kind, dual MAO-A/B inhibition (not the \"selective MAO-B\" some sources claim — IC50 favors MAO-A 15.5×) raises tyramine + serotonin-syndrome theoretical concerns at chronic dosing, documented UVA-photosensitization with DNA damage in cell models is a real and largely unquantified human risk, vendor identity verification is non-trivial for a research-chem with limited Trustpilot history, and the V5 stack already covers neurogenic + dopaminergic axes (cerebrolysin, bromantane, semax/adamax, low-dose selegiline) with vastly better human safety data. WATCH-LIST not SKIP because the mechanism profile is genuinely interesting and biohacker reports skew positive at 5-15 mg, but the risk/benefit at age 20with strong V5 alternatives makes \"wait for human safety data or independent replication\" the correct call. Would upgrade to OPTIONAL-ADD only if (a) a human Phase 1 / observational safety study lands, (b) photosensitivity is quantified at biohacker doses (not just UVA cell-culture), or (c) a user in this archetype develops a specific dopaminergic-deficit indication (post-modafinil tolerance, post-stim tolerance reset)."

This is the only ITP-validated lifespan extension drug in non-rapamycin / non-17α-estradiol Class III evidence — male mice +22%, female mice +5% lifespan extension at standard dose, replicated across multiple sites (Harrison 2014, 2019). Mechanism likely via attenuated post-prandial glucose spikes + altered gut microbiome (SCFA production). For Dylan at 20 with healthy glucose tolerance, no current case — but acarbose is plausibly the most evidence-backed longevity-positioning drug after rapamycin + metformin, and the GI side effects make it tractable to test (start ~25 mg with first carby meal, titrate to tolerance). WATCH-LIST — would flip to OPTIONAL-ADD in middle age if metabolic markers slip OR if Dylan wanted to add one more longevity tool with the cleanest mouse lifespan signal of the bunch.

"Mechanism is one of the most interesting in the pipeline (selectively amplifies endogenous BDNF/NGF without forcing constant Trk activation), but only Phase 1 + Phase 1b complete (April 2026), no human efficacy data, no Phase 2 readouts, and the only research-chem suppliers are Everychem (vendor flagged AVOID in this user profile) and Probechem with no community track record. WATCH-LIST not SKIP because Phase 2a is funded (€2.5M EIC grant Feb 2025, first payment Dec 2025) and TBI is a stated indication that maps directly to combat-sport context-subconcussive thesis. Would upgrade to OPTIONAL-ADD if: (a) Phase 2a Alzheimer's readout shows cognitive benefit, OR (b) a non-Everychem vendor with COA-verified material emerges and someone else trials first."

Plausibly a longer-acting Selank for anxiolytic use, but evidence base is essentially zero direct studies — all "Adalank does X" claims are really "Selank does X, and we assume Adalank does too because the active sequence is identical, just chemically armored." For this user, regular Selank already covers PRN anxiolysis with a real Russian Rx supply chain (CosmicNootropic) and verifiable product. Adalank earns a WATCH-LIST slot rather than SKIP because the chemistry rationale is sound (dual end-cap protection is the same logic that makes NASA worthwhile vs Semax) and a verified COA + 4-week trial replicating Selank effects at lower mcg with longer duration would justify upgrade. Promote to OPTIONAL-ADD if (a) verified vendor + COA, (b) this user's Selank PRN trial shows benefit but duration limitation matters, or (c) independent published PK confirms the longer half-life claim.

Community protocol curated by Scientific Sean (2026-05-10). Stack rationale is mechanism-coherent but lacks RCT data on the combination itself; component-level evidence varies. Verdict reflects community-validated framing, not blanket endorsement.

Community protocol curated by Scientific Sean (2026-05-10). Stack rationale is mechanism-coherent but lacks RCT data on the combination itself; component-level evidence varies. Verdict reflects community-validated framing, not blanket endorsement.

Interesting mechanism (sigma-1 + non-GABA anxiolysis) with Russian RCT base claiming GAD response without sedation or dependence. Western replication is absent. Same problem as most Russian pharmacology: methodology, blinding, and outcome assessment do not meet Western standards in most published trials, and the active-comparator data is weak. Subjective user reports range from "nothing felt" to "mild anti-anxiety with cognitive clarity." For Dylan with no anxiety indication, no current case. If anxiety control became a target, a clean placebo-controlled Western trial of fabomotizole would be needed before considering over established options (l-theanine, ashwagandha, low-dose SSRI under medical care). Stays WATCH-LIST.

"AHK-Cu has a clean ex vivo + small Korean cosmetic-RCT mechanism story for hair follicle elongation, but A-tier human RCT evidence is thin and most efficacy data is from formulations co-bundled with minoxidil/biotin/biochanin-A (Capixyl etc.) — the marginal contribution of AHK-Cu alone is hard to isolate. For a 20-year-old in this archetype with a full hairline and no MPB family-history flag in profile, AHK-Cu is a solution-in-search-of-a-problem. WATCH-LIST entry: revisit if (a) hairline starts receding, (b) this archetype's typical stacks minoxidil for any reason, (c) future bald-protocol planning. For skin/wound use, GHK-Cu is strictly better-evidenced and cheaper to find."

Real mechanism + concrete this user-relevance (cubital tunnel = peripheral small-fiber neuropathy; ARA-290's published human data is in sarcoidosis-associated small-fiber neuropathy, mechanistically the most adjacent indication). Animal data for sciatic nerve crush + axotomy is robust. **The case for adding ARA-290 to this user's BPC-157 + TB-500 cubital-tunnel protocol is mechanistically credible but evidentially thin** — only one published RCT (Heij et al. 2012, n=22, modest pain reduction in sarcoidosis-SFN), small follow-up cohorts, no peripheral-nerve-compression human trial. The verdict is WATCH-LIST not OPTIONAL-ADD because (a) the BPC-157 + TB-500 stack already covers the same nerve-regeneration territory with better-replicated rodent data + larger biohacker community evidence base, (b) ARA-290 sourcing through peptide vendors is more variable than BPC-157/TB-500 (smaller market = higher per-vial cost + lower COA standardization), (c) the marginal benefit of adding a third peptide to the cubital-tunnel cycle is unclear, and (d) the EPO-derived class membership creates a non-zero residual concern about off-target erythropoietic signaling at high doses or with long use, despite the molecular case for IRR-only activity. Confidence MEDIUM not LOW because the small-fiber-neuropathy targeting is genuinely mechanism-aligned for cubital tunnel (which has both demyelinating and small-fiber components when chronic), and the EPO-without-erythropoiesis safety thesis has held in 15+ years of trial work without a thrombotic / hematocrit / blood-pressure signal. Would upgrade to OPTIONAL-ADD if (a) this user's first 8-week BPC-157 + TB-500 cycle produces only partial cubital-tunnel response and a second cycle adding ARA-290 is reasonable, (b) a peripheral-neuropathy or post-surgical-nerve RCT replicates the sarcoidosis-SFN signal, or (c) Araim Pharma advances cibinetide to a confirmatory Phase 3 with positive readout. Would downgrade to SKIP-FOR-NOW if any erythropoietic signal emerges in long-term cohorts or a thrombotic event surfaces in self-experimenter community reports.

Community protocol curated by Scientific Sean (2026-05-10). Stack rationale is mechanism-coherent but lacks RCT data on the combination itself; component-level evidence varies. Verdict reflects community-validated framing, not blanket endorsement.

First oral rapid-onset antidepressant — Phase 3 (GEMINI, ASCEND) showed response at week 1 vs week 4-6 for SSRIs. For Dylan at 20 with no depression indication, no current case. Important to know because (a) it's a major new MoA in psychiatry, (b) the underlying DXM cough syrup mechanism is being investigated for many other indications, and (c) if mood support ever becomes relevant, this is one of the better modern options vs an SSRI default.

Community protocol curated by Scientific Sean (2026-05-10). Stack rationale is mechanism-coherent but lacks RCT data on the combination itself; component-level evidence varies. Verdict reflects community-validated framing, not blanket endorsement.

Standard-of-care for statin-intolerant ASCVD patients post-CLEAR Outcomes trial (NEJM 2023 — primary MACE reduction confirmed). For Dylan at 20 with no lipid concern, no current case. Important to know because if/when familial/early hypercholesterolemia ever surfaces, bempedoic acid + ezetimibe is the modern alternative to a statin-only path for users worried about statin side effects. WATCH-LIST.

"Mild psychoactive botanical with a thin published evidence base, dramatic alkaloid-content variability across commercial products (apomorphine ranged 0–detectable, nuciferine 10 ppb to 4,300 ng/g across studies — a 4-5 orders-of-magnitude span), case reports of ED visits with tachycardia + altered mental status from vape preparations, and no clinical efficacy trials. The mild relaxation niche is covered cleaner by L-theanine (free-tier, dose-controlled, 2025 meta-analyses) or kava (more robust evidence) without the product-roulette problem. The mild aphrodisiac claim is anecdotal; for ED specifically there's a separate Rx pathway (apomorphine sublingual/subQ) at properly characterized doses. For this user (20yo MMA athlete, no caffeine baseline, tested-tier eligibility): no clear use case — the relaxation/sleep niche is solved by L-theanine + magnesium glycinate + apigenin already in V4, and the dopaminergic-stim-curiosity niche has cleaner explorations (low-dose modafinil, bromantane). Would shift toward TRY-AS-RITUAL only if (a) bloodwork is clean, (b) sourced from a single COA-backed vendor with batch-tested alkaloid content, and (c) used at low dose for occasional ceremonial/mood context — never as a daily nootropic. Tested-athlete caution: apomorphine is on WADA's monitoring program (not banned, watched); nuciferine is not banned but a positive aporphine signature could trigger questions on a doping panel."

Same Khavinson pattern. For bone density indications, evidence-stronger options exist (vitamin D, K2-MK7, weight-bearing exercise, calcium adequacy, bisphosphonates if osteoporosis). WATCH-LIST.

Cheap, low-risk testosterone optimizer with the only credible human SHBG/free-T data being Naghii 2011 (n=8, +28% free T, -9% SHBG after 1 week at 6 mg/day) — a small open-label study that has not been independently replicated at scale. For a 20yo MMA athlete already on a comprehensive V4 stack, boron is a low-priority "WATCH-LIST" rather than a default add — modest expected effect size in non-deficient men, brief cycle pattern indicated, and stronger T levers (sleep, body composition, zinc + magnesium + vitamin D adequacy) should be confirmed first. Reasonable to layer in 6-10 mg/day for 1-2 week cycles around bloodwork pulls if labs show high SHBG / low free T despite total T being normal. Hard skip if SHBG is already low.

"Mechanistically elegant (avoids the PDE4D emetic site that doomed rolipram), preclinical evidence is A-tier for memory/LTP, and the 2021 Phase 2 Fragile X trial (Berry-Kravis, Nature Medicine) hit secondary cognition/language endpoints — but PICASSO Alzheimer's failed primary in 2020, EXPERIENCE Phase 2b/3 Fragile X readouts (post-Oct 2025) are still pending, and there are zero healthy-young-adult cognitive enhancement RCTs. For this-archetype: insufficient evidence to commit; revisit after EXPERIENCE readout. Confidence would jump to MEDIUM if EXPERIENCE-301/204 hit primary endpoints, and to HIGH only if a healthy-adult cognitive-enhancement RCT replicates the 10-20mg One Card Back signal from the 2017 Phase 1."

Tripeptide with at least a published sequence (Ala-Glu-Asp) and a plausible biological hook into type XI collagen biology — slightly above the average Khavinson black-box peptide. But Western-indexed RCTs are zero, evidence is Russian-only, and for users in this archetype's joint use case (MMA load, cubital tunnel) BPC-157 + TB-500 dominate on evidence and felt effect. Watch-list rather than skip because the cartilage angle is real for an aging OA cohort, and this user may want it on the radar later.

For the user's V5 sleep stack — late-chronotype migration, brain-priority value system, drug-tested-adjacent (MMA athlete who may face urine drug screens) — CBN is a poor fit. The published sleep-onset and sleep-maintenance signal at 5-25 mg pre-bed is small, inconsistent, and dominated by the long-discredited Karniol 1975 myth. Cleaner, cheaper, mechanism-aligned alternatives already in the user's stack (V4 magnesium glycinate + magtein, planned V5 l-tryptophan + apigenin) and in his V5-aware backup options (low-dose melatonin 0.3-0.5 mg for chronotype, glycine 3 g for thermoregulatory sleep onset, lemborexant or daridorexant if a real hypnotic ever becomes necessary) all outperform CBN on evidence, dose-response clarity, and morning-grogginess profile. The real-world CBN supplement market is also a quality disaster — most "CBN gummies" are mislabeled, frequently contain Δ9 or Δ8-THC contamination (problematic for any drug-tested athlete), and sometimes contain CBD instead of CBN. Verdict would shift toward OPTIONAL-ADD if (1) a high-quality multi-night PSG-validated RCT with clean isolate showed sleep-architecture benefit unique to CBN and not replicated by cheaper alternatives, or (2) the user developed a specific indication (e.g., chronic pain + sleep onset) where the entourage-with-CBD-and-CBN literature outperformed isolated alternatives. Neither condition is currently met. Status remains WATCH-LIST — worth knowing about, not worth adding.

Same evidence pattern. For Dylan with healthy heart at 20, no indication. If cardioprotective use case became relevant (CV risk, post-event), evidence-stronger options exist (omega-3, statins, ACE inhibitors per indication). WATCH-LIST.

"Animal data for testosterone support is genuinely promising (echinacoside drives steroidogenic enzyme expression), but human RCTs are sparse and underpowered. Heavily marketed claim of '62% testosterone increase in 8 weeks' is not supported by published human evidence. For a 20yo athlete with presumably normal T, the marginal benefit is unclear vs. the cost and signal-to-noise of T-boosting herbs."

For this-archetype, clonidine is **directionally wrong as a daily compound** (heavily sedating, BP-lowering, anti-alertness — same vector mismatch as guanfacine but worse) but has a **narrow PRN role** for stim-rebound mitigation if afternoon Adderall/modafinil crashes ever become a problem, sleep-onset rescue (0.05-0.1 mg HS), or pre-sales-call somatic anxiety where propranolol is contraindicated (asthma) or insufficient. The verdict is WATCH-LIST rather than SKIP because the PRN sleep-onset and stim-rebound use cases are real and well-documented, but **propranolol covers performance anxiety better with no sedation, and daridorexant/tryptophan/apigenin cover sleep onset better with cleaner pharmacology**. **Rebound hypertension on abrupt cessation is a real risk** that means even PRN use must be cadence-aware. Verdict would change to OPTIONAL-ADD PRN only if a specific use case emerges that the existing V4/V5 stack doesn't cover (e.g., this user goes on amphetamine for ADHD and needs afternoon-crash mitigation, or PTSD nightmares emerge as a target).

Community protocol curated by Scientific Sean (2026-05-10). Stack rationale is mechanism-coherent but lacks RCT data on the combination itself; component-level evidence varies. Verdict reflects community-validated framing, not blanket endorsement.

For this-archetype, cGP is mechanistically interesting — a homeostatic IGF-1 modulator that **normalizes** rather than amplifies free IGF-1, with a clean side-effect profile in human trials and neuroprotective signal in stroke/MCI populations. **But cGP is the same molecule as cycloprolylglycine (cPG), the active metabolite of noopept** — already documented as this user's noopept entry, which means direct cGP supplementation is functionally redundant with the noopept watch-list compound. Direct cGP via NZ blackcurrant or pure synthetic offers a non-prodrug delivery path (avoiding noopept's parent molecule + first-pass hydrolysis) and is more food-grade-positioned, but the active signaling species is identical. Confidence is MEDIUM not HIGH because (a) human clinical trial data is limited to a small number of NZ-based studies in MCI + post-stroke, (b) the IGF-1 homeostasis mechanism is well-characterized in animal models but mostly inferred in humans, (c) NZ blackcurrant cGP content is variable across products and dose-equivalence to noopept is rough. Verdict would upgrade to OPTIONAL-ADD if (i) this user wanted a food-grade non-Russian-peptide route to the same cPG signaling territory, (ii) post-concussion or stroke recovery context emerged, or (iii) bloodwork suggested IGF-1 dysregulation that a homeostatic modulator could address. Verdict would stay WATCH-LIST otherwise — cGP is on the radar as an interesting endogenous-metabolite candidate but does not displace noopept's slot in the cognitive-enhancement comparison set.

Among the most exciting metabolic drug classes of the last 15 years — replicated mortality reduction in HF + CKD across multiple Phase 3 trials, independent of diabetes status. Real longevity interest. For a 20yo healthy male: no current indication, mechanism (renal glucose dumping) imposes mild dehydration + caloric loss + theoretical DKA risk with low-carb eating. WATCH-LIST as a longevity tool to monitor — flips to OPTIONAL-ADD if Dylan develops metabolic risk markers (insulin resistance, hypertension, early CKD) at any future age, OR if convincing data emerges for healthy-aging populations (NIA-funded SGLT2-in-aging studies underway).

Premature ejaculation is not a stated indication for the user (20yo MMA athlete + business owner). If PE ever became an issue, dapoxetine is the cleanest tool by a wide margin — it is the only PE-specific approved drug, dosed on-demand rather than chronically, and avoids the chronic-SSRI side-effect profile (libido suppression, emotional blunting, weight gain, withdrawal) that off-label chronic paroxetine/sertraline/fluoxetine impose. Verdict would shift to OPTIONAL-ADD if PE became a concern, and to PRIMARY-PICK in that scenario for short-term use.

Best-in-class DORA for next-day cognition (8-hour half-life vs 12 hr suvorexant / 17-19 hr lemborexant), strongest total-sleep-time effect at 50 mg in head-to-head NMA, sleep-architecture preserving, low abuse liability. But a user in this archetype does not have insomnia — he has a chronotype problem, which DORAs do not directly fix. Reserved as the *escalation* tool if 4-6 weeks of behavioral chronotherapy + l-tryptophan + magnesium fail to migrate his bedtime. Verdict would shift to STRONG-CANDIDATE only if (a) sleep onset stays >45 min after non-pharmacological stack, (b) WASO becomes a real complaint, or (c) a sleep architecture concern surfaces in actigraphy.

"Mechanistically novel hexapeptide with a famous in-vitro potency claim, but the path to humans is broken: ZERO completed human trials of DIHEXA itself; the prodrug fosgonimeton ran for >7 years and failed the Phase 2/3 LIFT-AD primary endpoint in 2024; Athira's CEO Leen Kawas was found to have manipulated images in the foundational dissertation and four supporting Harding-lab papers (2021 internal investigation, Jan 2025 DOJ $4M False Claims settlement); the HGF/c-Met pathway is an oncogenic driver targeted by FDA-approved cancer drugs (cabozantinib, crizotinib, capmatinib) which makes a chronic agonist of the same axis a non-trivial theoretical concern; vendor identity verification is uniquely fraught for a hexapeptide that is cheap to substitute. For this-archetype (20yo, brain priority, no cognitive deficit, MMA recovery context with theoretical wound-healing/proliferation risk) the upside is poorly defined and the risk profile is wrong. Would upgrade to OPTIONAL-ADD only if (a) an independent academic lab — not Harding/Wright/Kawas-adjacent — replicates the synaptogenesis result with clean blinded methodology, (b) some honest human pharmacokinetic study lands (any route), or (c) a credibly post-fraud follow-on AD or PD trial reads out positive on a clean cognitive endpoint."

"Popular in male enhancement / 'estrogen blocker' circles but the mechanism is more nuanced than the marketing suggests — DIM modulates estrogen metabolism toward 2-hydroxyestrone rather than directly lowering total estrogen. RCT evidence in men is thin. For a 20yo male with no obvious estrogen excess and a normal T-stack, DIM is theoretically useful but practically unproven; better levers exist (body composition, sleep, alcohol moderation). Higher-priority in TRT/AAS users dealing with elevated estradiol — not this archetype. Skip unless specific indication."

Interesting peptide with mechanism-plausible sleep + stress + endocrine + analgesic effects, but the human evidence base is dominated by 1980s-90s small-N Soviet-bloc / Russian / Eastern European trials that have essentially zero modern Western RCT replication. Mechanism is poorly characterized — no confirmed receptor after 50+ years. Sourcing reliability is mixed (gray-market only; vendor QC variable). For users in this archetype (20yo MMA athlete + business owner) specifically, the day-to-day sleep problems are mostly a phase-shift / circadian-timing issue best addressed by low-dose evening melatonin + morning light + behavioral chronotherapy — DSIP's claimed slow-wave sleep enhancement does NOT shift the SCN clock and does not address chronotype migration. DSIP could plausibly be useful for refractory sleep issues (true insomnia after CBT-I + melatonin + DORAs fail, or chronic-pain-driven sleep disruption), but cleaner tools exist (lemborexant for sleep onset/maintenance; selank for stress-flavored insomnia; magnesium glycinate + apigenin for relaxation; and sleep architecture work via behavioral + light + temperature levers). Verdict would shift to OPTIONAL-ADD only if (a) chronic pain or stress phenotype changes, (b) a credible modern Western RCT replicates the Schneider-Helmert 1991 sleep-efficiency finding, or (c) post-V5 sleep architecture data (Colmi R06 or formal PSG) shows N3 deficiency warranting targeted intervention. Verdict would never reach STRONG-CANDIDATE without fundamental change in the evidence base.

Empagliflozin is the strongest cardio-renal-metabolic Rx of the past decade — EMPA-REG OUTCOME (38% CV death reduction), EMPEROR-Reduced/Preserved (HF benefit independent of diabetes), EMPA-KIDNEY (CKD progression slowed). Increasingly framed as a metformin-tier longevity candidate. But for a healthy 20yo MMA athlete with no T2D, no heart failure, no CKD, no metabolic dysfunction, the drug solves problems that don't exist. Off-label longevity rationale is mechanistically interesting (caloric restriction mimicry via glucosuria, ketogenesis, uric acid drop) but no aging-prevention RCT has run. Genitourinary infection risk and rare euglycemic DKA (especially relevant for a fighter who fasts/cuts weight + does ketogenic phases) are real costs. Verdict reopens at age 35+, after metabolic-marker drift, or if a longevity RCT (analogous to TAME) reads out positive.

Community protocol curated by Scientific Sean (2026-05-10). Stack rationale is mechanism-coherent but lacks RCT data on the combination itself; component-level evidence varies. Verdict reflects community-validated framing, not blanket endorsement.

"Mechanistically interesting and remarkably clean safety profile across decades of Russian use, BUT: (a) ~all pivotal evidence is single-lab (Khavinson/Anisimov, St. Petersburg Institute of Bioregulation and Gerontology) with 196 group-held patents, commercial sales conflict, and no NIA-ITP-grade replication; (b) the use-case for a 20yo with already-near-peak telomere length is theoretically weak — telomere attrition is plateaued in young adulthood, the Russian cohort data is in 60-80yo subjects; (c) the \"receptor priming for downstream peptides\" rationale this user flagged is a vendor/community claim, not directly proven; (d) Western academic uptake remains near-zero. **Would upgrade to OPTIONAL-ADD if:** an independent Western lab publishes telomerase activation replication in primary human cells (one such 2025 paper exists — see Evidence section, but author affiliation needs vetting); or if this user's Phase 3 (post-30) longevity protocol moves into actual implementation. **For now: park on watch-list; revisit at age 25-30 or when independent replication firms up.**"

Community protocol curated by Scientific Sean (2026-05-10). Stack rationale is mechanism-coherent but lacks RCT data on the combination itself; component-level evidence varies. Verdict reflects community-validated framing, not blanket endorsement.

The cleanest, most-replicated, most-cost-effective hair-loss drug ever — the Kaufman 1998 + 2002 long-term trials show ~65% of men maintain or regrow at 1 mg/day vs ~25% on placebo, sustained at 5 and 10-year follow-up. But: PFS (post-finasteride syndrome) — a small minority of users report persistent sexual dysfunction, mood, and cognitive symptoms that do not resolve after discontinuation. Whether PFS is mechanistically distinct, psychogenic, pre-existing, or rare-real depends on which lit review you read. The honest answer is: the absolute incidence is low (likely <1%, possibly <0.1%) but the persistence is unpredictable, the mechanism plausible (5α-reductase makes neurosteroids including allopregnanolone, important for GABA-A tone), and there is no recovery treatment if it happens. Verdict: WATCH-LIST for Dylan because at 20 with no MPB onset there is nothing to treat. Flips to STRONG (topical first, oral second) if visible MPB onset; flips to SKIP-PERMANENT if family history of psychiatric reactions to 5ARIs or if Dylan-specific risk-aversion to even-low-probability irreversible-mood-or-libido outcomes. Topical 0.25% finasteride solution reduces systemic absorption substantially while delivering similar scalp DHT suppression — preferable first try if hair-loss treatment becomes indicated.

Cleaner pharmaceutical-grade armodafinil exists with FDA approval and 25+ years of safety data. Flmodafinil is the gray-market potency-upgrade route — only rational pick for users who literally cannot access pharmaceutical-grade modafinil/armodafinil. Verdict moves to SKIP if user has any pharmacy access; moves to consider only if (a) modafinil/armodafinil sourcing collapses AND (b) reliable third-party-tested vendor (Kimera Chems, Lordheim, Mountain Pure tier with COAs) remains operational AND (c) user accepts the unsurfaced-toxicity tail risk.

"Strong A-tier evidence in mild-moderate AD (Cochrane meta confirms cognitive + ADL benefit; comparable efficacy to donepezil); the dual mechanism (AChEI + α7 nAChR allosteric potentiation) is genuinely interesting for working memory and is what lucid-dreaming community exploits with WBTB. **For a 20yo healthy MMA athlete already running citicoline as chronic choline donor: not a daily-stack candidate** — desensitization at α7 nAChR is real (so chronic daily use blunts the unique mechanism), cholinergic side effect load (N/V, sleep disruption, weight loss) is meaningfully higher than huperzine, and the AD benefit doesn't extrapolate to healthy young brains where ACh tone is already adequate. **Worth keeping on the list as a 1-2× per month lucid-dreaming PRN tool (4-8 mg, WBTB protocol)** — that's the only relevant-to-archetype use case that the dual mechanism actually delivers on. Verdict would shift to OPTIONAL-ADD if (a) emerging α7 nAChR data in healthy adults firmed up working-memory effect, or (b) this user's 23andMe shows APOE ε4+ (cholinergic deficit appears earlier)."

"Large body of mixed evidence — early small RCTs and meta-analyses showed modest cognitive benefit in mild dementia / vascular cognitive impairment, but the definitive trials in the demographic that matters most for users in this archetype (healthy young/middle-aged adults) are largely null. Solomon 2002 (JAMA, healthy adults) found no benefit; the GEM Study (Snitz 2009, JAMA — 8-year RCT, n=3,069 community-dwelling elderly) found no effect on rate of cognitive decline; DeKosky 2008 (JAMA) found no prevention of all-cause dementia or AD. Birks 2009 Cochrane concluded the evidence is \"inconsistent and unconvincing.\" Cleaner-evidenced cognitive enhancers exist for users in this archetype (citicoline, bacopa, ALCAR). The PAF-antagonist antiplatelet effect is the live safety concern: bleeding-risk additive with NSAIDs/aspirin/SSRIs/anticoagulants, and pre-surgical discontinuation (≥36-72 hr, conservatively 7 days) is required. WATCH-LIST because Ginkgo's strongest signals are in vascular cognitive impairment, vertigo of vascular origin, and intermittent claudication — none of which apply to a healthy 20yo MMA athlete. Verdict would upgrade to OPTIONAL-ADD only if a vascular indication develops or if a user in this archetype prioritizes peripheral arterial flow / Raynaud's-type symptoms."

Community protocol curated by Scientific Sean (2026-05-10). Stack rationale is mechanism-coherent but lacks RCT data on the combination itself; component-level evidence varies. Verdict reflects community-validated framing, not blanket endorsement.

Mild stimulant + reversible MAO-B substrate primarily used as a pre-workout potentiator for PEA. The PEA + hordenine combination is the canonical forum protocol — extends PEA's 5-15 min half-life to ~1-3 hours of usable focus/euphoria. Standalone effects are subtle (mild appetite suppression, mood lift, modest stimulation). Cardiovascular signal is real but modest at typical 50-100 mg supplement doses. Not WADA-banned, not DEA-scheduled, sold legally in pre-workout blends. Cleaner alternatives exist for stimulation (caffeine, paraxanthine) and for cognitive PRN (modafinil, the user's V5 stack). Worth knowing about as a niche pre-workout potentiator; not worth a daily slot.

"Mechanistically interesting endogenous mitochondrial peptide with the longest historical trail of any MDP (discovered 2001, 24+ years of preclinical work) and convergent positive signals across Alzheimer's, ischemia, atherosclerosis, type 2 diabetes, and aging models — but **zero published human RCTs of native Humanin or any analog as of May 2026**. All efficacy evidence sits in cell and rodent work; no analog has reached even Phase 1 in registered trials. The peptide-vendor scene around Humanin is small and quality is questionable. **For this user: NOT-ACTIONABLE-YET.** Brain-priority justifies tracking the literature given the Aβ-neuroprotection mechanism, but at 20 with no neurodegenerative target, no human dosing established, and higher-yield V4/V5 brain levers already deployed (Cerebrolysin, citicoline, DHA, modafinil, bromantane, Adamax/Semax), Humanin is a watch-the-pipeline compound, not an experiment-now compound. Would upgrade to OPTIONAL-ADD if (a) any registered Phase 1 opens with safety + biomarker readout, or (b) Cohen lab / independent group publishes a human pharmacokinetic study establishing dosing."

"Companion file to `glutathione.md` covering the IV / IM route specifically. For users in this archetype: WATCH-LIST. The legitimate medical case for IV GSH is narrow — A-tier in alcoholic / non-alcoholic fatty liver disease (Honda 2017), B-tier in early Parkinson's (Sechi 1996, Hauser 2009 weaker replication; intranasal has now eclipsed IV), C-tier in cosmetic skin-lightening with documented FDA safety warnings. NAC 1200 mg/day in V4 already supplies the rate-limiting cysteine substrate for endogenous GSH synthesis with cleaner BBB delivery and far better cost / safety / convenience profile. Liposomal oral (Sinha 2018) covers chronic peripheral GSH support at $30-80/month vs $50-200 per IV infusion. Verdict-confidence MEDIUM (not HIGH) because the route does have legitimate uses if hepatic stress, post-impact specialist neurology, or specific oxidative-stress states emerge — but the cosmetic skin-whitening trade-driven mass market is meaningfully unsafe at the unregulated tail and the felt 'IV cleanse' effect is largely placebo-amplified ritual. Verdict would upgrade to OPTIONAL-ADD only if: (a) NAFLD / AFLD / chronic GGT elevation with poor oral response, (b) physician-supervised functional-medicine context with sterile compounding, and (c) a credible indication beyond cosmetic. Otherwise, prefer oral liposomal or NAC."

For a healthy 20yo MMA athlete with no fat-loss goal, no carnitine deficiency, and no metabolic disease, injectable L-carnitine has no legitimate use case the oral form (already in stack discussions via ALCAR) doesn't cover at 1/100th the cost. The injection rationale collapses on inspection — (a) oral 1.5-3 g/day already produces 1.21 kg fat loss in meta-analysis (Pooyandjoo 2020); (b) the user is lean and doesn't have a body-composition target driven by carnitine; (c) injectable bypasses TMAO production but the TMAO concern is exactly why oral ALCAR is OPTIONAL-ADD with cycling — not a reason to escalate the route; (d) clinic injections cost $25-75 per shot vs ~$0.08/cap oral. The legitimate IV indications (PCD, ESRD, valproate toxicity) are clinical scenarios that don't apply. WATCH-LIST flips back into play only if (1) a documented carnitine deficiency emerges on bloodwork, (2) ESRD develops (not happening at 20), (3) a weight-loss-clinic program enters the picture for some reason, or (4) a head-to-head IM-vs-oral RCT for body composition shows IM produces a meaningfully larger effect (currently no such trial exists).

"Real signal in MCI/AD (Craft 2012) and healthy adults (Benedict 2004/2007) — but SNIFF 2020 missed primary endpoint largely due to a documented delivery-device failure mid-trial (the ViaNase II device performed differently than the original ViaNase I), confounding interpretation. Mechanism is well-characterized and side-effect profile is exceptionally clean for a chronic CNS-active intervention. For this user: not actionable until (a) 23andMe APOE status is in (APOE4 carriers show stronger cognitive response signals), (b) a cleaner delivery path exists than off-label compounded insulin + research-grade atomizer, (c) some direct healthy-young evidence beyond the small Benedict cohorts. Verdict would upgrade to OPTIONAL-ADD if APOE4 + Kurve VP3 or comparable device becomes accessible. Verdict would downgrade to SKIP-FOR-NOW if SNIFF-2 fails replication in 2027."

For this user specifically, ISRIB is a mechanism-aligned candidate for subconcussive-impact memory protection (preclinical TBI data is striking and replicated), but A-tier evidence is animal-only, the only human pharma development path (Calico/AbbVie fosigotifator analog) failed in 2025 ALS Phase 2/3 and the partnership ended November 2025, research-chem identity/purity carries vendor risk, and chronic dosing has a real (not theoretical-only) ubiquitin-proteasome-system concern published 2024. Would upgrade to STRONG-CANDIDATE if (a) users in this archetype take a documented concussion and wants an aggressive recovery stack, or (b) a CNS-penetrant successor (DNL343 / next-gen eIF2B activator) gets cleaner human safety data, or (c) Cerebrolysin + V4/V5 baseline is locked and he wants one experimental brain-protection layer on top with informed-consent risk acceptance.

Compelling preclinical story — reversed cognitive deficits in old 3xTg-AD mice, reversed age-related cognitive decline in non-AD aged mice, longer healthspan in SAMP8 progeroid mice. But zero human RCTs. Research-chem supply is the same gray-market peptide-vendor channel as the rest of the high-risk longevity compounds, with unknown identity verification. ATP synthase is a load-bearing protein and chronic agonism in healthy humans is uncharacterized — the rodent benefit is in pathological context (AD, aging), not healthy-young, and there is no theoretical reason a young healthy mitochondrion benefits from a synthase agonist. Verdict: WATCH-LIST tracking Schubert lab + Abrexa Pharmaceuticals → if a Phase 1 healthy-volunteer trial reads out with safety + biomarker signal, revisit. For a 20yo healthy user there is no current case.

"Genuine SRI activity is both kanna's main appeal and its main risk: stacks dangerously with any serotonergic medication or compound (SSRIs, SNRIs, MAOIs, tramadol, MDMA, 5-HTP, DXM, tianeptine, St John's Wort) — serotonin syndrome risk is real and potentially fatal with MAOI combinations. For a 20yo athlete not on serotonergic meds, low-dose Zembrin (25 mg) shows promising anxiolytic + mood signal across 3 small RCTs and one fMRI study, but the SRI mechanism means it functions like a mild antidepressant — not a casual nootropic. WATCH-LIST pending personal evidence of (a) absence of contraindications, (b) clearly defined situational use case (pre-event anxiolysis, post-stim parasympathetic reset), (c) no co-administration with any other serotonergic compound. Confidence would rise to STRONG-CANDIDATE with a clean 4-week situational trial showing benefit > side effects."

"Effective short-term anxiolytic with credible RCT support for GAD (comparable to buspirone/opipramol in some trials). Hepatotoxicity signal is real but largely concentrated in solvent extracts (acetone, ethanol), poor-quality cultivars, prolonged use, and co-medication. For occasional use of noble water-extracted kava in a healthy young athlete, risk is low — but redundant with safer GABAergics (lemon balm, magnolia, l-theanine), and combining with sparring-related head trauma risk and alcohol use is not advisable."

"For this-archetype (20yo, brain-priority, MMA, NO current depression), ketamine is a hold-for-trigger compound — not daily, not prophylactic, not for cognitive enhancement. The TRD evidence is A-tier and the rapid-antidepressant mechanism is genuine (Berman 2000 → Krystal/Sanacora replications → Spravato approval 2019), but a user in this archetype has no depression and no acute TBI requiring ICU sedation. The TBI-protection angle is theoretically attractive (NMDA glutamate excitotoxicity is a major secondary-injury mechanism in concussion) but the human data is mixed-to-neutral, the clinical trials are in severe TBI/ICU settings, and the protective effect requires acute administration immediately post-injury — not a chronic biohacker tool. Chronic recreational/at-home use carries real risks: ketamine bladder (interstitial cystitis, often irreversible), cognitive blunting in heavy users, fast tolerance, and dependence potential despite earlier \"non-addictive\" framing. Verdict would upgrade to OPTIONAL-ADD-PRN if a user in this archetype develops treatment-resistant depression that fails standard SSRIs/SNRIs/bupropion (then KAP via licensed clinic, 6-session induction, monthly maintenance). Verdict would upgrade to STRONG-CANDIDATE for a different archetype (current TRD patient who has failed two antidepressants). Verdict would drop to SKIP-PERMANENT if this user demonstrated any compulsive substance use pattern, history of dissociative misuse, or urinary symptoms."

Research peptide with minimal community use; mostly relevant if HPG-axis dysfunction emerges (low T with low LH/FSH on June 2026 bloodwork, post-AAS-restart need, or fertility issue). Cleaner, better-validated tools for testosterone support already exist for the more likely "secondary hypogonadism" case — enclomiphene (oral SERM, B+ evidence, telehealth-accessible) for upstream stimulation, and hCG (FDA-approved, decades of clinical use) for downstream Leydig stimulation. Kisspeptin's claim to fame is mechanistic elegance (preserves natural GnRH pulsatility rather than mimicking continuous LH like hCG) and IVF-trigger safety in OHSS-prone women — neither use case applies to a 20yo male MMA athlete with intact HPG axis. Watch-list rather than skip-permanent because (a) the post-AAS-restart use case is mechanistically attractive and is being actively explored in peptide community, (b) intranasal KP-54 (Abbara 2025) may transition kisspeptin from research-only to practical-route over 2026-2030, and (c) future fertility / hypogonadism scenarios would warrant re-evaluation. Not a rotation candidate at 20 with peak natural HPG output.

Genuinely fascinating endogenous longevity hormone with strong epidemiologic + mouse-KO evidence. But: no therapeutic. Cannot meaningfully raise serum klotho directly (no recombinant). Indirect interventions (exercise, caloric restriction, vitamin D) modestly increase klotho expression. Worth knowing as a biomarker (now offered by Quest and TruDiagnostic) and as a target for the next decade's longevity therapeutics. For Dylan at 20: confirm normal range if tested; otherwise nothing to do.

"For this user specifically — KLOW is a multi-component stack where the GLOW subset (GHK-Cu + BPC-157 + TB-500) already overlaps directly with the planned cubital tunnel cycle, and KPV may add value if perioral dermatitis persists despite clotrimazole + behavioral fixes. The full KLOW (with LL-37) is not load-bearing for this user's current targets — LL-37 is the wildcard with the thinnest evidence base, the hardest sourcing, and the only component with cytotoxicity-at-high-concentration concerns. WATCH-LIST means: keep the 3-peptide GLOW subset on the active shortlist for the cubital tunnel + skin protocol (already documented in stacks/cubital-tunnel-cycle.md and stacks/klow-glow-stack.md), but do not run the full 5-peptide KLOW unless skin/gut symptoms escalate to a degree that justifies the LL-37 sourcing/cost overhead. Confidence is MEDIUM because (a) zero clinical trials exist on this specific blend, (b) each component has its own evidence-base limitations (single-lab dominance for BPC-157, sparse human data for KPV/LL-37, gray-market sourcing variability across all 5), and (c) the synergy claim is mechanism-plausible but not RCT-validated. Would upgrade to OPTIONAL-ADD if (a) this user's perioral dermatitis or gut symptoms escalate AND clotrimazole/behavioral fixes fail, (b) the cubital tunnel cycle plateaus on BPC-157 + TB-500 alone and adding GHK-Cu + KPV produces incremental gain. Would downgrade to SKIP-FOR-NOW if behavioral measures resolve cubital tunnel + skin issues without peptide intervention."

Same evidence concerns. For a 20yo with no prostate symptoms, no current case. If prostatic indication develops with age, evidence-stronger options exist (tadalafil, saw palmetto, finasteride).

Genuine clinical signal in fibromyalgia (Younger 2013, 2014), Crohn's disease (Smith 2007, 2011), multiple sclerosis (small open-label studies). Mechanism plausible via TLR4 antagonism + endogenous opioid rebound. Cheap, low-risk, well-tolerated (rare vivid dreams + transient insomnia at start are the main complaints). For Dylan at 20 with no autoimmune/chronic pain indication, no current case. Flips to OPTIONAL-ADD if autoimmune flare or chronic pain context ever emerges — it's an unusually low-cost / low-risk first try.

"Cleaner side-effect profile than MTII (no priapism, much less nausea, no chronic appetite suppression) is the genuine pharmacological advance, and this user's Nordic-ancestry + minimal-sun-exposure phenotype is the textbook user case where MTI's photoprotection rationale is plausible — but the long-term safety question (does stimulating melanogenesis in DNA-damaged or pre-malignant melanocytes increase melanoma risk?) is unresolved at peptide-community doses, the FDA approval is for a narrow orphan indication (EPP) that doesn't map onto cosmetic use, and the gray-market injectable form is structurally distinct from the Scenesse implant (uncontrolled bolus pharmacokinetics vs. 60-day controlled release). For a brain-and-MMA-priority 20yo, this sits in WATCH-LIST: real mechanism, plausible fit, but evidence-of-safety bar isn't met. Verdict shifts to OPTIONAL-ADD if (a) 23andMe shows responsive MC1R genotype, (b) this user establishes dermatology baseline + total-body photography, and (c) he commits to 3-6 month derm follow-up. Verdict shifts to SKIP if 23andMe shows two LOF MC1R variants (mechanistically dead) OR if family history reveals melanoma / FAMMM."

The mechanism is real and well-characterized — Russel Reiter's life work plus replicated oncology and ICU/sepsis adjunct trials establish high-dose melatonin as a legitimate antioxidant + mitochondrial protectant. For this user's specific concern (subconcussive impact load from MMA), the rodent TBI literature is robust and the human-translation evidence is plausibility-tier rather than proven. Verdict is WATCH-LIST rather than STRONG-CANDIDATE because (1) chronic high-dose use in healthy 20-year-old males is essentially unstudied — the pharmacological literature is in cancer patients, ICU patients, and elderly populations where the risk/reward calculus is different; (2) heavy sedation, vivid dreams, and morning grogginess are essentially universal at 20-50+ mg, which conflicts with this user's brain-priority value system; (3) HPG-axis caveats — while clinical evidence in young males at supplement doses is reassuring, the data at 50-300 mg chronic dosing is genuinely thin. **The intermittent post-sparring PRN protocol (20-50 mg HS the night of a hard sparring session, ≤2× per week)** is the rational way to capture mechanism-aligned neuroprotection benefit with minimal chronic exposure. Verdict shifts to OPTIONAL-ADD if a credible TBI / subconcussive-impact human RCT lands positive; shifts toward STRONG-CANDIDATE only in a specific recovery context (post-major-illness, post-significant-head-injury). For chronic daily high-dose, verdict stays WATCH-LIST indefinitely absent better human longitudinal safety data in young adults.

Community protocol curated by Scientific Sean (2026-05-10). Stack rationale is mechanism-coherent but lacks RCT data on the combination itself; component-level evidence varies. Verdict reflects community-validated framing, not blanket endorsement.

Long historical / ceremonial use, low toxicity profile, and emerging clinical interest (Beckley + Journey Colab Phase 2 ongoing). For Dylan at 20 no clinical indication and Schedule I status. Cactus-sourced material is the typical community route — slow brew, intense nausea before peak, then 10-14 h experience. WATCH-LIST mirrors psilocybin verdict.

"Strong longevity rationale in older / pre-diabetic adults (Barzilai TAME thesis), but for a 20yo metabolically healthy MMA athlete the case is weak: blunts exercise-induced mitochondrial biogenesis (Konopka 2019), no glycemic problem to fix, and B12 depletion is real on chronic use. Good compound, wrong stage of life. Reconsider after age 35-40 or if a future bloodwork shows insulin resistance."

"Interesting Russian-pharma compound with a genuinely distinctive mechanism (antioxidant + indirect GABA-A + Complex II bioenergetic support — the succinate arm is unique among nootropics). Russian clinical evidence base is substantial (multi-decade approved use in stroke, anxiety, asthenia, alcohol withdrawal) and the safety profile is excellent (~3-5% AE rate, no dependence, no withdrawal). However: (a) all major human evidence is single-source Russian — open-label or weakly-controlled, (b) zero independent Western RCTs, (c) sourcing is complex (Russian pharmacy import is gray-market; research-chem vendors require COA verification), (d) Western anxiolytic alternatives (Selank, agmatine, ashwagandha) are cleaner for the user's typical use case, (e) the strongest niche (post-stroke neuroprotection, alcohol withdrawal) does not apply to this user. Verdict could shift to OPTIONAL-ADD if the user develops a specific oxidative-stress indication (e.g., heavy chronic stimulant load) or if independent Western evidence emerges."

"Powerful natural L-DOPA source — real effect on dopamine, prolactin, and testosterone (38% T increase in infertile men, 27% in healthy men over 90 days at 5 g/day). However, L-DOPA is a neurotransmitter precursor with the same dyskinesia, on-off phenomena, and receptor-desensitization concerns as pharmaceutical levodopa. Not for daily long-term use. Reasonable short-term (2-4 week) tool for prolactin-suppression / dopaminergic priming with cycling. Cross-reference l-dopa.md and dopamine-precursors discussion."

"Mechanistically the form of NAC that *should* work for brain protection — ~7-30× higher BBB penetration than parent NAC, demonstrably raises brain (not just liver) GSH in animals, theoretical fit-for-purpose for combat-sport subconcussive impact protection. But: (a) no healthy-adult RCTs anywhere — entire human evidence base is case reports + small open-label series in HIV cognition + addiction; (b) decades-shorter safety record than parent NAC; (c) sourcing is gray-market with limited reliable US vendors. WATCH-LIST until either a credible RCT lands, a reputable vendor with third-party COA emerges, or a compelling personal reason exists to swap V4 NAC. Verdict would upgrade to OPTIONAL-ADD if a reliable supplier with batch-verified purity becomes available; would upgrade to STRONG-CANDIDATE if any RCT in healthy adults or athletes confirms the brain-GSH benefit predicted by animal data."

"Sumi 1987 isolation paper and 30+ subsequent in-vitro / animal / human studies establish nattokinase as a real fibrinolytic enzyme with measurable effects on D-dimer, fibrinogen, and clot lysis time after oral dosing — meaningful given the molecule's size (~27.7 kDa) and the historical assumption that large enzymes shouldn't survive gastric digestion. Kim 2008 RCT (PMID 18799232; n=86 mild hypertensives, 8 weeks 2000 FU/day) is the canonical positive blood-pressure trial: ~5.5 mmHg systolic / ~2.8 mmHg diastolic reduction vs. placebo. Hsia 2009 (n=82, 2 months) replicated with additional lipid + fibrinogen improvements. Mechanism case is sound; clinical magnitude is modest (about half of what a single antihypertensive med achieves). The dominant uncertainty is **bleeding risk when stacked with anticoagulants / antiplatelets** — multiple case reports of cerebral hemorrhage in patients combining nattokinase with aspirin, warfarin, or DOACs. For a 20yo MMA athlete with no hypertension, no clot history, intact endothelium, daily impact exposure, and a stack already containing fish oil (mild antiplatelet effect) + occasional NSAIDs around training, **the bleeding-amplification risk dominates the modest cardiovascular-prevention upside.** Verdict: WATCH-LIST not SKIP because the molecule is genuinely interesting and the BP/D-dimer signal is real for older / hypertensive populations; not CONFIRMED because (a) the user has no current cardiovascular indication, (b) the bleeding-stack concern is non-trivial given training profile, and (c) absorption pharmacokinetics remain partially unresolved (oral bioavailability of a 27.7 kDa enzyme is mechanistically suspicious; the clinical signal exists but the route is incompletely characterized). Would upgrade to OPTIONAL-ADD if (a) the user develops hypertension, dyslipidemia, or elevated D-dimer / fibrinogen on bloodwork, (b) the user discontinues fish oil + NSAID overlap, or (c) higher-quality replication trials land confirming D-dimer / clot-lysis effects in healthy adults."

For this archetype (20yo MMA athlete, healthy BP, healthy cardio capacity), nebivolol has no current indication. Documented here because IF hypertension ever develops (family history, post-AAS, post-stimulant load, or just life), nebivolol is the cleanest beta-blocker for an aerobic athlete — the β3-NO arm offsets the traditional cardiac-output / peripheral-cooling penalty of older agents, and the high β1-selectivity preserves bronchodilation, lipolysis, and skeletal-muscle β2 signaling that matter for combat-sport conditioning. Verdict upgrades to PRIMARY-PICK (within the beta-blocker class) at first confirmed sustained BP >130/85 with athletic-load lifestyle, or SECOND-LINE-PICK if a cardioselective-first prescriber starts him on metoprolol. Verdict stays WATCH-LIST while BP and exercise tolerance remain in target ranges.

Community protocol curated by Scientific Sean (2026-05-10). Stack rationale is mechanism-coherent but lacks RCT data on the combination itself; component-level evidence varies. Verdict reflects community-validated framing, not blanket endorsement.

"For combat-sport context subconcussive prophylaxis use case, mechanism is genuinely interesting — L-type Ca²⁺ flux is one of the canonical mechanisms of impact-induced neuronal injury, and nimodipine is the most BBB-selective CCB available — but human evidence in healthy young athletes is essentially zero, the FDA-approved indication (aneurysmal SAH vasospasm) is mechanistically downstream of the same Ca²⁺ pathology in a totally different population, and the head-injury RCTs (HIT-I through HIT-IV) were disappointing despite the clean mechanism. Verdict would upgrade to OPTIONAL-ADD if (a) any positive human RCT in mild TBI / subconcussive impact reads out, (b) sourcing solidifies (US Rx is cheap but supply-disrupted; Indian OTC works but adds friction), or (c) a user in this archetype develops a documented concussion (then nimodipine becomes part of acute post-injury Ca²⁺-buffering protocol alongside cerebrolysin / NBP). For now: real interest signal but premature for V5 inclusion; reassess at V6 review."

For this-archetype, noopept is a credible nootropic with a genuinely interesting mechanism (endogenous-cPG generation, BDNF upregulation, AMPA potentiation) and a strong Russian clinical signal in cognitive impairment populations. But a user in this archetype is already running a Russian-peptide-heavy V5 stack (Semax, Bromantane, Adamax, Selank PRN) that covers the same neurotrophic + cognitive + anxiolytic territory through better-evidenced routes. Noopept's marginal contribution on top of that stack is unclear. Confidence is MEDIUM not HIGH because (a) virtually all human efficacy data is single-source Russian (Ostrovskaya / Zakusov Institute lineage), (b) Western replication is essentially absent, (c) BDNF claims rest on Ostrovskaya animal data with thin healthy-adult human BDNF measurement, (d) the "1000× piracetam" framing is widely misunderstood. Verdict would upgrade to OPTIONAL-ADD if (i) Adamax or Semax fails to deliver subjective benefit and a different-mechanism Russian compound is wanted, or (ii) a user in this archetype wants a sublingual fast-onset option for high-cognitive-demand acute use. Verdict would upgrade to STRONG-CANDIDATE only with independent Western RCT.

Nortadalafil has no upside over the FDA-approved parent (tadalafil) for any user with legitimate access. Tadalafil generic is $0.30-0.80 per 20mg pill via the same Indian pharmacies that sell modafinil — same gray-market sourcing reality, but with 20+ years of safety data, validated PK, and FDA-grade purity. Nortadalafil's only purchase is "research-chem-only sourcing" framing — i.e., scenarios where you genuinely cannot get tadalafil. For a 20yo with telehealth access AND existing Indian-pharmacy supplier relationships, that scenario is hypothetical. Stays on watch-list because the class itself is interesting (the cognitive-flow / vascular hedge is real for tadalafil) and because nortadalafil shows up as an adulterant in counterfeit "natural male enhancement" products — worth knowing how to recognize and avoid. Verdict would change to SKIP-ALWAYS only if FDA escalated to schedule it; would never change to OPTIONAL-ADD because the cleaner alternative dominates.

Hippocampal neurogenesis is theoretically high-value for users in this archetype's brain-priority + MMA subconcussive thesis, and the compound has unusually long human safety exposure (~3 trials, no serious AEs). But TWO independent Phase 2b failures on the primary MADRS endpoint (Neuralstem 2017, Alto 2024) — the second specifically designed to rescue the responder signal via a verbal-memory cognitive biomarker — substantially weaken the "actually does something useful in humans" thesis. Animal hippocampal volume gains did not translate to MRI volume changes in human Phase 1b. Until Alto's Phase 3 (or a re-purposing readout in PTSD/bipolar) reads positive, this is a "wait, don't pay" not a "buy". Would upgrade to OPTIONAL-ADD if (a) Alto Phase 3 hits, (b) credible long-term human neurogenesis biomarker data emerges, or (c) a user in this archetype develops a specific hippocampal-deficit indication (post-concussion verbal memory drop).

Identical compound to noopept.md — verdict, mechanism, dosing, sourcing, and full analysis live there. This file exists for searchability under the INN name "omberacetam" used by some Western and pep-pedia-style sources.

Same Khavinson pattern + naming confusion that undermines confidence in the framework. WATCH-LIST. Not relevant to male archetype.

"Robust preclinical (rodent AD/TBI/aging) data on neurogenesis + cognitive rescue, plus mechanistic appeal to this user's brain-priority thesis (BDNF axis, anti-amyloid, hippocampal). However: human evidence is essentially absent (Phase 1 safety only), gray-market sourcing is variable, and Cerebrolysin already covers the same neurotrophic-mimetic space with decades of human RCT data. Would upgrade to OPTIONAL-ADD if (a) Phase 2 human data reads out positive, (b) reliable QC'd vendor channel emerges, (c) this user accumulates subjective signal that Cerebrolysin alone leaves gaps in."

Same Khavinson pattern. For glucose/metabolic indications, metformin + lifestyle have orders-of-magnitude more evidence. WATCH-LIST.

"Mechanism is genuinely novel and well-characterized at the preclinical level — TREK-1 blockade is the most robustly validated rapid-antidepressant target outside of ketamine/NMDA, and the Mazella lab's mouse data is internally consistent across forced swim, tail suspension, and chronic social defeat models. **But there are zero published human trials of PE-22-28 (or any spadin analog) as of May 2026.** No human PK, no human dosing, no human safety, no human efficacy, no human anything. For this user — 20yo, no diagnosed depression, brain-priority profile — there is no use case that justifies experimental peptide self-administration when the mechanism only matters in clinical depression, the Mazella data has not been independently replicated outside the originating lab, and far better-evidenced mood tools (selank for anxiety, agomelatine for circadian-mood combo, bupropion if anhedonia ever emerges) cover any plausible relevant-to-archetype indication with orders of magnitude more safety data. Verdict would shift only on (a) at least one peer-reviewed Phase 1 human PK/safety study, (b) this user developing treatment-resistant depression (extremely unlikely given current presentation), or (c) independent replication of Mazella mouse data by a non-Nice group. Until then: watch the literature, do not order."

Track Phase 3 readouts. Same class as retatrutide / survodutide / mazdutide — multi-receptor incretin agonists with substantial obesity + metabolic effect. For Dylan at 20 with normal body composition, no current case. Worth knowing because this class is becoming the third generation of GLP-1-family drugs (Wegovy → Mounjaro/Zepbound → multi-agonist).

"Re-evaluated from prior SKIP-FOR-NOW after user surfaced an external longevity-protocol claim of \"Phase 3 receptor priming.\" Honest assessment: mechanism class is interesting (epigenetic / DNA-binding tripeptide), some legitimate in vitro neuroprotection signal (oxidative stress, dendritic spine preservation in 5xFAD-M mouse model), one small Russian human TBI/cerebrasthenia trial (n=72, oral 0.4 mg/d × 20-30 d). But ALL evidence still originates from Khavinson's group, no independent Western replication, no ClinicalTrials.gov registry entries, and the \"receptor-priming\" / \"Phase 3 prime\" claim from external longevity protocols is an inferential leap from in vitro signaling work — it has not been demonstrated clinically. Move to OPTIONAL-ADD only if (a) a user in this archetype is already running an Epithalon longevity cycle, (b) bloodwork is clean, (c) cost is trivial relative to other priorities. Otherwise Cerebrolysin + Semax + Adamax already cover the brain-protective peptide role with multi-source evidence."

Promising preclinical signal (BDNF/NGF upregulation, AChE inhibition similar to but milder than huperzine A) but human RCT evidence is sparse and largely from Korean BT-11 trials in dementia cohorts. Subjective reports are mixed: some users report dream vividness + memory-recall boost, others report nausea + anxiety. Glycine-NMDA partial modulation is the most interesting mechanism for cognitive plasticity but is not well-mapped pharmacokinetically in humans. Verdict flips to OPTIONAL-ADD if Korean BT-11 dementia RCTs replicate at standard supplement dose, or if a clean self-experiment shows reliable recall improvement without GI side effects. Stays at WATCH-LIST otherwise because [[lions-mane]] + [[bacopa-monnieri]] cover similar ground with better human data.

"Novel, mechanism-distinct hair-loss therapy with very early but encouraging clinical signal: Phase 1 (n small, 7-day Ki67 PoM) showed statistically significant stem-cell activation; Phase 2a (NCT06393452, n=78, 4-week treatment + 12-week follow-up) showed 31% of men with higher-degree hair loss had >20% density increase at week 8 vs 0% placebo, with terminal hair emerging from previously bald regions — a qualitatively different signal from minoxidil's anagen prolongation. Mechanism (MPC inhibition driving lactate-mediated HFSC activation) is anchored in the Flores/Lowry/Christofk 2017 Nature Cell Biology paper that demonstrated genetic Mpc1 knockout and topical UK-5099 both accelerate hair cycle in mice. Topical-only formulation with undetectable systemic absorption compartmentalizes the metabolic intervention to scalp. Could be transformative IF Phase 3 validates: it would be the first AGA drug with a new mechanism of action in 20+ years (since finasteride 1997). Confidence is HIGH on \"watch list\" classification (not on the verdict that it works) — the verdict that PP-405 will deliver on Phase 3 endpoints remains genuinely open. Sourcing is realistic only via clinical trial enrollment; gray-market access is unreliable (structure undisclosed, vendors selling JXL069 mislabeled). Would upgrade to STRONG-CANDIDATE on Phase 3 success + FDA approval; would downgrade to OPTIONAL-ADD or SKIP if Phase 3 fails or unforeseen safety signals emerge from longer-duration use. For 20yo MMA athlete archetype with no current AGA: not actionable now — track development through 2027-2029 approval window."

Encyclopedia entry because Dylan WILL encounter this at some point (injury, asthma flare, autoimmune workup, allergic reaction, dental work). Short courses (<14 days, "burst dose") are very low-risk and standard-of-care for many indications — including post-injury inflammation in combat sport. Chronic use is where the harm sits (HPA suppression, osteoporosis, diabetes, infection, cataracts, weight gain, mood disturbance). WADA in-competition ban means a Medrol Dosepak after a fight injury has a washout requirement. Verdict WATCH-LIST: not preventive, not biohacking, but know it, know the WADA washout, know not to take it longer than the indication requires.

Interesting upstream lever but conversion direction (androgen vs estrogen vs glucocorticoid arm) is highly variable per user and tissue. Real signal exists in clinical populations (schizophrenia adjunct, PTSD, bipolar depression) at 100-500 mg/day. OTC cognitive claims at 5-50 mg/day are mechanistically plausible but evidence in healthy young adults is thin. For a 20yo with peak endogenous output, supplementation is hormonally redundant and conversion direction can't be reliably steered without bloodwork. Hold for bloodwork-driven candidacy only.

Genuine plasticity tool with replicated human RCT signal for depression and end-of-life anxiety (Carhart-Harris 2021, Davis 2021, Goodwin 2022 COMP360 trial). Not for chronic daily use. The case for healthy-user microdosing is much weaker — Cameron 2020 + de Wit 2022 placebo-controlled trials found null effects on mood, cognition, creativity at microdose. Macrodose ("journey dose", 2-3.5 g dried mushrooms / 20-30 mg psilocybin) is where the published benefit sits. Verdict: WATCH-LIST for Dylan — not a fit for a 20yo with no depression/anxiety/PTSD indication, but worth knowing the mechanism and tracking the COMP360 + Usona Phase 3 readouts. Flips to OPTIONAL-ADD only with (a) documented indication, (b) screened psychiatric history (no personal/family bipolar or psychosis), (c) trip done in supported setting, (d) integration plan. Schedule I status means any non-clinical-trial use is felony possession in most jurisdictions.

Situational-use compound — FDA-approved 2019 (Vyleesi, premenopausal HSDD) with strong RCT evidence (Kingsberg 2019 RECONNECT trials, PMID 31509541); off-label ED use is reasonable for situational sexual dysfunction, especially PDE5-non-responsive or psychogenic patterns. For users in this archetype (20yo MMA athlete with peak HPG-axis function, no reported sexual dysfunction), no current indication exists — verdict is WATCH-LIST rather than STRONG-CANDIDATE because PT-141's mechanism (central arousal signal generation) requires a deficit to remediate, and adding it to an intact baseline produces side effects (nausea ~25-40%, flushing, transient BP) without a clear benefit ceiling. Documented as the FDA-approved cleaner cousin of MTII to keep on the watch list for situational scenarios — verdict shifts to OPTIONAL-PRN if the user develops post-SSRI sexual dysfunction, situational psychogenic erectile difficulty with persistent distress, or vascular ED non-responsive to PDE5i at any future age. Verdict shifts to STRONG-CANDIDATE in the alternate universe where a user is a postmenopausal woman with HSDD or a 50+ male with vascular ED unresponsive to sildenafil/tadalafil.

Genuinely interesting — topical AR antagonists are the cleanest theoretical answer to MPB if they work (local effect, no systemic DHT change, no PFS risk in theory). Kintor's KX-826 Phase 2 MPB readout (2022) was mixed — primary endpoint not unambiguously met in some arms, hair count improvement was real but smaller than expected. Phase 3 ongoing. For a 20yo without MPB, nothing to evaluate. Flips to STRONG-CANDIDATE if Phase 3 reads cleanly positive AND a verified-COA source becomes available. Current research-chem supply is the same opaque channel as the rest of the gray-market hair compounds — identity, concentration, and purity not verifiable without LC-MS.

"Well-tolerated, low-risk botanical with the strongest replicated SSRI-comparable mood signal in the supplement literature. Three independent meta-analyses (Hausenblas 2013, Lopresti & Drummond 2014, Tóth 2019) show non-inferiority vs fluoxetine 20-40 mg/day and imipramine 100 mg/day in mild-to-moderate MDD at 28-30 mg/day standardized extract. Secondary signals for PMS (Agha-Hosseini 2008), SSRI-induced sexual dysfunction (Modabbernia 2012, Kashani 2013), MCI/AD (Akhondzadeh 2010 x2), pediatric ADHD (Baziar 2019), age-related macular degeneration (Falsini 2010), and sleep quality (Lopresti 2020). NOT a replacement for prescribed antidepressants in clinical MDD — saffron sits as a first-lever-to-try for subclinical low mood, an adjunct under clinician oversight for diagnosed depression, or a sexual-side-effect rescue for SSRI users. For this user (20yo MMA + business owner, no current mood/anxiety diagnosis, rhodiola + ashwagandha already covering the adaptogen layer), saffron is WATCH-LIST: low risk, modest signal, would consider if subjective baseline mood drifts and existing adaptogens are insufficient. Sourcing is easy (affron / Satiereal widely available); cost moderate ($15-30/month at affron 28 mg/day). Adulteration with safflower, marigold, or turmeric is rampant in the spice and bulk-supplement market — third-party-tested standardized extract is mandatory."

Genuinely novel mechanism with single ex vivo paper from a reputable hair lab. No human in vivo RCT yet. Cosmetic formulations marketed for hair growth (Crown Affair, Giuliani Bioscalin Triactive, etc.) use sandalore as an ingredient but with no controlled efficacy data. For Dylan with no MPB, no current case. Worth tracking — if a clean human in vivo study replicates the ex vivo signal, this becomes a fourth-mechanism adjunct to consider stacking with minoxidil + topical fin.

Same Khavinson-class concerns. Cartilage target is interesting for combat-sport injury context but standard tools (BPC-157, glucosamine + chondroitin, MSM, type II collagen, properly-loaded rehab) have better evidence. WATCH-LIST.

Community protocol curated by Scientific Sean (2026-05-10). Stack rationale is mechanism-coherent but lacks RCT data on the combination itself; component-level evidence varies. Verdict reflects community-validated framing, not blanket endorsement.

"Mechanistically interesting — a Wnt activator is a credible new lever for AGA, distinct from the existing minoxidil + 5αRI canon, and Phase 2 produced a real (if modest) signal at the 0.15% concentration with the unexpected pattern of *continued* gains during washout. But (a) Phase 3 results have never been publicly disclosed and Biosplice removed the asset from active pipeline, the strongest possible negative read in commercial pharma, (b) the inverted dose-response (0.15% > 0.25%) was concerning and never explained, (c) the sister Wnt-pathway program lorecivivint (SM04690) for knee OA also failed Phase 3 — platform-credibility hit, (d) for users in this archetype: no MPB at 20 with intact HPG axis, so there is no substrate for any AGA drug (same logic as minoxidil/finasteride for this user). Watch-list because the mechanism is interesting and a successful re-licensee or successor compound (PP-405 in particular is a different angle on the \"wake stem cells\" thesis) would be relevant if MPB ever appears, but as currently constituted SM-04554 is a failed trial drug with no commercial path. Do not self-trial — research-chem topical applied at random vehicle concentration is dosing for nothing."

Community protocol curated by Scientific Sean (2026-05-10). Stack rationale is mechanism-coherent but lacks RCT data on the combination itself; component-level evidence varies. Verdict reflects community-validated framing, not blanket endorsement.

Re-eval lift from prior SKIP — 2024-2025 data is genuinely interesting (SHARP cognitive trial in OSA, FOCUS Phase 3 ADHD success, NEJM Evidence shift work data), and 71% real-world preference over modafinil/armodafinil among switchers is a meaningful signal. But this user's PRIMARY-PICK is modafinil at $0.50-1.50/pill gray-market vs solriamfetol at $1,100-1,200/mo brand-only with no generic until ≥2031, and the BP-elevation profile is real (more pronounced than modafinil). Verdict would shift to STRONG-CANDIDATE if a user in this archetype develops modafinil intolerance (rash, headache, anxiety) AND can secure US Rx via sleep specialist; would shift to OPTIONAL-ADD if FOCUS-style ADHD data replicates or off-label prescribing pathway opens.

Community protocol curated by Scientific Sean (2026-05-10). Stack rationale is mechanism-coherent but lacks RCT data on the combination itself; component-level evidence varies. Verdict reflects community-validated framing, not blanket endorsement.

Striking rodent potency story but zero modern human trials, no GMP supply, and reports of seizures/headaches at higher doses. The mechanism overlap with TAK-653 makes the clinical-stage compound the safer way to chase the same effect. Would upgrade to OPTIONAL-ADD only if (a) a human dose-finding trial appears, (b) a vendor with verified COAs emerges, and (c) the seizure question is resolved.

Same evidence concerns. For pancreatic exocrine insufficiency, real prescription enzyme products (Creon, Zenpep) are the standard of care. For general "metabolic" use case, no current indication.

Same evidence concerns. For hepatoprotection / regeneration, TUDCA + milk thistle + NAC have better evidence and clearer mechanism. WATCH-LIST.

"Powerful weight-loss tool — TIPO-1 (Astrup 2008, Lancet, PMID 18815042) showed dose-dependent ~10.6% placebo-subtracted weight loss at 1 mg/day over 24 weeks, the largest oral non-injectable obesity signal on record. Mexico approval as Tesomet (tesofensine + metoprolol, 2024) legitimizes the molecule for chronic obesity. BUT: not FDA-approved, real cardiovascular signal (HR + BP elevation) derailed FDA pursuit, and the user has no relevant indication — he's a 20yo MMA athlete at competition weight, lean (185–190 lb), brain-dev concerned, zero-caffeine baseline. A long-half-life (~9 day) DAT/NET stimulant with cardiovascular load opposing aerobic training, sleep-disruption opposing recovery, appetite-suppression opposing 3,000–4,500 kcal/day MMA fueling, and likely WADA S6 in-competition stimulant-class scrutiny is the wrong drug for the wrong problem. WATCH-LIST (not SKIP-PERMANENT) because the molecule is genuinely interesting and Mexico's regulated-market approval is a real signal worth tracking. Verdict would shift toward OPTIONAL-ADD only if (a) user's body comp goals shift toward serious cut for sanctioned competition weight class, (b) post-MMA-career weight gain produces a real obesity indication, or (c) US FDA approval lands with better-characterized cardiovascular safety profile."

Interesting "anti-munchies" CB1 antagonist with metabolic benefits in Phase 2 obesity + T2D trials. Now widely available in vape + edible products from cannabis dispensaries; concentration in commercial product varies enormously. For Dylan with no metabolic indication, no current case. Worth knowing because: (a) the appetite-suppressant cannabinoid niche could become a real product class, (b) novel CB1-antagonist mechanism distinct from rimonabant (which was withdrawn for depression/suicide signal) since THCV partial agonism may avoid that.

Russian-only RCT base claiming immune restoration in immunodeficient + post-surgical + chronic infection cohorts. Western pharmacology has not replicated. Common pattern: methodology + blinding insufficient to assess; mechanism plausible but not characterized at Western evidence standards. For Dylan with intact immune system + no specific indication, no current case. WATCH-LIST as part of the Khavinson catalog for encyclopedia depth.

"Tα1 has the cleanest safety record of any immune-modulating peptide in this research base (>11,000 patients studied across 30+ trials, <1% serious adverse events, approved in 35+ countries for 30+ years), so the floor on harm is low. Confidence is MEDIUM-HIGH because: (a) for the indications it's approved for — chronic HBV, chronic HCV non-responder adjunct, sepsis-ICU adjunct, chemotherapy immune support, primary immunodeficiency — the evidence is A-tier, multi-decade, multi-country, FDA-orphan-designated; (b) for users in this archetype's actual likely use case — heavy-training-block immune support + acute illness recovery — the evidence is mostly **mechanistic extrapolation from approved indications + Castell-style post-marathon URTI immune-dip literature + peptide-clinic anecdote**, not direct sport-medicine RCT. Verdict is WATCH-LIST not STRONG-CANDIDATE because a user in this archetype is a healthy 20yo with intact immune function — the marginal benefit is small in the absence of an active immune challenge. PRN-during-illness use is the highest-leverage application; reasonable to keep a vial on hand for cold/flu season or post-illness convalescence. Verdict would upgrade to OPTIONAL-ADD if a user in this archetype develops chronic post-training URTI pattern (>3 colds in 3 months), gets an acute moderate-to-severe illness needing recovery support, or has a competition prep block where any immune dip is high-cost. Would upgrade further to STRONG-CANDIDATE if a sport-medicine immune-support RCT in trained athletes reads positive. Verdict would downgrade to SKIP-FOR-NOW only if a major safety signal emerged (none currently in 30 years of clinical use)."

"Thymulin is mechanistically elegant — endogenous thymic nonapeptide, zinc-dependent activation, cholinergic anti-inflammatory action via α7-nAChR potentiation, broad NF-κB/p38 inhibition, no toxicity at high doses in animal models — but the **clinical development gap vs Thymosin Alpha 1 is decisive**. Confidence is LOW-MEDIUM because: (a) the **A-tier human evidence base is essentially absent** — most data is rat, mouse, and cell culture; the few human-relevant trials are small French and Argentinian work in age-related immune decline and neonatal immunology from the 1980s-2000s, never replicated at modern scale; (b) thymulin requires zinc to function, so any \"thymulin response\" is partially conflated with zinc-status response — the marginal benefit over zinc supplementation alone is genuinely unclear; (c) the active analog PAT (thymulin-related peptide) carries most of the recent rat-pain-model literature, not native thymulin, so even the preclinical case is thinner than it appears; (d) sister peptide Thymosin Alpha 1 has 30+ years of clinical development, 35+ country approval, >11,000-patient safety dataset, and an FDA orphan drug designation — for any immune-modulation use case this user might have, **Tα1 is the dominant choice with strictly more evidence**. Verdict is WATCH-LIST low priority not OPTIONAL-ADD because this-archetype healthy 20yo MMA athlete has no compelling indication where thymulin out-competes Tα1, zinc + Vit D adequacy, or simple sleep + recovery. Verdict would upgrade to OPTIONAL-ADD only in narrow scenarios: (1) a documented zinc-thymulin axis deficiency on testing (rare and not a routine clinical lab), (2) a chronic neuropathic pain indication where the α7-nAChR + spinal microglial mechanism becomes uniquely relevant, or (3) a future replicated human RCT that closes the evidence gap. Verdict downgrades to SKIP if a safety signal emerges (none currently, but the safety dataset is small enough that a moderate negative finding is plausible). For this user: **track the literature; don't buy or inject.**"

"Topilutamide (fluridil / Eucapil) is the most clinically validated topical AR antagonist for AGA — it has actual decades-long commercial use in Czech Republic and Slovakia, a published double-blind placebo-controlled trial (Sovak 2002, J Am Acad Dermatol — pmid 12174057) showing safety, no systemic absorption, and AGA hair-count benefit, and a designed-for-local-use breakdown profile that is more pharmacokinetically explicit than RU58841's. For a 20-year-old in this archetype with no documented MPB and an intact HPG axis, there is zero current indication, so this is treatment for a problem not yet present. Verdict moves to OPTIONAL-ADD if any visible miniaturization appears (Hamilton-Norwood II+, photographic confirmation over 6-12 months) and the user wants a topical-only option, in which case topilutamide is arguably the first topical AR antagonist to consider — ahead of RU58841 — because of better-published human data and a more conservative absorption design. The Pyri community reference in the user's framing actually points to KX-826 (pyrilutamide), a related but distinct Kintor Pharmaceutical compound whose Chinese Phase 3 program reported disappointing primary-endpoint readouts in 2023-2024 — this is a watch-out for any topical AR antagonist optimism but does not directly retire topilutamide/fluridil itself, which is a different molecule with its own (modest, short, but supportive) clinical record."

Genuinely interesting α7 nAChR partial-agonist mechanism with PET-confirmed CNS occupancy at clinical doses (Hashimoto 2013) and a positive schizophrenia-adjunct trial improving P50 sensory gating and cognition (Shiina 2010, Zhang 2012); but healthy-young-adult cognitive evidence is essentially nonexistent (one PET binding study, no efficacy RCT in healthy adults), the α7 PAM/agonist class as a whole has been deeply scarred by encenicline's phase III failure for AD/schizophrenia cognition (forte trials, 2014-2016), 2014 EMA dose reduction post-arrhythmia signal, US sourcing is research-chem-only with quality risk, and this user's existing cholinergic stack (citicoline + planned alpha-GPC + planned ALCAR) covers the substrate side of α7 signaling at far lower regulatory and side-effect cost. Verdict shifts to OPTIONAL-ADD if (a) post-23andMe this user turns out to be a CYP2D6 normal/extensive metabolizer AND (b) emerging healthy-adult α7 PAM cognitive data firms up in 2026-2028 (TAK-071, ACD-856, or follow-on tropisetron healthy-volunteer work).

Same Khavinson-class evidence concerns — Russian preclinical + small clinical series only, no Western replication. The vascular-endothelium target is theoretically interesting for longevity but the oral tripeptide is destroyed by gut peptidases in any meaningful percentage. Even the injectable form has uncharacterized PK. For Dylan with intact endothelium, no current case.

Same evidence pattern as thymogen — Russian-only data, immune-restoration claim, no Western replication. For Dylan with no immune indication, no current case.

Cognitive enhancement claims (FOCUS DSST, CONNECT vs duloxetine) are real and replicated in MDD with cognitive symptoms — the strongest pro-cognitive signal of any modern antidepressant. But the validated indication is MDD with cognitive complaints, not "off-label nootropic for healthy 20-year-olds." For a 20yo MMA athlete + business owner with no MDD diagnosis, this is NOT a nootropic — the cognitive signal is the residual effect of treating depression-linked cognitive dysfunction, not a clean enhancement in healthy controls. Would consider STRONG-CANDIDATE only if (a) a future clinical episode of MDD develops where cognitive complaints dominate the presentation (DSST drop, executive dysfunction, "depressive pseudo-dementia" pattern), (b) cleaner SSRIs (escitalopram, sertraline) have been tried and either failed or caused unacceptable sexual dysfunction, and (c) prescriber agrees vortioxetine's cognitive-symptom data is the relevant tiebreaker. Sexual dysfunction profile is genuinely better than SSRIs (5-HT7 antagonism + reduced SERT-saturation), which matters for an athlete archetype, but again — not a reason to take it absent indication. Nausea (5-HT3 antagonism) is the dominant side effect; long half-life (~66 hours) is forgiving.

"Yohimbine is a real pharmacological tool with a narrow, situational use case — fasted-state pre-cardio fat oxidation in already-lean lifters trying to mobilize the last 1-3% body fat in an α2-rich depot. The McCarty 2002 mechanism + Galitzky 1988 + Ostojic 2006 (lean soccer players) literature supports the use. BUT — this user is a 20yo MMA athlete with a brain-priority frame, anxiety-baseline that's modest but trackable, and a chronotype migration in progress. Yohimbine's anxiogenic ceiling is sharp and dose-dependent (Charney 1984: it is *literally the lab panic-challenge agent*); it stacks badly with caffeine and modafinil; CYP2D6 substrate status means plasma levels are unpredictable until 23andMe lands (~June 2026). The fat-loss case for a 20yo combat athlete who is *already lean and already doing fasted morning cardio* is weak — the marginal body-comp benefit is small and the anxiety + sleep + cardiovascular costs are not worth it in a brain-priority frame. Verdict reopens narrowly to OPTIONAL ADD if (a) a specific contest cut requires last-3% mobilization, (b) CYP2D6 phenotype is normal/extensive (not PM), (c) anxiety baseline is low, (d) total caffeine/sympathomimetic load that day is zero."

Banned in supplements by FDA since 2013 because it caused multiple deaths (military service members on training runs in Afghanistan 2011, gym-going civilians 2011-2013, hemorrhagic stroke + MI + hypertensive crisis case reports). Not a "this is risky but might be worth it" compound — it is a "documented to kill people in pre-workout doses" compound, with no medical indication and no athletic advantage that ephedrine or caffeine + paraxanthine + phenylpiracetam cannot match more cleanly. WADA-banned (drug-tested fighters, never). For a 20yo MMA athlete + business owner this is one of the few hard NO compounds in the entire encyclopedia. Verdict will not flip without (a) a clean reformulation under medical supervision, which is not on the horizon, and (b) a clinical indication, which does not exist for DMAA. The cleaner positional isomer 1,4-DMAA (also banned 2017) and the post-DMAA replacement DMHA (warned by FDA 2019) both inherit the same problem.

Same drug-tested ban exposure as 1,3-DMAA (WADA S6 covers structural analogs); FDA-illegal in supplements; sourcing reliability is **worse than 1,3-DMAA** because the molecule has no pharmaceutical pedigree, was first identified by analytical chemists *in finished pre-workouts* in 2017 as a banned-substance dodge by labs evading DMAA enforcement, and dose-per-serving in caught products ranged 21–94 mg — a >4× spread that confirms there is no good-manufacturing-practice path. There is zero published human PK or efficacy data for the 1,4 isomer specifically. For a 20yo MMA athlete pursuing competitive licensure, this is a hard skip on doping-policy grounds alone; the safety profile is even less characterized than parent 1,3-DMAA's already-thin record.

For this user, L-tryptophan is the strictly better choice — it preserves the TPH/IDO regulatory bottleneck that quality-controls serotonin synthesis, while 5-HTP overrides it and produces serotonin disproportionately in the periphery (GI, cardiovascular). 5-HTP's only real advantage is faster onset, and that gain is modest. Would shift to OPTIONAL-ADD only in a context where TPH/IDO is genuinely blunted (e.g., chronic high-CRP inflammation diverting tryptophan to kynurenines, or documented TPH2 loss-of-function variant) and a clinician is using 5-HTP tactically rather than chronically.

Genuinely useful for altitude prophylaxis (Everest base camp, etc.) where it cuts AMS risk substantially. No relevance for a sea-level combat athlete. WADA-banned without TUE. SKIP-FOR-NOW unless altitude exposure planned with TUE pathway available.

Elite-sport injectable recovery tool with a long Russian + German + Italian football medicine track record but no clean Western RCT signal — Cochrane reviews of actovegin in stroke and PAD consistently come back "insufficient evidence." Hamstring injury return-to-play data (Lee 2014, Pfister 2010, Wright-Carpenter 2004) is the strongest sports-medicine signal, all retrospective or small-N. Injection-volume WADA limit (50 mL) is the practical constraint for elite athletes. For Dylan in combat sport with no specific injury context, no current case. Even with injury, BPC-157 + TB-500 + standard recovery protocols are better-documented in his archetype. Flips to WATCH-LIST if a hamstring/muscle injury appears and standard care is inadequate.

Re-research confirms ZERO peer-reviewed human or animal Adamax-specific studies exist (only inferences from Semax + P21 parents). Vendor copy contains material structural and historical contradictions. For this user's brain-priority profile, NA-Semax-Amidate covers the same use-case with vastly better evidence and identity-verifiable supply chain. Adamax becomes STRONG-CANDIDATE only if (a) a vendor produces a public batch-specific HPLC + MS COA matching the canonical sequence AND (b) a user in this archetype has run a clean 4-week NA-Semax-Amidate baseline first.

For this user specifically (20yo, brain-priority, MMA athlete, no clinical ADHD diagnosis) the brain-development concerns + appetite suppression + dependence trajectory + lack of healthy-adult cognitive enhancement evidence make modafinil the cleaner pick. Verdict would flip to STRONG-CANDIDATE with a clinical ADHD diagnosis, or CONSIDER if modafinil + bromantane stack fails to deliver cognitive output after a fair trial.

A-tier rodent disease-modification data (cognitive deficits + amyloid + tau + neuroinflammation reverted, effect persisted 5 wk post-washout) is mechanistically exciting, BUT (a) zero clinical efficacy data in any cognitive-decline indication, (b) the sister sigma-1-only compound blarcamesine (ANAVEX 2-73) just had its EMA application recommended for refusal Dec 11 2025 — meaningful negative signal for the platform, (c) Phase 2 schizophrenia readout Oct 2025 was a safety primary endpoint with only "encouraging trends" on biomarkers, no efficacy hit, (d) human PK shows a 3.5-hr half-life that argues against simple translation of the rodent pulsed-dosing → 5-week-persistent-effect protocol, (e) research-chem availability is real (MCE, TargetMol) but priced for academic milligram screens, with no community dose, no community subjective base, no COA-verified human-grade vendor. Mechanism interesting; translation thin. Would upgrade to WATCH-LIST → OPTIONAL-ADD if (1) FTD orphan trial reads positive on cognition, or (2) Anavex's own M1-PAM thesis survives the blarcamesine EMA refusal and the sigma-1-platform stops looking like a stumble, or (3) a credible second-source replicates the rat 5-wk-persistence finding.

Beautiful mechanism, ugly drug. (1) Oral bioavailability is near-zero → must be injected for activity. (2) Half-life ~1-2h means it requires impractical dosing schedules to mimic the rodent endurance protocol. (3) Most "AICAR" sold as research chem is unconfirmed peptide-supplier material with no third-party COA — same supply chain as the worst of the AAS gray market. (4) WADA-banned, so anyone competition-tested is out. (5) The endurance benefit in the Narkar study was at doses that scale to grams per day in humans, well above any practical "biohacking" use. Reasonable alternatives that target the same AMPK pathway with vastly better risk profile: metformin, berberine, exercise, fasting. Verdict flips to WATCH-LIST only if (a) a real oral prodrug becomes available (the GP531 / acadesine pulmonary-hypertension trials hinted at one), or (b) Dylan moves to a non-tested ultra-endurance context with documented sourcing. Stays SKIP-FOR-NOW now.

Long European track record (Pantostin marketed since 1980s). Hoffmann 2002 showed modest hair density improvement vs vehicle. Smaller effect size than minoxidil or finasteride and less data than either. For a 20yo with no MPB, nothing to evaluate. Could be an OPTIONAL-ADD alongside minoxidil in early MPB for someone unwilling to risk oral fin — but topical fin and KX-826/ru58841 have better mechanism-to-evidence ratio.

'For a 20yo MMA athlete + business owner with no diagnosed panic disorder or GAD, no seizure history, brain-priority + reaction-time goals, and zero indication, alprazolam is the worst chronic-use choice in the benzodiazepine class — it has the highest dependence/abuse liability among common benzos due to the combination of fast onset (30-60 min), short half-life (~11 hours), strong inter-dose rebound anxiety (the dependence-loop substrate), pronounced euphoria-on-rapid-rise, and the 2020s street-supply reality where pressed counterfeit "Xanax bars" are the single most common fentanyl-contaminated benzodiazepine in the US drug supply (DEA, CDC, multiple coroner-data reports 2018-2024). Cleaner, non-dependence-forming tools cover every plausible use case for this archetype: propranolol 10-40 mg PO 1 hour pre-event for somatic / performance anxiety (pre-fight, pre-presentation), buspirone for chronic GAD-pattern anxiety (5-HT1A partial agonist, no dependence), L-theanine 200-400 mg for low-grade situational anxiety (OTC, no dependence), CBT and exercise for behavioral baseline. Verdict-change conditions: would only flip to PRN-UNDER-PRESCRIBER if a true panic disorder diagnosis emerges with documented failure of SSRI/SNRI/buspirone/CBT/propranolol — and even then the prudent prescriber-led choice within the class is clonazepam or diazepam (longer half-life, less inter-dose rebound, easier taper), not alprazolam.'

"SKIP-AT-20 with maximum confidence for a 20-year-old MMA athlete + business owner. Anadrol is the worst-fit AAS in the entire SKIP-AT-20 cluster for this archetype because (1) it produces the most severe hepatotoxicity of any commonly-used oral AAS — the Hengge/Schroeder 2003 Phase 3 trial documented that 27-35% of subjects on 100-150 mg/day developed ALT elevation >5× ULN within 16 weeks, and case series document peliosis hepatis, hepatic adenoma, and hepatocellular carcinoma in chronic users; (2) its paradoxical estrogenicity (gynecomastia + water retention despite zero aromatization) means standard AI-based estrogen management fails — only SERMs (tamoxifen, raloxifene) work, and the gyno risk is among the highest of any AAS; (3) the cardiovascular load is severe — HDL crashes 50-80% within weeks, BP rises sharply, hematocrit can exceed 55%, and the combination produces a meaningful acute MI/stroke risk profile poorly suited to MMA training cardiac demands; (4) for an MMA athlete with peak endogenous testosterone (~600-900 ng/dL at age 20), no documented hypogonadism, and a multi-decade competitive arc ahead, the post-cycle hypogonadism + persistent hypothalamic-pituitary-testicular dysfunction risk (Rasmussen 2016) trades 4-6 weeks of supraphysiologic mass for years of recovery; (5) Anadrol shows up on every WADA, USADA, IBJJF, NCAA, and most state athletic commission tested-list — career-ending for any tested combat athlete. Verdict reverses ONLY for the same medical indication clusters that justify ANY 17αAA — severe AIDS-wasting cachexia, severe aplastic anemia, Fanconi anemia, severe burn (>40% TBSA) — none of which apply. There is no recreational, performance, or aesthetic use case under which Anadrol is the right tool for this archetype: oxandrolone (Anavar) has a substantially milder hepatic profile for cutting; methandrostenolone (Dianabol) provides similar mass with somewhat lower per-mg liver hit; injectable testosterone esters dominate for foundational anabolic effect at a fraction of the hepatic burden. Anadrol's only competitive niche is \"fastest oral mass + strength gain in 4-6 weeks\" — and that niche is dominated by other tools at every other axis. Verdict applies universally for under-25 brain-priority athletes; would not change with V4/V5 stack optimization, genetics results, or training context."

For a 20-year-old eugonadal male with intact HPG axis, no AAS, no TRT, no documented high E2, no gynecomastia, and combat-sport training load — arimistane has zero indication and a portfolio of avoidable downside. Three independent reasons stack to HIGH-confidence skip. (1) **No indication — same logic as anastrozole/exemestane** — crashing E2 in a young man whose E2 is supporting bone density, joint health, libido, mood, and recovery is iatrogenic injury, not optimization. (2) **Weak evidence base for arimistane specifically** — unlike anastrozole (ATAC, MA.27, decades of RCTs) and exemestane (TEAM, IES, also RCT-supported), arimistane has essentially no published RCT evidence of efficacy or safety in humans. The "evidence" is bodybuilding-forum case reports, vendor copy, and mechanistic extrapolation from exemestane. PK in humans is poorly characterized, half-life is uncertain, dose-response is unestablished. (3) **Supplement-grade quality is unverified** — OTC arimistane is sold by "designer supplement" vendors with the same long-tail QC problems as any pro-hormone-adjacent product — no FDA oversight of identity, potency, or contamination. Verdict shifts to WATCH-LIST only contingent on TRT or AAS use (not on roadmap) AND an unwillingness or inability to access pharma-grade exemestane (which dominates arimistane on every axis — same mechanism, RCT-validated, pharma-grade purity, identifiable PK).

For this user specifically (20yo MMA athlete with no cardiovascular risk factors, no prior CV event, no diabetes, no inflammatory condition requiring chronic NSAID), aspirin offers no net benefit. The 2018 ARRIVE/ASPREE/ASCEND trial trio + 2022 USPSTF update collectively dismantled the routine "take baby aspirin for prevention" advice for low-risk primary prevention — bleeding harm matches or exceeds CV/cancer benefit in this risk stratum. Cancer chemoprevention signal exists (Rothwell colorectal) but requires 5-10 years of daily exposure to manifest, and current USPSTF judges it insufficient for routine recommendation in healthy young adults. Antiplatelet effect (10-day duration) is actively counterproductive for a combat sports athlete who routinely sustains microtrauma + risks ocular/intracranial bleeding. Verdict flips to OPTIONAL-ADD if future bloodwork reveals strong CV risk factors (LDL/ApoB elevation refractory to statin, high Lp(a), familial premature CAD, ASCVD 10y >10%) AND post-careful benefit/bleed conversation with primary care.

"The mechanism class (mitochondrial protonophores / DNP-class uncouplers) has killed dozens of confirmed users via hyperthermia — DNP fatalities continue today in the bodybuilding underground. BAM-15 is a credible attempt to engineer that risk away by sparing the plasma-membrane potential, and the rodent data (Kenwood 2014, Alexopoulos 2020, Childress 2018) is genuinely encouraging — fat loss, NAFLD reversal, insulin sensitization without observable hyperthermia at therapeutic doses. **But: zero published human Phase 1, zero published human PK, zero registered human trials, no IND on public record, no published clinical safety data of any kind as of May 2026.** For a 20yo lean MMA athlete + business owner whose actual goal is performance and longevity (not weight loss), there is **no plausible benefit** that justifies being a guinea pig for a research-chem version of an uncoupler class with a body count. **Cleaner alternatives exist for every plausible use case:** for fat loss → semaglutide, tirzepatide, retatrutide (all FDA-approved with massive safety datasets); for metabolic health → exercise, sleep, V4 stack already running; for mitochondrial function → urolithin A (OTC, safe), training. **SKIP-FOR-NOW until a human Phase 1 reads out clean.** What would change this verdict: (a) a published human Phase 1 with full safety + PK data, (b) FDA IND filing or trial registration on ClinicalTrials.gov, (c) published chronic rodent oncology + cardiac safety data at therapeutic doses, (d) a clinical reason for fat loss in this user (he is a 20yo lean athlete — there is currently no such reason)."

Effective for adult severe alopecia areata (BRAVE-AA1/AA2 Phase 3 — ~35-40% achieved 80%+ scalp coverage at 36 weeks at 4 mg/day). Not for MPB. Boxed warnings + cost mean it's only used for the AA indication. For Dylan with no AA diagnosis, no current indication. Mention here because the user asked about hair-loss adjacent compounds; baricitinib is the more potent JAK inhibitor in the AA space, vs ritlecitinib's slightly cleaner JAK3-selective profile.

"If protein intake is adequate (~1.6-2.2 g/kg), BCAAs are functionally obsolete — the leucine in any whey shake or chicken breast already saturates mTORC1. The 2010s research wave (Wolfe 2017, Phillips 2014) showed that isolated BCAAs without the other essential amino acids actually slightly decrease net protein synthesis vs whey. The remaining niche use case — fasted training where intra-workout EAA exposure matters — is better served by 5-10g of EAAs (essential amino acids, all 9) at ~$0.50/serving than BCAAs at the same price. Marketing momentum has kept BCAAs popular long past their evidence-based shelf life. Skip."

"Dietary beta-carotene from food (carrots, sweet potatoes, leafy greens, squash) is unambiguously beneficial. Supplemental synthetic beta-carotene at high doses (15-25 mg/day) is the only category of antioxidant supplement that demonstrably INCREASES mortality, lung cancer, and CVD risk in smokers and possibly other groups (ATBC, CARET trials). For a non-smoking 20yo athlete, even non-smoker harm signal is unclear but the upside is also nil — just eat the vegetables. Skip the supplement."

Topical formulations relevant for dermatologic indications; otherwise same class as prednisone/dexamethasone. For a combat athlete, intra-articular injection for joint inflammation is a real option but requires WADA TUE in-competition. SKIP-FOR-NOW absent indication.

Works for the cosmetic indication (denser/longer eyelashes, ~25% length / 100% density at 16 weeks per FDA label trial). Off-label scalp use has less data and the cost is higher than minoxidil. For a 20yo with no specific cosmetic eyelash goal and no scalp MPB, no current indication. Flips to OPTIONAL-ADD if (a) Dylan wants cosmetic eyelash density specifically, or (b) MPB onset and adjunct to minoxidil/finasteride/dutasteride considered. Periocular skin pigmentation (darkening of eyelid skin) and iris pigmentation change (irreversible, hazel→brown) are the dominant cosmetic side effects; both rare at correct application but documented.

"Biotin deficiency is essentially nonexistent in healthy adults eating any varied diet — gut bacteria synthesize meaningful amounts and the daily requirement is tiny (~30 mcg). The hair/skin/nails marketing is largely unsupported in non-deficient subjects. Major concern: high-dose biotin (5,000-10,000 mcg in 'beauty' products) interferes with streptavidin-biotin lab assays — falsely high T4/T3 and falsely low TSH being the most clinically dangerous; can also distort troponin readings during MI workup. Skip unless documented deficiency."

"For this-archetype (20yo, peak natural T, brain-priority, MMA athlete on 185-190 lb / 6'0-6'1 frame, no aesthetic / mass goals stated as priorities) — boldenone is a B-tier body-comp tool from a class that's a SKIP-AT-20 across the board. Same family logic as testosterone-enanthate, methenolone, trenbolone: HPG-axis suppression at 20 risks permanent shutdown of an HPG axis still maturing; lipid (HDL crash + LDL/oxLDL rise), polycythemia (boldenone is among the most RBC-elevating AAS — clinically relevant hematocrit elevation is documented), and BP elevation are core signals; gray-market sourcing means QC variance + counterfeit risk; veterinary-grade injectables carry contamination concerns. MEDIUM (not HIGH) confidence because boldenone is genuinely milder than trenbolone or testosterone on the side-effect profile (less DHT-pathway, less aromatization, no neurosides) — if this user ever decides to run AAS post-30 with bloodwork backing, EQ is one of the more defensible Tier-2 picks. But \"milder than tren\" is not \"good idea at 20.\" Aesthetic / mass goals are explicitly downstream in the priority stack, brain wins over body, and the appetite stimulation that's part of the EQ value proposition is irrelevant for a 185-190 lb athlete who's already hitting protein. Would change verdict only if this user reaches 28-30+, completes a final-state HPG / fertility checkpoint, has a documented competitive aesthetic goal, AND has measured baseline + monitoring plan."

Historical first. Superseded by oral zuranolone for the PPD indication. No biohacking case.

"Specifically for users in this archetype: no anxiety indication, so no reason to use. For anxiety-prone archetypes: STRONG-CANDIDATE — buspirone is the cleanest non-benzodiazepine anxiolytic with no abuse potential, no cognitive impairment, and no dependence. Fully reversible to OPTIONAL-ADD if this user profile shifts toward anxiety. Distinct advantage: cognitively neutral (some weak pro-cognitive signals via 5-HT1A in PFC), unlike benzos."

SGLT2 class effect similar to dapagliflozin + empagliflozin. The amputation signal from CANVAS is the differentiator and reason most prescribers prefer dapagliflozin or empagliflozin even though FDA removed the boxed warning. For Dylan no current indication. SKIP-FOR-NOW in favor of sister-class SGLT2s if any SGLT2 ever becomes relevant.

Mechanism precision is very thin, evidence is thin Russian-only with zero Western replication, and the broader Khavinson short-peptide framework itself is contested — many cleaner liver-protection options (NAC, milk thistle, choline) cover the same use case with stronger evidence.

"Mixed evidence in osteoarthritis — some trials positive (Reginster, Bruyère studies; GAIT trial showed benefit only in moderate-severe pain subgroup), most large independent trials null or marginal (Wandel meta-analysis 2010 in BMJ: pooled effect size of 0.04 across 10 RCTs, essentially placebo). For an asymptomatic 20-year-old MMA athlete without arthritic joints, the indication doesn't exist. Glucosamine + chondroitin combinations are popular in combat-sport recovery culture but the evidence in young athletes with healthy joints is essentially nonexistent. Better prophylactic joint tools: collagen peptides (UC-II, hydrolyzed type 1 collagen) with growing tendon-and-joint evidence."

"For a 20-year-old in this archetype — endogenous GH/IGF-1 axis is at lifetime peak, exogenous GHRH agonism on a peak-functioning HPS axis offers minimal upside, brain development still ongoing (IGF-1 is a developmental signal — chronically supraphysiologic levels during late-adolescent neurodevelopment have unknown long-term consequences), and the two indications a user would actually feel (recovery, body composition) are not this user's bottlenecks. Verdict is SKIP-FOR-NOW (revisit at 30+) rather than SKIP-PERMANENT because the drug isn't medically wrong-fit for him in the way retatrutide is — it just has no positive risk/reward at his current physiology. What would change verdict: age 30+ with declining IGF-1 on bloodwork, or post-MMA-career recovery problems that don't resolve with sleep/nutrition. MEDIUM confidence (not HIGH) because human PK data is solid but long-term safety data is essentially absent and the GH/IGF-1 oncology question remains theoretically open."

"For this-archetype (20yo, peak endogenous GH/IGF-1, MMA athlete with existing cubital-tunnel symptoms, brain-priority): exogenous GHRH agonism on a peak-functioning HPS axis offers no demonstrable upside; the DAC variant specifically trades pulsatility preservation (the gentlest argument for any GHRH analog at this age) for sustained continuous-style stimulation that flattens natural rhythm; chronic supraphysiologic IGF-1 during late-adolescent neurodevelopment is uncharacterized; GH-driven fluid retention worsens his existing ulnar-nerve compression risk (and DAC's sustained signal produces meaningfully more edema than sermorelin or no-DAC at comparable GH AUC); and the recovery / body-composition benefits aren't his bottlenecks. **HIGH confidence** (higher than the parent CJC-1295 entry's MEDIUM rating because the FDA 2024-09-27 Category 2 removal + December 2024 PCAC vote against 503A inclusion has now closed the cleanest legal access path, leaving only gray-market with documented quality variability — the regulatory signal is itself information about the risk/benefit calculus). Would change verdict if this user reaches 30+ AND develops documented GH-axis decline AND a recovery problem emerges that doesn't respond to behavioral/nutritional interventions — and even then, sermorelin or CJC-1295 (no DAC) would be the gentler first-line GHRH analog choice."

Racemic clomiphene is the legacy form. For male HPG axis support / TRT-alternative use, pure enclomiphene (see [[enclomiphene]]) is the better choice — same desired mechanism without the zuclomiphene tail that can cause mood disturbance, visual disturbance, and prolonged HPG manipulation. For a 20yo with intact HPG, no indication for either. Flips to OPTIONAL-ADD if documented secondary hypogonadism + desire to preserve fertility (vs TRT which suppresses fertility); even then enclomiphene preferred.

"Same skip rationale as Ritalin IR — methylphenidate-class is a clinically valid ADHD treatment but a user in this archetype does not have an ADHD diagnosis, and Concerta's defining feature (12-hour smooth coverage) is **actively bad** for a 20yo late chronotype migrating bedtime to midnight: an 8 AM dose is still therapeutically active at 8 PM, when wind-down for a midnight bedtime should be underway. Modafinil already owns the wakefulness/focus lane with a much cleaner sleep profile (12-15 hr half-life is real but the alerting effect plateaus and the second half is forgiving — methylphenidate's effect rises into the afternoon). Verdict would shift to STRONG-CANDIDATE only if (a) clinical ADHD diagnosis emerges from psychiatric eval, (b) modafinil + bromantane stack fails to produce sustained focus, AND (c) this user's chronotype has stabilized at midnight bedtime — even then, Focalin XR or Ritalin IR PRN would likely beat Concerta because they offer dose control Concerta's monolithic 12-hour shell does not."

Cerebrolysin owns this exact lane (porcine brain peptide hydrolysate, neurotrophic / anti-apoptotic claim, BBB penetration) with vastly more evidence — multi-decade Western + Russian + Chinese RCT base, CAPTAIN TBI trials, 2023 ESO stroke guideline mention, and an actual mechanistic story (BDNF/GDNF/CNTF mimetic activity, characterized peptide fractions). Cortexin has the same animal-cortex-hydrolysate concept but with a thinner B-tier Russian clinical dossier (stroke / encephalopathy / pediatric ADHD trials, mostly Khavinson-network), zero Western replication, zero ClinicalTrials.gov entries, and no characterization of which peptide(s) within the complex are actually doing anything. The "Khavinson family receptor-priming" framing some longevity protocols apply to Cortexin is unverified — the compound is sold and used in Russia primarily for neurology indications, not as a longevity primer, and the priming-receptor claim does not map onto any specific identified mechanism. **Skip for now in favor of Cerebrolysin** which delivers the same neurotrophic-cocktail thesis with substantially better evidence quality. Revisit only if (a) this user tolerates Cerebrolysin poorly and needs an animal-cortex-hydrolysate alternative, (b) independent Western replication of Cortexin's Russian stroke / pediatric trials publishes, or (c) a head-to-head Cortexin vs Cerebrolysin trial shows Cortexin non-inferiority.

Same loophole-product concerns as HHC. Isomerization synthesis process leaves measurable Δ9-THC + other reaction byproducts in commercial product (FDA + state lab testing has consistently found this). For drug-tested athletes, frequently produces positive THC tests because of Δ9 contamination. No biohacking case.

Hospital/specialist drug. For a 20yo outpatient archetype, prednisone is the more common encounter and the better-known washout for WADA purposes. Dexamethasone occasionally used for short bursts (dental surgery, severe allergic reaction). Permanent-harm profile same class as prednisone but per-dose more potent → easier to overshoot.

At 20yo with no ADHD diagnosis, brain-development concerns dominate (animal data shows adolescent amphetamine exposure disrupts PFC dopamine axon growth via Netrin-1/DCC, male-specific). "Cleaner than Adderall" is mildly true but doesn't change the verdict — it's the same d-amphetamine that's in Vyvanse and the same compound class with brain-dev risk. Verdict flips to STRONG-CANDIDATE if this user gets a clinical ADHD or narcolepsy diagnosis with prescriber support.

At 20yo this user's endogenous DHEA-S is at lifetime peak (~age 20-25); exogenous supplementation is hormonally redundant and can perturb HPG axis with no upside. Would reconsider only if bloodwork (~June 2026) shows unexpectedly low DHEA-S — extremely unlikely at this age.

'For a 20yo MMA athlete with peak endogenous testosterone and DHT, intact HPG axis, no documented hypogonadism, no gynecomastia, no micropenis, and no prostate concerns, exogenous DHT is unambiguously SKIP-FOR-NOW. The endogenous physiology is already operating at lifetime peak. Adding exogenous DHT delivers no benefit while introducing hair loss + prostate + lipid risks MORE aggressively than even testosterone — because DHT does not aromatize, the protective E2 effects on HDL, bone, mood, and libido are absent. The non-aromatizing "feature" that makes DHT clinically useful in EU indications (gynecomastia regression via paradoxical AR competition, hypogonadism with prior E2 sensitivity, pediatric micropenis without bone-age advancement) is irrelevant to a young eugonadal athlete. Hair loss specifically: DHT is the proximate molecular driver of androgenic alopecia — exogenous DHT bypasses the 5αR conversion step that finasteride/dutasteride block, so MPB cannot be pharmacologically rescued during exogenous DHT exposure. Prostate: dose-dependent BPH driver; risk minimal at 20 but compounds with chronic exposure. WADA S1.1 banned (mass spec detection for exogenous DHT distinguishable from endogenous via IRMS). Combat sport context: no athletic performance, recovery, or cognitive benefit beyond what endogenous DHT already provides. Verdict reverses ONLY if user develops documented hypogonadism with severe E2 sensitivity OR treatment-refractory idiopathic/hypogonadal gynecomastia AND age >35 AND under endocrinology supervision in a country where Andractim is legally available — clinically implausible for this user now or in the foreseeable future. If exogenous androgen ever becomes appropriate (35+ with documented persistent hypogonadism after enclomiphene-first trial), the conversation starts with testosterone (the parent molecule), and DHT enters only if T-induced E2 elevation produces specific problems. The hair-loss + prostate dimension makes DHT riskier than even testosterone for a young athlete.'

For a 20-year-old MMA athlete + business owner with an intact HPG axis at peak endogenous testosterone production, Dianabol fails on every axis — (1) zero medical indication; the user has no hypogonadism, no catabolic illness, no anemia, no muscle-wasting condition; (2) hepatotoxicity (LiverTox Likelihood A) is the dominant concern — cholestatic jaundice, peliosis hepatis, and rare hepatic adenoma are documented at chronic 4-6+ week oral exposure, and even a 'safe' 4-week kickstart cycle produces measurable ALT/AST elevation, HDL crash 30-50%, LDL elevation, BP creep, and HPG-axis suppression; (3) MMA-context cosmetic + performance penalties — water retention adds bad weight for combat sport, pre-competition water-cut is harder, gyno from 17α-methylestradiol is cosmetically devastating and may require surgical correction; (4) WADA-banned, USADA-banned (UFC), most state athletic commissions test — potential career-ending sanction; (5) legality — Schedule III felony possession in US, no legitimate source for retail; UGL product carries counterfeit + mislabeling + contamination risk; (6) reversibility — most gain is water/glycogen and reverses post-cycle; HPG-axis recovery 6-12 weeks even from a short cycle. Verdict would only flip in a counterfactual where (a) the user developed a medically diagnosed catabolic-wasting state, AND (b) injectable testosterone replacement was contraindicated or insufficient — neither is on any realistic horizon. Even then, Dianabol is strictly dominated by injectable testosterone esters (T-cypionate / T-enanthate) for hepatic safety, and by oxandrolone for any mild oral-AAS use case.

| Gray-market designer AAS with effectively zero formal human evidence base. The single meaningful pharmacology study (Friedel 2006, Hershberger rat assay) found anabolic potency comparable to testosterone propionate at equimolar dose plus a hepatomegaly signal absent with TP. Modern use is entirely underground bodybuilding "lean mass without water retention" framing. For a 20yo MMA athlete + business owner with peak endogenous testosterone (~600-900 ng/dL), brain-priority goals, and combat-sport training, DHB addresses no problem he has. SKIP-AT-20 logic stacks — (1) HPG suppression during ongoing axis maturation with persistent post-cycle hypogonadism risk (Rasmussen 2016, PMID 27536957); (2) atherogenic lipid profile (DHT-class HDL crash without E2 protection — non-aromatizing makes lipid worse on this dimension, not better); (3) accelerated androgenic alopecia in genetically predisposed users (already 5α-reduced; finasteride/dutasteride cannot rescue); (4) crippling post-injection pain (PIP) — uniformly reported as among the worst of any AAS, often disabling for 3-7 days, directly counterproductive for a combat athlete who needs daily training capacity; (5) community-reported kidney strain signal that the class-level FSGS literature (Herlitz 2010, PMID 19917783) and renal sonography data (Kantarci 2018, PMID 29148625) make plausible but DHB-specifically unverified; (6) WADA / USADA / state athletic commission detection — career-ending for any tested combat athlete via cypionate's weeks-to-months detection window; (7) gray-market supply chain with notable counterfeit / mislabeling rates. Verdict reverses ONLY for an older, advanced, fully-recovered, lab-monitored bodybuilder in active contest preparation with documented medical supervision — clinically implausible for this user now or ever. Honest summary — DHB is a niche underground compound where everything specific you read about it is community lore on a tiny formal evidence base. Skip on basis of class effects + zero positive case for this archetype.

"Classic 1970s-80s era 'cerebroactive' compound with mostly dated, low-quality positive trials and several modern null/refuting RCTs. Mechanism (choline analog → acetylcholine precursor) is dubious in vivo and largely supplanted by better-characterized cholinergics (alpha-GPC, CDP-choline). Notably, dc community side-effect profile (fatigue 19, brain-fog 18, headache 11, depression 10 from 210 reports) is unusually heavy for a 'nootropic.' Animal teratogenicity data is concerning for childbearing-age users. Better choline tools exist at every dose/cost point."

| For a 20-year-old eugonadal MMA athlete + business owner with intact cardiovascular health and a brain-priority goal hierarchy, DMHA stacks four independent reasons to skip with high confidence. (1) **Cardiovascular signal is real and dose-dependent** — Cohen et al. 2019 (J Med Toxicol) reviewed the case-series and pharmacology and documented BP elevation, tachycardia, palpitations, and isolated cardiovascular events in supplement users at the 100-200 mg per scoop doses found in retail pre-workouts; for a combat-sport athlete subject to repeated high-sympathetic-load training and weight-cut stress, additional sympathomimetic load from a poorly-characterized stimulant is a poor trade. (2) **FDA declared DMHA "not a dietary ingredient" in 2019** — products containing DMHA are explicitly subject to FDA enforcement action under the FD&C Act; the regulatory posture is identical to DMAA after the 2013 ban. Buying or possessing DMHA is not personally illegal (it is not DEA-scheduled), but the supply chain is unsupervised, label accuracy is poor (Cohen 2018 detected DMHA in pre-workouts at doses 73-271 mg per scoop with high inter-product variance), and any product still sold is by definition non-compliant with FDA. (3) **No medical indication, no competitive niche** — DMHA's only validated historical medical use (1950s octodrine as a nasal vasoconstrictor under the brand "Vaporpac") was abandoned decades ago, has no current authorization, and is not a credible recreational nootropic. The "pre-workout stimulant" use case is dominated on every axis by safer, better-characterized tools — caffeine (3-6 mg/kg, A-tier ergogenic, decades of RCT data), paraxanthine (cleaner caffeine metabolite, RCT-supported, OPTIONAL-ADD-rated in this user's plan), modafinil (FDA-approved, V5-locked for this user), or phenylpiracetam (occasional-use, characterized PK, evidence-supported). (4) **WADA S6 in-competition ban + tested-athlete career risk** — DMHA is detected by standard WADA stimulant screens (analogous to DMAA / octodrine / methylhexanamine handling); a single in-competition positive ends careers. For this user (recreational MMA, currently untested), this is not a hard block today but is a hard block the moment any sanctioned competition enters his roadmap. **Verdict reverses ONLY** in a hypothetical context where pharma-grade stimulants (modafinil, methylphenidate, dextroamphetamine) are not accessible AND the user accepts the cardiovascular + regulatory + supply-chain risks — a context that doesn't exist for him. Compare DMAA (banned 2013, same regulatory pattern, same skip verdict) and ephedrine (Schedule IV-equivalent precursor restrictions, abandoned in pre-workouts after 2004 ephedrine ban) — DMHA inherits the worst features of both predecessors with thinner clinical evidence than either.

Massively-validated FDA drug for Alzheimer's, but the only halfway-decent healthy-young trial is Yesavage 2002 (n=18 pilots, single-domain, never replicated); the side-effect profile (GI, vivid dreams + insomnia from HS dosing, bradycardia/syncope, REM behavior disorder reports) is not justifiable for a 20yo with no cognitive deficit and a citicoline + alpha-GPC + (planned) modafinil + bromantane stack already covering the cholinergic + arousal axis. Verdict would only change if (a) a properly-powered healthy-young replication of Yesavage emerged with cleaner cognitive endpoints, or (b) this user developed a specific procedural-skill retention use case (rare).

At 20 with intact HPG axis, no hair loss, and no BPH, there is zero current indication. PFS risk + 5-week half-life + young age = wrong tool right now. Topical ru58841 is a safer first-line if MPB ever appears. Verdict flips to WATCH-LIST if visible MPB onset, and STRONG only after topicals fail in older user.

"For a tested MMA athlete this is a hard skip. WADA Monitoring Program listing (2020 onward) means it could be banned at any annual update — and a positive 20E/turkesterone metabolite test would mean an automatic suspension on a substance that has barely-replicated efficacy. Parr 2019 (the most cited positive trial) had product-purity confounds: actual extracted ecdysterone was 6 mg vs labeled 100 mg, so 'effective dose' claims are unstable. Multiple null trials exist. Plus the only well-conducted positive study used n=46 untrained men over 10 weeks — squarely irrelevant to a trained competitive athlete with real protein/training optimization already in place."

At 20yo with no documented hypogonadism, intervention is cosmetic/preemptive against an HPG axis that is already at peak natural function. Risk-benefit is unfavorable until June 2026 bloodwork establishes baseline. Verdict re-evaluates to STRONG-CANDIDATE *only* if total T < 350 ng/dL with low LH/FSH (i.e., true secondary hypogonadism), which is biologically unlikely at 20 absent obesity, head trauma, opioid use, or pituitary pathology — none apply to this user.

"Real vascular/NO mechanism with population-level benefit but a very modest dose-response in healthy young athletes. The myostatin-inhibitor hype is built on one small, methodologically thin trial (n=6, no placebo, no actual myostatin numbers published — only ratios). Schwarz 2018 showed epicatechin supplementation actually **inhibited** aerobic training adaptations in healthy young men, which is a real concern for an MMA athlete in conditioning blocks. If polyphenols are wanted, dark chocolate (70%+ cacao) at 20-30g/day is cheaper, more pleasant, and has the supporting evidence; isolated epicatechin supplements at $30/month are not justified by the human data."

For a 20yo male with intact HPG axis and normal endogenous estradiol, exogenous E2 is wrong — would cause negative feedback suppression of LH/FSH, gynecomastia, water retention, libido / sexual dysfunction. The legitimate use cases are: (a) female HRT (post-menopause, premature ovarian insufficiency), (b) feminizing GAHT in trans women, (c) very specific male HRT contexts (post-orchiectomy, severe HPG failure with documented low E2 and symptoms). None apply. Worth having an encyclopedia entry because Dylan should know what his E2 is (sensitive assay) as part of bloodwork — too low is as bad as too high in males.

Same family rationale as parent Adderall analysis — for users in this archetype (20yo, brain-priority, MMA, no clinical ADHD diagnosis), the brain-development concerns + appetite suppression + dependence trajectory + lack of healthy-adult cognitive enhancement evidence apply identically here. Evekeo's 50:50 racemic split adds *more* peripheral noradrenergic load (HR/BP), which is strictly worse for a daily-cardio combat athlete. Brand-only US pricing (~$400/mo) makes the practical case still weaker. Verdict would flip to SAME-AS-ADDERALL (STRONG-CANDIDATE) only with a clinical ADHD diagnosis where the prescriber specifically wanted higher l-amphetamine ratio for clinical reasons — vanishingly unlikely scenario.

At 20yo with intact HPG axis, intact estradiol, and no AAS use, there is zero indication. Exemestane has community use as a post-cycle therapy (PCT) AI and as a daily-low-dose lipid/body-comp tweak in TRT contexts — neither applies. Verdict flips to OPTIONAL-ADD only inside a documented TRT or AAS context where estradiol is measured high AND a non-steroidal AI failed or caused joint pain (exemestane's steroidal structure tends to spare joints vs anastrozole). Crashing estradiol is the dominant risk and irreversible-binding makes overshoot harder to back out of than non-steroidal AIs.

"Fadogia agrestis sits in a uniquely shallow evidence puddle: ZERO human RCTs as of mid-2026, all testosterone claims rest on Yakubu 2005 (a 5-day rat study, n=20-something male albino rats, aqueous stem extract at 18-100 mg/kg) and a follow-up Yakubu 2008 28-day rat study that found dose-dependent IRREVERSIBLE testicular damage at 50-100 mg/kg. The viral popularization came from Andrew Huberman 2021-2022 podcast appearances (Huberman Lab + Joe Rogan), which moved a folkloric Nigerian aphrodisiac into the biohacker default stack with no human safety data backing the 600 mg/day dose he reported using. The 2024 Yakubu (already 2009 in publication) mode-of-cellular-toxicity paper documented lipid-peroxidation-driven membrane disruption in rat liver + kidney at 50-100 mg/kg over 28 days. A 2025 American Thoracic Society case report (Coalson et al., AJRCCM 211:A3862) documented a 51yo male who died of biventricular failure + ARDS + DIC after concurrent use of Fadogia + trimethylglycine + anastrozole + AAS — Fadogia is one of several causal candidates but the case is the first published fatality flagged to it. For Dylan (20yo MMA athlete, peak endogenous testosterone, no documented hypogonadism), the upside is essentially zero (T already at ceiling), the downside is non-trivial (rat hepatotoxicity + 1 fatality case + complete absence of human safety envelope), and the marketing-vs-evidence gap is dishonest enough to warrant a confident skip. SKIP-FOR-NOW because (a) zero human evidence, (b) demonstrated rat hepato/nephrotoxicity at doses overlapping the human-extrapolated supplement range, (c) one published fatality with Fadogia in the polypharmacy, (d) sourcing is unstandardized (10:1 vs 50:1 vs whole-plant extracts with no enforceable identity), (e) cleaner T-modulating tools exist for the rare archetype that needs them (Rx TRT with monitoring, dietary fat + zinc + sleep optimization). Verdict would change to NEEDS-FURTHER-DATA only if a Phase 2 RCT in hypogonadal men published with ≥3-month safety follow-up + LFT/renal monitoring; verdict will NEVER reach PRIMARY-PICK for archetypes with normal baseline T."

Lafon CRL-series compound that never advanced past 1970s-80s animal pharmacology — zero published human trials, zero established human safety profile, zero validated dosing. Modafinil is strictly better on every metric (cheap, abundant clinical data, established sourcing, known interactions). Verdict would change only if (a) someone publishes an actual human PK/PD study on fladrafinil AND (b) modafinil sourcing collapses globally — currently inverted.

No OCD diagnosis. CYP1A2 inhibition would dramatically amplify caffeine if reintroduced, blocking a primary nootropic lever. Sigma-1 pro-cognitive claim is interesting in principle but not actionable for a healthy 20-year-old MMA athlete absent indication. Side-effect cost (sexual dysfunction, sedation, drug-interaction burden) outweighs unproven cognitive upside.

"For this user's daily-driver question, modafinil dominates Focalin on every axis (lower brain-dev risk, lower abuse liability, no Schedule II logistics, longer effective duration, vastly better sourcing). Focalin remains a legitimate PRN-tool tier OPTIONAL pick — methylphenidate-class is the lowest-brain-dev-risk classical stimulant — but is not warranted before modafinil has been tried and either failed or hit a ceiling. What would change the verdict: (1) clinical ADHD diagnosis after baseline workup, (2) modafinil non-response or intolerance after 8-12 weeks, (3) specific high-output day where the sharp-focus stimulant signature outperforms eugeroic mechanism."

Strong animal hypertrophy signal but failed clinical program (Acceleron ACE-031 cardiac/vascular safety halt, ACE-083 missed efficacy endpoints), thin healthy-adult human evidence, and peptide-vendor identity is questionable for a 30+ kDa glycoprotein that almost certainly cannot survive subQ injection intact. Verdict could shift if a gene-therapy trial demonstrates clean safety in healthy adults or if a credible non-glycosylated peptide mimetic emerges with proper COA chain.

Mechanism is robust (Belgian Blue cattle, double-muscled mice, primate AAV1-FS344 trials all confirm myostatin blockade → hypertrophy), but human evidence for *injectable peptide* FS-344 is essentially zero — the dramatic results (Mendell 2015 Becker MD, Kota 2009 primates) all came from AAV gene therapy providing sustained expression, NOT subQ peptide injection with a 90-min half-life. For this user at 20yo with peak natural muscle growth potential, this is unjustified anabolic risk-stacking against a glycoprotein vendors almost certainly cannot synthesize bioactively. Verdict shifts only if (a) credible engineered FST-Fc variant reaches clinical-grade availability, or (b) a user in this archetype develops a muscle-wasting indication.

LABAs are maintenance asthma drugs, not rescue. For non-asthmatic, no indication. Off-label "anabolic LABA" claims exist (improved muscle protein synthesis in rodents at supratherapeutic dose) but no clean human data; WADA threshold makes legitimate inhaled use possible but cosmetic body-comp use is banned. SKIP-FOR-NOW.

Mechanism (adenylyl cyclase → cAMP → CREB → BDNF) is real and elegant, but human cognitive RCTs are essentially nonexistent — the LTP/memory story rests on hippocampal slices and rodent models. Body-comp marketing is industry-funded and weakly replicated. this user already has better cAMP/BDNF tools planned (bromantane, Semax/Adamax, Cerebrolysin) that come with actual human evidence. Would upgrade to OPTIONAL only if (a) a credible human cognitive RCT emerges, or (b) a user in this archetype develops a specific use case (older relative, glaucoma, etc.).

"For a 20-year-old in this archetype — same core \"no marginal benefit at peak natural GH/IGF-1 axis\" rationale as ipamorelin/CJC-1295, plus an additional layer: GHRP-2's cortisol + prolactin spillover is a categorical disadvantage versus the cleaner selective GHRP (ipamorelin) for any user who would actually consider this class. The hierarchy is: in young healthy users, no GHRP needed; in users where one is appropriate, ipamorelin replaces GHRP-2 on every dimension except raw GH-pulse magnitude (which is rarely the limiting factor). MEDIUM rather than HIGH because the 30+ longevity-clinic context where some operators still prefer GHRP-2's stronger pulse is genuine — not relevant for users in this archetype but the compound has a non-zero use case. Verdict moves to SKIP-PERMANENT only if this user stays untested-amateur indefinitely with no career path involving sanctioned testing AND we confirm ipamorelin dominates on his future use cases (which it does on first principles)."

"At 20 with peak HPG/HPS axes, exogenous GH-axis stimulation has no meaningful upside — and GHRP-6 is the dirtiest GHRP in the family on the spillover axis (cortisol, prolactin, aldosterone) plus brings the strongest appetite stimulation, which a user in this archetype does not need. Effectively obsolete: anyone considering GHRP-class agonism in 2026 should use ipamorelin (cleaner) or GHRP-2 (stronger GH pulse) — GHRP-6's only remaining niche is bulking-phase appetite stimulation in older lifters with low food drive, which is irrelevant here. Verdict moves to OPTIONAL only at 30+ AND with documented poor appetite during bulking, AND if ipamorelin's cleaner profile is somehow inadequate — a narrow scenario that almost never wins on a head-to-head."

"For this-archetype, guanfacine is **directionally wrong** — it is sedating, anti-alertness, BP-lowering, and works against the wakefulness/output goals of his V5 stack. The Arnsten α2A-PFC mechanism is real and elegant, but the clinical evidence for cognitive enhancement in healthy adults is thin (1 small positive trial 1999, 1 null trial 2005, null in older adults 2018), the indication is ADHD adjunct or PFC-impaired populations, and the side-effect bill (sedation 36%, fatigue 20%, orthostatic hypotension, bradycardia) is unattractive for a healthy 20-year-old whose limiter is \"stay alert and output for 6-12 hr.\" Verdict would change to OPTIONAL-ADD only in a future ADHD-adjunct context with formal Rx (e.g., if this user ever gets a formal ADHD diagnosis and goes on stimulants but needs evening sleep onset / impulsivity damping). For general cognitive enhancement: skip."

Highest-amplitude GH pulse in the GHRP family but the fastest tolerance buildup (somatotroph desensitization in 2-3 weeks of daily dosing) and dirty hormone-spillover profile (cortisol/prolactin elevation comparable to GHRP-2). For a 20-year-old in this archetype with peak endogenous GH/IGF-1, all three downsides land — peak baseline means no marginal GH benefit, fast tolerance means the compound self-destructs, and CD36 cardioprotection has no relevance to a healthy 20yo. The CD36 cardiac angle is mechanistically real but only matters in older or post-MI populations and remains animal-only. Verdict moves to WATCH-LIST experimental for cardiac-protection applications at 50+ if human cardiac outcomes ever validate; for GH purposes, ipamorelin or CJC/ipamorelin combo dominates.

"For this-archetype (20yo, peak endogenous GH/IGF-1 axis, MMA athlete, brain-priority) — exogenous HGH on a peak-functioning system is the single clearest \"wrong drug, wrong patient\" call in the GH-axis class. Direct GHR agonism bypasses every feedback loop the GHRH analogs and secretagogues at least partially preserve; supraphysiologic IGF-1 elevation is essentially guaranteed at any meaningful dose; all the same mechanistic concerns that drive SKIP-AT-20 for sermorelin/CJC-1295/MK-677 (peak natural baseline, late-adolescent neurodevelopment, fluid retention worsening cubital tunnel) apply with greater magnitude because HGH produces a larger and more sustained GH/IGF-1 surge than any upstream secretagogue. Plus: the long-term safety record of supraphysiologic GH exposure in healthy adults is the worst in the GH-axis class — Liu 2007 Annals meta-analysis documented significant increase in adverse events (edema, carpal tunnel, glucose intolerance) without clinically meaningful body-comp benefit; the Rudman 1990 NEJM paper that birthed the entire anti-aging-clinic industry was n=12 over 6 months and never showed mortality or longevity benefit (Rudman himself died at 67 of complications related to his own research subject participation). HGH is also unambiguously criminalized for off-label distribution (21 USC § 333(e)). The ONLY archetypes where HGH is appropriate are documented adult or pediatric GH deficiency on bloodwork (STRONG-CANDIDATE under endocrinology supervision), HIV wasting / cachexia, and FDA-approved indications. For 20yo healthy peak-axis this user, this is the most decisive SKIP in the whole GH-axis branch — HIGH confidence (vs. MEDIUM for CJC-1295, MEDIUM-HIGH for sermorelin and MK-677). Would NOT change verdict at 30+ unless documented adult-onset GH deficiency on stim test (insulin tolerance test or glucagon stim) — sermorelin/tesamorelin/CJC + ipamorelin are far better risk/reward for general age-related GH decline; HGH belongs reserved for genuine deficiency or specific FDA-approved indications."

Semi-synthetic loophole cannabinoid with limited safety data. The hydrogenation process leaves residual catalyst (platinum, palladium, rhodium) that has been detected in commercial product. Drug-test detection inconsistent — most THC tests detect HHC metabolites + some don't. For a drug-tested combat athlete (WADA S8 in-comp cannabinoids), unpredictable detection is its own risk. No biohacking case.

"Adequate whole-food protein intake (2g/kg) provides enough leucine that endogenous HMB production saturates the mechanism. Meta-analyses in trained athletes show small-to-null effects vs placebo. The strong-effect populations (elderly, untrained, bedrested, cachectic) are not this user. Athletes who would benefit most are those eating low protein or in a substantial deficit — neither describes a 20-year-old MMA athlete on a well-built stack. ISSN consensus paper supports clinical applications but is appropriately cautious about trained-athlete claims. Skip in favor of optimizing whole-protein intake; if hyper-marginal gains are sought, creatine has 50x the evidence at similar cost."

Cognitively interesting class with a real mechanism (BDNF upregulation, hippocampal LTP enhancement), but IDRA-21 specifically has zero modern human safety data and is sold only via research-chem channels with no COA standardization. The credible ampakine candidates for human use have moved to TAK-653 / NBI-1117568 / org-26576 in clinical trials — IDRA-21 is mostly a 1990s relic. Would upgrade to WATCH-LIST if a credible vendor with COAs emerged AND TAK-653 access stalled; would upgrade further only with at least one human dose-finding study.

Same SKIP-AT-20 rationale as parent IGF-1, *amplified* by LR3's pharmacokinetic profile — long half-life + IGFBP evasion = sustained supraphysiologic free IGF-1, which is exactly the exposure pattern most strongly linked to permissive cancer signaling, acromegalic-pattern soft-tissue overgrowth, and severe hypoglycemia. For a 20-year-old in this archetype with peak endogenous IGF-1 (~250-400 ng/mL typical), no body-comp gap, brain still maturing through mid-20s, and brain-priority ranked above all else — there is zero benefit case. Verdict reverses ONLY for documented severe primary IGF-1 deficiency under endocrinology supervision (and even then, native rhIGF-1 / Increlex is the appropriate molecule, not LR3).

Cleanest of the GHRP family on the hormone-spillover axis (no cortisol/prolactin spike), but for a 20yo at peak natural GH/IGF-1 the marginal endogenous-GH-pulse benefit doesn't justify HPG/somatotrophic axis perturbation, glucose modulation risk, or WADA exposure. Same logic as CJC-1295. Verdict moves to OPTIONAL-ADD only at 30+ with declining recovery, sleep architecture changes, or documented low IGF-1 — and even then, behavioral GH levers (deep sleep, training, fasting) come first.

"Don't supplement without lab evidence of deficiency. Adult males almost never need iron; storage tends to accumulate (lifetime risk of hemochromatosis/iron overload in genetically susceptible). MMA athletes have modest risk of low ferritin from foot-strike hemolysis and exercise-induced hepcidin spikes, but iron status should always be confirmed by ferritin + TSAT + CBC before supplementing. If genuinely low: ferrous bisglycinate or alternate-day high-dose protocols."

"Isotretinoin is the most powerful systemic acne therapy ever developed (~80%+ long-term remission of severe nodulocystic acne in landmark Layton 1993 + multiple subsequent meta-analyses), but for users in this archetype's specific situation — perioral dermatitis around the nose and tinea cruris, no severe nodulocystic acne — it is wildly disproportionate first-line. POD (perioral dermatitis) responds to behavioral fixes + topical metronidazole / azelaic acid / pimecrolimus + oral tetracyclines in >90% of cases; tinea cruris is fungal and isotretinoin doesn't address it at all. For a 20yo MMA athlete with brain priority, the off-label low-dose isotretinoin protocol for recalcitrant POD (5-10 mg/day, used by some dermatologists when topicals + tetracyclines fail) is **theoretically on the table** but only as a third- or fourth-line move after dermatologist supervision. The two specific deal-breakers that keep this SKIP-FOR-NOW: **(1) the depression / suicidality black box warning**, controversial in literature (some cohort studies show RR ~1.5; others null; 2024 Cochrane more reassuring) but a real risk for someone with brain-priority self-experimentation profile, and **(2) arthralgia + myalgia** at typical doses, which is a meaningful problem for an MMA athlete (musculoskeletal stiffness, reduced exercise tolerance, theoretical increased injury risk). Would upgrade to STRONG-CANDIDATE if a user in this archetype develops actual moderate-to-severe nodulocystic acne resistant to topicals + oral tetracyclines. Would consider WATCH-LIST low-dose only if perioral dermatitis becomes truly recalcitrant after a properly run dermatologist-supervised protocol of behavioral fixes + topical metronidazole + oral doxycycline 50-100 mg/day for 6-8 weeks."

"SKIP-FOR-NOW for this user's profile (20yo MMA athlete + business owner) and for nearly any non-trial use. Reasons: **(a) zero published human safety data outside small oncology trials** — no Phase 1 healthy-volunteer PK/safety, no exercise-physiology human studies, no chronic dosing data; **(b) WADA M1.2 prohibition** — banned in and out of competition with published detection methodology, hard stop for any drug-tested combat trajectory; **(c) sourcing reliability is extremely low** — ITPP appeared briefly on research-chem markets ~2014-2018 and has been intermittent since, vendors rarely have verified mass-spec confirmation, polyphosphate stability is delicate, and misidentification or degradation is highly likely; **(d) the rodent endurance signal is mechanistically real** but the human translation gap is enormous given (i) RBC entry kinetics differ between species, (ii) the human O2-unloading curve already operates with high efficiency and the headroom for shift is debated, (iii) cumulative phosphate load and unknown renal handling at gram-per-kg dosing in humans is uncharacterized; **(e) cleaner endurance and oxygen-economy levers exist** — periodized cardio, altitude exposure, iron status optimization, beta-alanine, creatine, RBC mass via legitimate training — all already-stack-fit for this user's profile. **What would change verdict to OPTIONAL-ADD/STRONG-CANDIDATE:** completion of OXY111A or successor Phase 2 with safety data + biomarker shift in humans; FDA-approved indication; established pharmacy-grade sourcing; AND user shifts away from any drug-tested competition trajectory. Until then: SKIP-FOR-NOW with HIGH confidence — this is not a \"wait six months\" molecule, it is a \"wait for proper human evidence + verified sourcing + non-tested context\" molecule. Mechanism is interesting; the operational picture is bad."

"L-DOPA is a real dopaminergic — that's both its appeal and its problem. In Parkinson's disease, where endogenous dopamine production is failing, L-DOPA is the gold-standard treatment. In a 20yo healthy male with intact dopamine synthesis, supplementing L-DOPA (via mucuna pruriens or otherwise) pulses CNS dopamine in ways that, with chronic use, downregulate D2 receptors and produce tolerance, mood crashes, and sexual dysfunction on cessation. The V5 stack already contains 9-Me-BC + (potentially) selegiline — additional dopaminergic load is a tolerance/desensitization risk. Acute use occasionally (mucuna 100-300mg L-DOPA equivalent pre-task) has anecdotal pro-motivational effects but is poorly studied for non-PD populations. Skip until/unless a specific dopamine-deficiency phenotype is documented."

This is replacement therapy for documented hypothyroidism. For a 20yo with normal TSH + free-T4 + free-T3 + no symptoms, there is no indication. "Biohacking" use cases circulate (subclinical hypothyroid optimization, T3-T4 combination for energy/cognition) but the data do not support healthy-euthyroid supplementation. Iatrogenic over-replacement (TSH < 0.1) increases atrial fibrillation, bone loss, and cardiac event risk. Dylan's reasonable path is: get TSH + free-T4 + free-T3 + reverse-T3 + TPO antibodies as part of bloodwork; if any abnormal, work with an endocrinologist; if all normal, do not take this drug. Flips to STRONG only with documented hypothyroidism diagnosis.

HPG-axis suppression in still-developing 20yo endocrine + brain-development concerns + documented hepatotoxicity case reports + FDA prohibited + research-chem product identity questionable. Nothing about this user's stated priorities (brain #1, MMA performance) is meaningfully advanced by a body-comp anabolic. Verdict would change only at age 30+ with bloodwork-supported HPG recovery plan, post-cycle therapy access, and verified product COA — and even then the evidence/risk ratio is poor vs alternatives.

NAC 1200 mg + glycine in V4 already drives endogenous GSH synthesis with stronger evidence base and lower cost; liposomal GSH addresses GI bioavailability but not BBB delivery, and the brain protection thesis is the priority. Verdict would flip if a chronic-NAC failure profile emerges (no objective GSH/oxidative-stress improvement on bloodwork) or if a credible RCT lands showing CNS GSH elevation from oral liposomal GSH.

Direct dopamine receptor agonism carries class-warning impulse-control-disorder (ICD) risk — pathological gambling, hypersexuality, compulsive shopping/eating — at population rates of 2.8-8% in PD patients, and the receptor-level mechanism does not care whether the user is 70 with PD or 20 with a developing prefrontal cortex. Lisuride is the cleanest ergoline on the cardiac axis (5-HT2B antagonism actively prevents valvulopathy that killed pergolide and benched cabergoline) but cleanness vs. its ergoline siblings is irrelevant when the question is whether a 20-year-old MMA athlete should be a chronic direct DA agonist user. Verdict would change to OPTIONAL-CONSIDER if a user in this archetype develops a prescriber-managed Parkinson's-adjunct context (he won't), or to WATCH-LIST if a credible PK-tuned microdose protocol with prospective ICD monitoring emerges in the biohacker literature (none exists — current biohacker use is anecdotal Ray-Peat-forum off-label and mostly for prolactin lowering, which a user in this archetype does not need).

"Two converging lines of evidence make this a clean SKIP for a 20-year-old in this archetype: (1) the placebo-controlled microdose RCT literature (de Wit, Hutten, Szigeti, Bershad 2019) is mostly null or expectancy-driven once blinding is enforced — the Yanakieva 2018 positive signal has not held up to subsequent rigorous replication, and (2) macrodose use in a still-developing 20yo prefrontal cortex with no treatment-resistant indication is hard to justify against the Schedule I legal exposure, HPPD risk, valvulopathy theoretical concern at chronic micro use (5-HT2B partial agonism), psychosis-precipitation risk in undiagnosed family history, and dangerous interaction with lithium (seizure reports) + serotonergic drugs. Documented for completeness; not a daily nootropic and not a defensible recreational tool at this life stage. Would only revisit at age 25+, after brain maturation, with a documented clinical indication (treatment-resistant depression, end-of-life anxiety, AUD), under a DEA-licensed clinical trial or regulated psilocybin/MDMA/ketamine analog program — and even then this is not the molecule of first choice given Schedule I friction."

"Cosmetic-AAS archetype with zero modern clinical evidence base for healthy adults — entirely a bodybuilding \"show prep hardening\" compound used in low-body-fat states for stage aesthetics. The historical 1961-1970s breast cancer indication (Drolban) is real but irrelevant to current use. No cognitive, athletic-performance, recovery, or longevity case for any healthy young adult. Same-family AAS skip-at-20 logic applies: HPG suppression during ongoing axis maturation (peak HPG at 20yo), atherogenic lipid changes (DHT-class HDL crash without E2 protection — non-aromatizing makes lipid profile worse on this dimension, not better), accelerated androgenic alopecia in genetically predisposed users (potent peripheral androgen, no 5α-reductase protection because already DHT-class), gray-market supply chain with high counterfeit rates. For this user (20yo MMA athlete, brain-priority, no contest-prep aesthetic goal), Masteron addresses no problem he has and produces no benefit he wants. Verdict reverses ONLY for older bodybuilder in active contest preparation with documented medical supervision — irrelevant to this user now or ever (combat sport ≠ bodybuilding aesthetics)."

"Cosmetic-AAS archetype with zero modern clinical evidence base for healthy adults — entirely a bodybuilding \"show prep hardening\" compound used in low-body-fat states for aesthetic vasculature/dryness. No cognitive, athletic-performance, recovery, or longevity case. Same-family AAS skip-at-20 logic applies: HPG suppression during ongoing axis maturation (peak HPG at 20yo), atherogenic lipid changes (DHT-class HDL crash without E2 protection — non-aromatizing makes lipid profile worse on this dimension), accelerated androgenic alopecia in genetically predisposed users (potent peripheral androgen, no 5α-reductase protection because already DHT-class), gray-market supply chain with high counterfeit rates. For this user (20yo MMA athlete, brain-priority, no contest-prep aesthetic goal), Masteron addresses no problem he has and produces no benefit he wants. Verdict reverses ONLY for older bodybuilder in active contest preparation with documented medical supervision — irrelevant to this user now or ever (combat sport ≠ bodybuilding aesthetics)."

Wrong tool for users in this archetype's brain-priority + MMA stack. Limited use case (cosmetic tanning + sexual function), receptor-promiscuous side effect profile dominated by nausea + spontaneous erections + nevus darkening that materially complicates melanoma surveillance — a fundamental dermatologic concern with no easy mitigation in a 20yo with limited UV exposure history. Verdict would shift to OPTIONAL-WITH-CAVEATS only if this user specifically prioritized year-round tan and accepted dermatology baselining + 3-6 month surveillance commitment. For sexual function specifically, FDA-approved bremelanotide (PT-141) is the better tool with cleaner receptor selectivity.

WADA-banned (S4.5.1) since January 2016 — instant no-go for any user who may ever compete in a tested federation, and for an MMA athlete this is the controlling factor. No FDA approval, no Western RCT base, sourcing is gray-market with mixed reliability (Russian/Latvian Grindeks blister packs vs. counterfeit Indian and Chinese supply). Mechanism is genuinely interesting (forced glucose-oxidation shift, ischemia protection, modest endurance signal) but the upside is small for a healthy 20yo with no cardiovascular indication, and the cost-of-getting-caught is total. Re-evaluate only if (a) WADA delists it (extremely unlikely), (b) the user transitions to fully untested MMA / personal training only with zero competition aspirations, AND (c) a credible Western trial in healthy athletes lands.

'AAS at 20 — even "mild" DHT-derivatives suppress HPG axis and risk durable endocrine harm during late puberty/HPG maturation; reputation as "clean" is mostly relative to harsher AAS, not absolute; expensive + heavily counterfeited makes risk/reward worse than oxandrolone if AAS were ever justified.'

Methylin is the Mallinckrodt brand name for generic methylphenidate IR — pharmacokinetically and clinically identical to Ritalin IR. Verdict tracks parent file (ritalin.md) one-for-one. SKIP-FOR-NOW for users in this archetype's daily question because (1) modafinil dominates as first-line at 20yo, (2) within MPH-class Focalin (d-isomer-only) is the cleaner version of this exact drug, and (3) Schedule II Rx access is gated. **OPTIONAL-ADD as PRN tool** if clinical ADHD diagnosis ever opens Rx access. The only Methylin-specific differentiator is its **chewable tablet + oral solution formulations** (pediatric-friendly liquid/chewable), which have minor practical advantages for patients who can't swallow pills but no relevance for users in this archetype. **Refer to ritalin.md as the canonical methylphenidate-IR file.**

a user in this archetype has no MPB at 20. Minoxidil is a treatment for active androgenetic alopecia (or refractory hypertension), not a preventive optimization — there is nothing to prolong-anagen on, no miniaturization to reverse. Verdict flips to STRONG (topical first) on visible MPB onset, and OPTIONAL combo with finasteride/dutasteride/ru58841 if MPB becomes aggressive. Oral LDOM moves to STRONG only if topical fails or is intolerable.

Mirtazapine's primary clinical effects (sedation, appetite stimulation, +2-10 lb weight gain in 3-6 months) are direct inversions of combat-sport context performance + body-composition + cognitive-output goals. Verdict would only flip to OPTIONAL-ADD if a user in this archetype develops clinical depression with comorbid insomnia + appetite loss, in which case mirtazapine becomes a tier-1 Rx specifically because of the same effects that disqualify it now. No nootropic case; no chronotype-migration case; no off-label use that survives the cost-benefit for an athlete.

Isolated mitragynine extracts are much more potent per gram than dried leaf — community use of "kratom" via tea / capsule of dried leaf is qualitatively different from chronic high-dose extract use. The whole-leaf use case has a reasonable harm-reduction profile (mild stimulant at low dose, analgesic/sedative at high dose, modest withdrawal at chronic use). Isolated mitragynine + 7-OH-mitragynine extracts shift the risk profile toward opioid dependence + several US deaths from extract-overdose cases. For Dylan with no chronic pain indication, no current case. SKIP-FOR-NOW; less harmful than O-DSMT but in the same general opioid risk class.

"For a 20-year-old in this archetype — endogenous GH/IGF-1 axis at lifetime peak; sustained tonic GH/IGF-1 elevation (vs. natural pulsatile pattern) has unfavorable risk/benefit on a peak-functioning system; appetite increase is directly counterproductive for combat-sport weight management; documented A-tier glucose intolerance and edema at chronic dosing; congestive heart failure cases in older Phase 3 trials (frail elderly, but signal exists). Strong-candidate at 30+/40+ for sarcopenia or recovery-decline contexts. What would change verdict: 30+ age + bloodwork showing declining IGF-1 + body-composition decline that doesn't respond to standard interventions + accepted oral-pill convenience tradeoff vs. injectable CJC/ipamorelin combo. MEDIUM-HIGH confidence (higher than CJC-1295's MEDIUM) because the MK-677 evidence base is genuinely larger (Phase 3 trials in elderly + multiple healthy-adult RCTs) and the side-effect profile is more empirically characterized — i.e., we know more about what it does and don't, and the picture is less favorable for a young athlete than for a sarcopenic older user."

Common "anti-aging" peptide stack component (mod GRF + ipamorelin pre-bed). Real GH pulse produced; clinical effects modest (small improvements in sleep depth + recovery anecdotally; body comp effects require dose levels that approach exogenous HGH territory). For a 20yo with intact GH axis, no indication — endogenous GH peaks are already maximal during deep sleep, and pharmacological augmentation doesn't have a clear benefit at this age. WADA ban + research-chem supply chain + redundancy with sermorelin (which is at least Rx + cleaner sourced) make this SKIP-FOR-NOW.

Recreational dissociative profile with no cognitive use case; theanine + magnesium + tryptophan/glycine cleaner for sleep/anxiety; gummy market is a vendor lottery with documented adulteration, hospitalizations, and deaths (Diamond Shruumz 2024).

Same MAS chemical as Adderall plus a 16-hour duration that is uniquely incompatible with a delayed-sleep-phase chronotype (sleep onset destruction is the central differentiator from IR/XR) — confidence is HIGH (rather than MEDIUM like parent Adderall) because the duration mismatch alone is a categorical disqualifier independent of the parent skip rationale. Verdict would flip only with a clinical ADHD diagnosis AND a chronotype that tolerates 16-hour stimulant exposure.

For this user-archetype (20yo MMA athlete + business owner, peak endogenous T, brain-priority stack) — nandrolone is a SKIP across every dimension. (1) HPG-axis suppression is among the deepest of any AAS — single doses of 100-200 mg ND suppress LH/FSH for weeks; multi-month cycles produce HPG recovery times routinely measured in 6-18 months and well-documented permanent hypogonadism in young users; the long decanoate ester releases for 4-6 weeks after final injection so PCT must be timed to ester clearance. (2) The signature "Deca dick" mechanism — PR agonism → dopamine suppression → prolactin elevation → erectile dysfunction + libido crash — is exactly the OPPOSITE of what an MMA athlete training brain-body coordination needs; the biohacker workaround (cabergoline) introduces a serotonin-pathway dopamine agonist with valvulopathy risk and adds prescriber friction. (3) WADA S1.1a banned with the LONGEST detection window of any commonly-used AAS — 12-18 months in urine via 19-norandrosterone metabolite; precludes any pivot to sanctioned amateur or pro MMA competition for ~18 months post-cycle. (4) The "joint pain relief" thesis (Tatem 2020 pilot) is real but extrapolated from hypogonadal middle-aged men; in a 20yo with peak endogenous T, the marginal benefit over BPC-157 + collagen + load management is essentially zero while the harm profile is enormous. (5) Lipid profile (HDL crash, LDL/ApoB rise) and modest BP elevation are class-typical; nandrolone is on the milder end of the AAS lipid-disruption spectrum but still clinically meaningful at multi-month doses. (6) Recent 2026 Prokopidis meta-analysis of 20 RCTs found ND modestly increased lean soft tissue (+1.59 kg) but did NOT improve handgrip strength or consistently improve BMD — meaning even the strongest "earned" claim (mass gain) doesn't translate to functional strength in controlled trials. HIGH (not MEDIUM) confidence because the verdict converges across HPG/fertility (deep suppression at young age), sport regulation (WADA + 18mo detection), sexual function (the PR-mediated mechanism is unique and severe), and the user's specific brain-priority + athletic-tested-status profile. Would change to OPTIONAL-ADD only if the user is post-30, post-fertility-checkpoint, has documented hypogonadal joint pain refractory to BPC-157/load management, AND is competing in non-tested categories — none of which apply.

For this archetype (20yo MMA athlete + business owner with no diagnosed mood/anxiety disorder), Nardil is overkill — a non-selective MAOI with daily tyramine-cliff lifestyle constraint, B6 depletion, hepatotoxicity tail risk, and 2-week washout window before any other serotonergic agent (including OTC DXM, tramadol, SSRIs) can be safely used. Zero indication for a healthy 20yo. However phenelzine has the strongest evidence base in social anxiety disorder among all MAOIs (Liebowitz 1992 RCT, replicated). Flag for consideration ONLY if user develops treatment-resistant social anxiety later in life — e.g., enterprise sales calls, on-camera podcast/keynote work, public-speaking-heavy business pivot — AFTER trialing propranolol PRN, buspirone, SSRI baseline, and CBT. Verdict would shift to OPTIONAL-ADD only with that specific indication + treatment-resistance documentation.

Wrong compound at the wrong time for users in this archetype — mechanism is interesting (the only non-direct-agonist way to raise NMDA-glycine-site tone, theoretically activity-dependent and therefore safer than direct agonists), but human evidence in healthy adults is essentially zero, the development program has been stalled at Phase 2 since ~2010-2015 with no public readout of cognitive endpoints, anecdotal corpus is one or two YouTube reviews and no real Reddit/forum body, and stacking a novel NMDA-glycine PAM with TAK-653 (AMPA PAM) was already flagged in the encyclopedia as too aggressive (two unproven glutamate enhancers). Verdict would upgrade to WATCH-LIST if Rottapharm/successor publishes Phase 2 cognitive data with cleanly positive MATRICS/PANSS-cognition signal AND independent lab-grade COA-verified vendor product becomes routine; would upgrade to OPTIONAL-ADD only after FDA-pathway revival or replication by an unaffiliated group; would stay SKIP-FOR-NOW if no further development announcements appear by 2027.

Brief euphoric + dissociative effect (~30-60 s). Used routinely in dentistry + obstetrics with excellent safety record at clinical doses. The recreational-use harm signal has emerged with the rise of large-cylinder "balloon" use over the past 5-10 years — heavy daily users developing irreversible B12-related myelopathy + peripheral neuropathy + leukoencephalopathy in their 20s. For Dylan: no biohacking case. Medical/dental use is fine; recreational chronic use is a permanent-harm vector.

At 20yo with peak natural HPG axis, AR-axis modulation is gratuitous; ostarine's documented HPG suppression (less than LGD-4033 but still real and dose-dependent), unresolved hepatotoxicity case-report signal, and complete absence of long-term safety data in young eugonadal men make this a textbook risk-stack-without-need scenario. Combined with research-chem-only sourcing (FDA-prohibited supplement channel + counterfeit/contamination-prone gray market), the appropriate verdict is firm SKIP. Verdict would not change pre-25 absent unforeseen indication; would re-evaluate post-25 only with documented anabolic-deficient state and validated pharmaceutical-grade source.

Same-family logic to all anabolic-androgenic steroids skip-at-20 cluster. Even the "mildest" AAS reliably suppresses the HPG axis in young eugonadal males at typical bodybuilder doses (20-50mg/day), produces marked atherogenic lipid changes (LDL up, HDL crash), and obligately stresses the liver via 17α-alkylation. For this user at 20yo with peak endogenous testosterone (~600-900 ng/dL typical), no documented hypogonadism, and brain-priority + longevity orientation, the risk constellation (HPG suppression with potential post-cycle anhedonia / mood crash, atherogenic dyslipidemia, hepatotoxicity, modest body-comp upside that's achievable through training + nutrition + creatine alone) is straightforwardly unfavorable. Verdict reverses ONLY for documented severe catabolic medical indication (HIV wasting, >40% TBSA burn, severe trauma) under endocrinology / burn-unit supervision — clinically implausible for users in this archetype.

"Three converging reasons to skip: (1) the entire intranasal-oxytocin literature is in a replication crisis — most early \"trust / social cognition / pro-social\" findings (Kosfeld 2005, Baumgartner 2008, Domes 2007) have failed independent replication (Lane 2016 meta, Walum 2016, Nave 2015 review); (2) actual CNS bioavailability after intranasal dosing is mechanistically uncertain — Leng 2016 (Biological Psychiatry) shows the nasal-to-brain pathway may deliver far less peptide centrally than the field assumed, with most subjective effects possibly placebo or peripherally mediated; (3) for users matching this archetype's use cases (sales calls, sparring, content creation), Selank covers the anxiolytic axis with vastly better evidence, and propranolol covers somatic performance anxiety — oxytocin adds no incremental value those tools don't already provide. Verdict-confidence is MEDIUM-LOW (not LOW) because true effects probably exist at smaller magnitudes than original claims, with substantial trait × context × sex moderation, so the compound isn't \"fake\" — it's just not a good investment for users in this archetype right now. Verdict would upgrade to WATCH-LIST if pre-registered Western RCTs in this user-archetype (young, healthy, performance contexts) emerge with effect sizes worth chasing; would NOT upgrade based on more anecdote."

User has no MDD diagnosis. Restrictive tyramine-free diet is incompatible with MMA athlete fueling (high-protein, mom-cooked dinners frequently include aged cheeses, cured meats, soy sauces, fermented foods). Drug-interaction surface is enormous and overlaps multiple OTC categories (DXM cough syrup, pseudoephedrine, phenylephrine). Would only consider if treatment-resistant MDD diagnosis emerged with documented prior SSRI/SNRI failures AND user accepted the lifestyle constraint. The selegiline low-oral tier already covers any nootropic MAOI curiosity at <1% of the safety liability.

No MDD or anxiety diagnosis in this archetype. If an SSRI ever becomes indicated, escitalopram (cleanest profile) or sertraline (modest activation, lowest CYP burden) are better-tolerated first-line choices. Paroxetine's anticholinergic burden, prominent weight gain, pronounced sexual dysfunction, severe withdrawal syndrome, and largest CYP2D6 interaction surface make the entry/exit cost much higher than peer SSRIs without offsetting efficacy advantage (Cipriani 2018 mid-tier efficacy, worst acceptability of common SSRIs).

Mechanism is plausible and mechanistically distinct from mature IGF-1 (less mitogenic systemic signaling, more local satellite-cell focused); the 2011 Kandalla landmark paper specifically positioned MGF as combating sarcopenia "without IGF-1 oncogenic side effects." But human RCT evidence is essentially absent — the case rests on in vitro + rodent + rabbit models. For a 20yo MMA athlete with peak endogenous satellite-cell function, intact natural MGF response to eccentric loading, and BPC-157/TB-500 already pursued for cubital tunnel, PEG-MGF adds gray-market injection burden + theoretical IGF-axis exposure for a marginal hypothetical recovery delta. Verdict would shift toward OPTIONAL only with (a) documented sarcopenia/wasting state (impossible at 20yo healthy) or (b) significant chronic injury that BPC-157 + TB-500 + sleep + nutrition cannot resolve. MEDIUM rather than HIGH because the safety case is genuinely better than mature IGF-1 LR3 — just not justified for this profile.

"L-phenylalanine is upstream of L-tyrosine in the catecholamine pathway, but L-tyrosine is the rate-limited step and is consistently better-studied for acute cognitive/stress applications. Supplementing phenylalanine to boost catecholamines is a strictly inferior choice vs. tyrosine. The DL-form (DLPA) has weak/anecdotal evidence for chronic pain and depression via enkephalinase inhibition. For an athlete with adequate dietary protein (which provides ~2-4g phenylalanine/day), supplemental phenylalanine doesn't fix any actual problem. Skip unless there's a specific opioid-mediated pain use case being explored."

"For this-archetype, modafinil owns the wakefulness lane at ~$0.50-1.50/pill gray-market with 25+ years of safety data and a much better cognitive enhancement signal in healthy adults; pitolisant at $4,300+/mo brand-only with effectively zero gray-market footprint, an 8-week titration to clinical effect, and **no published cognitive enhancement data in healthy non-EDS adults** is a poor fit as a primary play. Verdict would shift to STRONG-CANDIDATE if a user in this archetype develops modafinil intolerance (rash/SJS watch, persistent headache, anxiety) AND secures US Rx via sleep specialist with insurance/copay program, OR if a narcolepsy/IH diagnosis emerges. Re-eval lift from prior implicit \"bad side effect profile + thin cognitive evidence\" framing in encyclopedia: **the side-effect profile is actually favorable** (rates comparable to placebo in the 2025 meta-analysis), but the **thin cognitive evidence in healthy adults stands** — pitolisant's wake-promotion is well-supported, but cognitive lift is wakefulness-derived, not direct cognitive enhancement. Verdict softened from \"SKIP\" to \"SKIP-FOR-NOW\" with explicit triggers for re-eval."

PPAP is the first CAE compound and a historical-mechanistic milestone, but its successor BPAP is ~130× more potent in vivo (full antagonism of tetrabenazine depression at 0.05 mg/kg vs PPAP's 2.5 mg/kg), enhances serotonin in addition to catecholamines, and is the actively-researched compound in this family. For this-archetype the rational move at this CAE-class slot is BPAP if the watch-list moves to active, OR low-dose selegiline (which has 40+ years of human data and Rx access) if MAO-B inhibition is also wanted. PPAP has zero unique value vs BPAP and zero human RCTs. Would re-evaluate ONLY if BPAP sourcing collapses AND a human PPAP trial emerges — not expected.

"PQQ has interesting in vitro and rodent data on mitochondrial biogenesis (PGC-1α activation), but human clinical evidence is thin: a handful of small Japanese trials (Nakano 2012, Harris 2013) showed modest effects on fatigue, mood, and CoQ10 levels. No good replicated RCTs in young athletes. Mitochondrial biogenesis claims are intriguing but training itself is the most potent mito-biogenesis driver — the marginal value of PQQ on top of heavy MMA training is unclear. Cost is high. Reasonable to revisit in 2-3 years when more human data lands; not high-leverage today."

For this-archetype (20yo MMA athlete + business owner, 185-190 lb, peak natural T, brain-priority, no stated aesthetic / mass goals) — methenolone is a SKIP-AT-20 by the same family logic that rules out testosterone-enanthate, boldenone, and the rest of the AAS class. (a) HPG-axis suppression at 20 risks long-term shutdown of an axis still consolidating its mature setpoint — Rasmussen 2016 (J Clin Endocrinol Metab) documented persistent hypogonadism years after AAS withdrawal in a sub-population, and the risk concentrates in younger users with extended cycles. (b) WADA S1.1a-prohibited at all times — for an MMA athlete who may compete in any tested promotion (USADA / VADA / state commissions), this is a career-ending positive. Methenolone's long-term sulfate metabolites are detectable >30 days post-cycle per Albertsdóttir 2020. (c) Counterfeit problem is severe — methenolone API costs roughly 5-10× testosterone per gram, and published mass-spec analyses (Magnolato 2017, Coopman 2022 PMC9288681) find 42-67% of seized "primobolan" is actually substituted with cheaper compounds (testosterone, nandrolone, boldenone). The user pays primobolan prices to inject something else, with no way to verify without third-party lab analysis. (d) The "mild and safe" reputation is overstated — methenolone still suppresses LH/FSH at 400+ mg/week, still raises hematocrit, still negatively shifts lipid panel (HDL drops, LDL/ApoB rises), and at 600+ mg/week the side-effect profile converges with other AAS. The relative-mildness is real but 20 isn't the age to be running ANY AAS. HIGH (not MEDIUM) confidence because there is no plausible 20yo MMA athlete + business owner reframe that flips this verdict — even competitive cutting goals are better served by 12 weeks of dietary discipline than by a Schedule III androgen with a 30+ day detection window. Would change verdict only if user reaches 30+, has aged out of competitive MMA, has documented HPG checkpoint completed, has non-tested aesthetic / hormone-replacement context, and chooses methenolone over more cost-effective AAS specifically for the female-friendly or low-aromatization profile (which doesn't apply to a male user).

Solid A-tier evidence for pediatric + adult ADHD, but no evidence for cognitive enhancement in healthy adults — same logic as atomoxetine. Non-stim ADHD niche only; subjective profile is subtle, weeks for onset, and side effect surface (somnolence, suicidal-ideation black box) is meaningfully worse than modafinil/bromantane/Adamax/Semax for users in this archetype's brain-priority cognitive-output use case. Verdict would change only if this user received a formal ADHD diagnosis with explicit non-stim preference.

Most HPG-suppressive of common SARMs + hepatotoxicity case reports + brain-priority profile makes endocrine disruption a non-starter at 20yo; would change only with clean long-term human data and verified COA-tested supply (neither exists).

"For this archetype (20yo, peak endogenous GH/IGF-1 axis, MMA athlete, business owner, brain-priority, lean-mass not the bottleneck) — pharmaceutical rHGH on a peak-functioning natural axis is the single clearest \"wrong drug, wrong patient\" call in the entire GH-axis class. Direct GHR agonism bypasses every feedback loop the GHRH analogs and secretagogues at least partially preserve; supraphysiologic IGF-1 elevation is essentially guaranteed at any meaningful dose (even 1-2 IU/day clinic protocol pushes IGF-1 above age-normal in healthy young adults). All the same mechanistic concerns that drive SKIP-AT-20 for sermorelin/CJC-1295/MK-677 (peak natural baseline, late-adolescent neurodevelopment, fluid retention worsening cubital tunnel, no demonstrated benefit for combat-athlete bottlenecks) apply with **greater magnitude** because rHGH produces a larger and more sustained GH/IGF-1 surge than any upstream secretagogue. Plus: the long-term safety record of supraphysiologic GH exposure in healthy adults is the worst in the GH-axis class — Liu 2007 Annals meta-analysis (31 RCTs, 220 participants over 27 years) documented significant increase in adverse events (edema 44%, arthralgia 28%, CTS 24%, gynecomastia 18%, glucose intolerance 8%) without clinically meaningful body-comp benefit. The Rudman 1990 NEJM paper that birthed the entire anti-aging-clinic industry was n=12 over 6 months, never showed mortality or longevity benefit. rHGH is unambiguously criminalized for off-label distribution under 21 USC § 333(e) — unique among Rx drugs. Counterfeit gray-market product (\"blue tops\", \"red tops\", \"Hygetropin\", \"Kigtropin\") frequently underdosed (50-90% of label) or substituted with HGH-fragment 176-191. The lean-mass concept doesn't address combat-athlete bottlenecks (sleep, cervical injury, weight management, mental health, nervous-system fatigue all higher leverage). The ONLY archetypes where rHGH is appropriate are (a) documented adult or pediatric GH deficiency on stim test (insulin tolerance test gold standard, glucagon stim alternative, GHRH+arginine alternative) under endocrinology supervision — STRONG-CANDIDATE; (b) HIV wasting / cachexia (FDA-approved Serostim); (c) other FDA-approved indications. **Higher confidence than CJC-1295 (MEDIUM) or MK-677 (MEDIUM-HIGH)** because rHGH's evidence base is unambiguous, the magnitude differential is clear, and the legal/regulatory exposure is the largest in the class. Would NOT change verdict at 30+ unless documented adult-onset GH deficiency on stim test — sermorelin / tesamorelin / CJC + ipamorelin remain better risk/reward for general age-related GH decline; rHGH belongs reserved for genuine deficiency or specific FDA-approved indications."

Modafinil is preferred at 20 (cleaner mechanism, lower brain-dev risk, daily-safe). MPH-class beats amphetamine class on developmental concerns, but Ritalin specifically is dominated by Focalin (cleaner d-isomer-only) within the class. Verdict flips to STRONG-CANDIDATE if this user ever gets a clinical ADHD diagnosis and Rx access — at that point cheap generic IR is a reasonable second-tool-in-pocket.

Genuinely effective for severe AA (ALLEGRO Phase 3 — ~25% achieved 80%+ scalp coverage at 6 months at 50 mg). Not for MPB / androgenetic hair loss — completely different mechanism. For a 20yo without alopecia areata, no indication. Flips to STRONG if AA diagnosis appears (would be specialist-managed, not biohacker self-prescribed).

Alzheimer's / Parkinson's dementia drug. For a 20yo with intact cognition, no indication. Cholinergic side effects (nausea, vomiting, diarrhea, bradycardia, syncope) make it a poor candidate for biohacking use — even huperzine A is a more tractable AChE inhibitor for healthy users curious about cholinergic enhancement.

"Off-label cognitive use is supported by two real human RCTs (Van Duinen 2018 episodic memory in healthy elderly; Gilleen 2018 schizophrenia adjunct) but the catalytic-site, non-subtype-selective binding produces nausea/diarrhea/weight loss in 10-20% of users — the same problem that killed rolipram. For this-archetype: BPN14770 (allosteric PDE4D NAM, primate-specific binding pocket) is the cleaner version of this exact mechanism, already documented on the wiki, and that's where the cognitive-PDE4 thesis should live until/unless a topical or subtype-selective replacement emerges. Verdict would not change without a healthy-young-adult cognitive RCT showing tolerable risk-benefit at chronic dosing."

Triple-disqualifier for this user. **(1) No clinical indication** — 20yo MMA athlete with no anemia, no CKD, normal Hb/Hct/iron panel; this drug is built to fix renal failure-driven hypo-erythropoiesis, not enhance physiology. **(2) FDA rejected on cardiovascular safety** — CRDAC 13-1/12-2 votes citing thrombosis (vascular access thrombosis RR 1.5, DVT RR 3.9 in DD-CKD; seizures, infections, MACE signal in NDD-CKD), Complete Response Letter Aug 2021, AstraZeneca walked away from US rights entirely. The endurance gain athletes seek (raising hematocrit) is exactly the mechanism that drove the thrombotic events that killed the FDA filing — combat sports already raise stroke risk via head impact, and a young athlete stacking hematocrit on top of subconcussive trauma is moving the wrong direction on the risk curve. **(3) WADA-banned in and out of competition.** Even if he were tested at the amateur MMA level today, sanctioned competition (USA Boxing, USADA-tested events, future pro license) would catch detectable metabolites for ~30+ days post-dose; multiple positive cases on record (Simona Halep 2022, several cyclists, equine doping). The legitimate altitude-adaptation analog is **actually train at altitude or use a hypoxic tent** — same HIF stabilization, no thrombosis signal, no anti-doping risk, no $300+/month gray-market exposure. Would only revisit if he developed a documented anemia of CKD (extremely unlikely at 20) AND moved to a jurisdiction with EU/Japan/China approval AND obtained legitimate prescription. None of those are imminent.

a user in this archetype has no documented hair loss at 20 with peak HPG axis function. RU58841 is a hair-loss intervention, not a preventive optimization, and the human safety dataset is thin enough that running it without indication is buying tail-risk for zero benefit. Verdict moves to OPTIONAL-ADD if any visible MPB onset occurs (recession at temples, vertex thinning, Hamilton-Norwood ≥II), and to STRONG-CANDIDATE if this user ever experiences post-finasteride/dutasteride sexual or mental side effects and needs a local-only AR antagonist option.

NAC at 1200 mg/day already in V4 supplies the rate-limiting cysteine substrate for endogenous GSH synthesis at lower cost and with stronger replicated brain evidence; SAG's incremental advantage over NAC at the brain is theoretical and direct cognitive RCTs are absent. Confidence is LOW because (a) SAG's oral bioavailability advantage over plain GSH is real (Fanelli 2018, Cai 2022), (b) liposomal GSH out-performs SAG on some peripheral GSH markers, and (c) a credible scenario exists where NAC fails and a direct-GSH delivery route (SAG or liposomal) becomes useful. Would re-evaluate if this user's NAC-on bloodwork shows persistent oxidative-stress markers (low GSH/GSSG, elevated 8-OHdG, elevated F2-isoprostanes), if a specific GSH-deficiency genetic signal lands (GCLC/GCLM/GSTM1-null), or if direct human cognitive-endpoint RCTs on SAG read out positive.

For a non-asthmatic, no biohacking case. The "salbutamol as mini-clenbuterol" gray-market use is occasional in bodybuilding circles, but the short half-life means impractically frequent dosing for sustained lipolytic effect, and the cardiac stimulation profile (tachycardia, tremor, hypokalemia at high dose) is real. For a tested combat athlete, the WADA permitted-inhaler-threshold makes it usable for legitimate asthma — but exceeding the threshold (even via nebulizer or stacking inhalers) has produced WADA failures. Verdict flips to STANDARD-OF-CARE for documented exercise-induced bronchoconstriction with a TUE; SKIP-FOR-NOW otherwise.

Asthma maintenance drug. No biohacking case. WADA threshold makes legitimate inhaled use possible. SKIP-FOR-NOW for non-asthmatic.

"Strong, replicated A-tier evidence as a schizophrenia adjunct (Tsai 2004, Lane 2008, multiple meta-analyses) for negative symptoms + cognition when added to non-clozapine antipsychotics. Essentially zero healthy-adult cognitive evidence — the entire clinical literature is built on patients with NMDA hypofunction, a condition a user in this archetype does not have. The mechanism is inherently a \"fix what's broken\" tool rather than a \"push above baseline\" tool, because the NMDA glycine site is approximately saturated in healthy adults under normal conditions (same logic as oral glycine — see glycine.md). Verdict would shift to WATCH-LIST only if a credible RCT in healthy young adults showed cognitive benefit independent of the schizophrenia population (none currently exists and none is expected, as the mechanism predicts null effect in saturated systems). For this user: no indication, no reason to trial."

"Genuine 5-alpha-reductase inhibition makes saw palmetto useful for androgenetic alopecia and BPH — but for a 20yo athlete with presumably normal androgen status, anti-androgenic supplementation has real downsides: potential mood/libido/recovery impacts, blunted training response. Cite-able evidence for hair-loss benefit is modest (smaller effect than finasteride). Only worth using if hair loss is already evident AND finasteride is rejected AND lab-monitored. Default: skip until specific indication arises."

Wrong-fit profile for users in this archetype at 6'0-6'1, 185-190 lb athletic — appetite suppression + ~40% lean-mass-loss-fraction documented for the class actively counters MMA fueling and protein needs. SKIP-FOR-NOW (not SKIP-PERMANENT) because plausible future scenarios reopen the question — significant weight gain past athletic career, T2D diagnosis, or established CV risk would all flip the verdict. The drug is genuinely best-in-evidence-class for its actual indications; verdict is about this user profile, not the drug.

"For this-archetype (20yo, peak endogenous GH/IGF-1, brain-priority, MMA athlete with existing cubital-tunnel symptoms) — sermorelin is mechanistically the gentlest GHRH analog (preserves pulsatility better than CJC-1295 DAC, shorter exposure than tesamorelin, smallest receptor-desensitization risk), but the indication doesn't apply: peak natural GH baseline means agonism on a peak-functioning system has no demonstrated upside, late-adolescent neurodevelopment + chronic supraphysiologic IGF-1 elevation is uncharacterized, GH-driven fluid retention worsens nerve-compression risk (cubital tunnel relevance), and the recovery / body-comp benefits aren't this user's bottlenecks (sleep + nutrition + training periodization are). MEDIUM-HIGH confidence (higher than CJC-1295 because sermorelin's pediatric-GHD pharmacology is well-characterized from 1990-2008 and the safety profile is the cleanest in the GH-axis peptide class) but the same SKIP-AT-20 reasoning applies. Would change verdict if this user reaches 30+ AND develops documented GH-axis decline (low IGF-1 on bloodwork) AND a recovery problem emerges that doesn't respond to behavioral/nutritional interventions. The older anti-aging clinic context is a different patient population: at 50+ with declining GH baseline and metabolic creep, sermorelin moves to OPTIONAL-ADD because the risk/reward profile shifts."

Beautiful mechanistic story from Garza's Penn lab — but Kythera/Allergan Phase 2 in MPB did not meet endpoints clearly enough to advance, and the program has been quiet since. Research-chem supply unverified. No advantage over minoxidil + topical fin + ketoconazole at the current evidence level. Flips to WATCH-LIST only if a fresh trial (any sponsor) reads positive. For a 20yo with no MPB, nothing to evaluate.

"For a 20yo MMA athlete who is already a daily-trained combat athlete with maximally-engaged endogenous ERR/PGC-1α tone, SLU-PP-332 is a clear SKIP-FOR-NOW. The reasons stack: **(1) Zero human safety data** — no completed Phase 1, no registered human trials on ClinicalTrials.gov as of May 2026; everything is rodent or in vitro. **(2) Theoretical cancer concern is non-trivial** — ERRα is overexpressed in breast / ovarian / colorectal / prostate / endometrial human tumors and drives Warburg-like tumor metabolism; the GW501516 (PPARδ) precedent ended exactly here (multi-site rat carcinogenicity in chronic 2-year studies → program abandoned 2007). **(3) Sourcing is research-chem-only with extreme vendor-purity variance** and emerging stim-contamination reports. **(4) No human PK** — community 10-30 mg/d doses are 3-10× *below* surface-area-converted equivalents of mouse doses with no PK basis. **(5) Decades of cumulative-exposure runway** — wrong demographic for early adoption of an unvalidated nuclear-receptor agonist. **(6) Plenty of validated alternatives** — actual training periodization, sleep, creatine, beta-alanine (already in stack), urolithin A (OTC, characterized in humans) all hit the same conceptual layer with vastly better safety profiles. The \"next Cardarine\" buzz in the biohacker community is exactly the wrong reason to take this — Cardarine itself ended in cancer concerns. **What would change verdict to WATCH-LIST:** any human Phase 1 reads out safe with biomarker signal. **What would change verdict to OPTIONAL-WITH-CAVEATS:** chronic rodent oncology study at exercise-mimetic doses shows no tumor promotion, AND human Phase 1 PK data exists. **What would lock verdict to SKIP-PERMANENT:** any chronic rodent study shows tumor promotion, OR early human signal of cardiac arrhythmia / hepatic toxicity, OR FDA / regulatory action."

Oral spironolactone is a female-pattern-hair-loss / female-acne tool. For a 20yo male it would produce gynecomastia and libido reduction at hair-loss-effective doses. Topical 5% spiro is sometimes stacked with minoxidil + ketoconazole in male MPB protocols; data is sparse and effect size unclear. Not a useful tool in male MPB compared to topical fin / ru58841 / KX-826. Verdict: SKIP-FOR-NOW for male users; would be OPTIONAL-ADD in female MPB context which is out of scope for this archetype.

For a 20-year-old MMA athlete + business owner with intact HPG axis at peak endogenous testosterone production, brain-priority archetype, Superdrol fails on every axis with the hepatotoxicity argument dominant — (1) zero medical indication; methasterone has never been FDA-approved for any condition; (2) hepatotoxicity is the dominant concern and arguably worst-in-class — multiple peer-reviewed case reports of severe cholestatic hepatitis in healthy young users (Singh 2009 PMID 19232584, Schwartz 2008 PMID 18391541, Nasr 2009 PMID 19412565, El Sherrif 2014 PMID 24190502, Jasiurkowski 2006 PMID 16863581), with bilirubin commonly 20-30 mg/dL, prolonged hospitalization required, and at least one published case progressing to liver transplant evaluation; LiverTox Likelihood A; (3) MMA-context career risk — WADA-banned, USADA-banned (UFC), state athletic commissions test, detection windows for designer-steroid metabolites are long; (4) legality — Schedule III felony possession in US since DASCA 2014; UGL product carries counterfeit + mislabeling + contamination risk; (5) lipid and CV impact severe — HDL crash 60-80%, LDL elevation 40-60%, BP elevation, polycythemia risk; (6) reversibility limited — DILI from Superdrol can take 8-16 weeks to normalize; cholestatic injury has been reported to present or worsen up to 4-8 weeks AFTER cessation; (7) no estrogen-mediated cosmetic side effects (non-aromatizing, no ER binding) is the only "advantage" — that is the entire reason it became popular and the entire reason it killed people's livers. Verdict would only flip in counterfactuals (medically diagnosed catabolic-wasting state with both injectable testosterone and oxandrolone contraindicated) that are not on any realistic horizon and would still strictly favor cleaner alternatives. Among all oral AAS, Superdrol is the single hardest SKIP for the user's archetype.

First DORA approved (2014, Merck), most real-world data and longest tail of post-market evidence — but the 12-hour half-life produces measurably more next-day grogginess than daridorexant's 8 hr, and the 2025 network meta-analysis ranked it weakest of the three approved DORAs on subjective TST. a user in this archetype does not have insomnia (chronotype problem, not sleep-onset problem), and if a DORA is ever needed, daridorexant is the better-fit tool for a brain-priority 20yo. Verdict would shift to OPTIONAL only if (a) daridorexant becomes unavailable or unaffordable, (b) a sleep-maintenance indication emerged where suvorexant's longer half-life is actually wanted, or (c) the long-term amyloid-clearance signal (Lucey 2023) gets replicated and a 20-year prevention case opens up.

"Cerebrolysin already owns this user's neuroprotection lane with multi-decade RCT data; Synapsin's combined-blend evidence is laboratory-only with zero published human RCTs on the formulation — adding it on top of Cerebrolysin is mechanism-stacking without evidence. Confidence is LOW because the underlying Rg3 + NAD+-precursor mechanisms are individually plausible (TBI rodent data is real), Synapsin-specific evidence might emerge, and it could become a reasonable Cerebrolysin alternative if EU sourcing breaks. Would re-evaluate if: (a) any human RCT on the compounded blend reads out positive, (b) Cerebrolysin sourcing fails and a user in this archetype needs an at-home, needle-free neuroprotection proxy, or (c) a user in this archetype develops needle aversion that compromises Cerebrolysin adherence."

Most potent topical retinoid commercially available — but the irritation profile makes it second-line to tretinoin or adapalene for most users. Indicated for plaque psoriasis (off-label for severe acne, photoaging). For Dylan: no current need. Adapalene + benzoyl peroxide covers the acne case; tretinoin or retinaldehyde covers photoaging-prevention case. Tazarotene is a "if those don't work" tier.

Asthma + obstetric drug. No biohacking case. WADA-prohibited without TUE at any route — stricter than salbutamol. SKIP-FOR-NOW.

"For this-archetype (20yo, peak endogenous GH/IGF-1, brain-priority, MMA athlete, 185-190 lb on 6'0-6'1 frame with no visceral adiposity) — tesamorelin is the cleanest GH-axis peptide in its class (preserves pulsatility, FDA-approved, best-characterized safety profile, real RCT visceral-fat data) but the indication doesn't apply: no excess VAT, no metabolic syndrome, no NAFLD, no HIV-associated lipodystrophy, peak natural GH baseline. Adding exogenous GH stimulation at 20 carries glucose-intolerance risk (HbA1c increase signal in trials), edema/carpal-tunnel risk (relevant given this user's existing cubital-tunnel concern), and IGF-1 elevation into a range where 47% of trial subjects exceeded +2 SDS at 26 weeks (theoretical cancer-promotion concern over decades). MEDIUM confidence not HIGH because tesamorelin is genuinely the best-validated of the GH-axis peptide family and \"skip\" doesn't mean \"bad drug\" — it means \"wrong patient.\" Would change verdict if this user reaches 30+ AND develops measurable visceral adiposity (waist >40\", elevated VAT on DEXA, NAFLD on imaging) AND brain-priority no longer dominates the optimization stack. The cognitive-function angle (HIV-NCD trial 2024-2025) was negative — VAT reduced but cognition did not improve significantly vs. SOC, removing the only mechanism that would have made this brain-relevant."

For a healthy 20yo MMA athlete with no documented hypogonadism, exogenous testosterone is unambiguously SKIP. (1) Endogenous T is at lifetime peak in eugonadal 20yo males — typical total T 600-900+ ng/dL with no symptomatic deficit. (2) Exogenous T suppresses an HPG axis that's still consolidating in early adulthood — fertility loss is real and sometimes permanent (Coward J Urol 2013, multiple case reports of persistent oligospermia after a single heavy cycle in young men). (3) Polycythemia risk (Hct >54% → thromboembolic), lipid deterioration, mood lability, and acne are all dose-dependent — at supraphysiologic athletic 'blast' doses the side-effect profile is meaningfully worse than at TRT. (4) TRAVERSE 2023 reassures only for hypogonadal middle-aged/older men at TRT doses — does NOT extrapolate to supraphysiologic use in young eugonadal athletes. (5) For a brain-priority profile, the cognitive return on T in eugonadal young men is essentially zero per the literature. (6) MMA combat sport context adds health/aggression considerations on top — supraphysiologic androgens in late-adolescent PFC development is a soft but real concern. Verdict FLIPS only with documented hypogonadism (total T <300 ng/dL × 2 morning draws + symptoms); even then enclomiphene is the preferred fertility-sparing first-line in young men, NOT exogenous T. Revisit at age 35-40+ if natural decline crosses symptomatic threshold despite optimized lifestyle (sleep, training, BF%, sun, stress, micronutrients).

Testosterone cypionate is pharmacologically near-identical to enanthate (slightly longer ester, same molecule, same effects); the SKIP-AT-20 logic for any exogenous testosterone applies here too — endogenous T is at lifetime peak, HPG suppression risk is real, fertility impact possible, and zero documented benefit in eugonadal 20yo males. Verdict flips only with documented hypogonadism (total T <300 ng/dL × 2 morning draws + symptoms) — and even then enclomiphene is preferred first-line in young men. Revisit at 35-40+ if natural decline crosses symptomatic threshold.

Endogenous testosterone is at lifetime peak in healthy 20yo males; supraphysiologic intervention disrupts a still-developing HPG axis with documented fertility, mood, and lipid risks. Verdict flips to legitimate TRT only if June 2026 panel documents persistent hypogonadism (total T <300 ng/dL on two morning draws + symptoms).

Program was discontinued by Theranexus in 2022 — no commercial product exists. Even if it returned, narcolepsy Phase 2 missed primary endpoint, modafinil monotherapy already covers this user's wake-promoting use case, and adding a class IC antiarrhythmic to a healthy 20yo with no cardiac monitoring infrastructure adds risk without clear consumer benefit. Verdict would shift to WATCH-LIST only if (a) program revives under licensing partner with positive Phase 3, or (b) a user in this archetype develops residual modafinil non-response after 6+ months of optimization.

"Same-family logic to all anabolic-androgenic steroids skip-at-20 cluster, with three turinabol-specific aggravators that make the verdict harder than for typical AAS in this user's archetype. (1) For a 20yo MMA athlete with peak endogenous testosterone (~600-900 ng/dL typical), no documented hypogonadism, and brain-priority + longevity orientation, the standard AAS risk constellation applies — HPG suppression with potential post-cycle anhedonia / mood crash, atherogenic dyslipidemia (turinabol crashes HDL particularly hard among AAS — non-aromatizable + DHT-pattern + 17α-alkylated triple-whammy), obligate hepatotoxicity via 17α-alkylation, modest body-comp upside achievable through training + nutrition + creatine alone. (2) Turinabol-specific: the M3 long-term metabolite (~20βOH-NorDHCMT) is detectable in urine up to 9-12+ months post-use via Sobolevsky-Rodchenkov 2012 LC-MS/MS, and the 2016 reanalyses of Beijing 2008 + London 2012 samples produced ~80 retroactive AAFs with cascading medal stripping. For ANY plausible competitive future (state amateur MMA, USADA-tested promotion, pro card path), CDMT is uniquely catastrophic — even years-old use is detectable. (3) Historical/safety-data weight: the East German State Plan Topic 14.25 (1968-1989) administered turinabol to ~10,000 athletes, many adolescent female swimmers/throwers/runners, producing a documented epidemic of virilization, liver tumors, cardiovascular disease, infertility, gynecological pathology, and offspring deformities (Franke + Berendonk 1997 Clinical Chemistry). It is one of the most thoroughly documented \"what happens when adolescents are given an AAS for years\" datasets in medicine, and the answer is \"long-term harm.\" Verdict reverses ONLY for documented severe catabolic medical indication under endocrinology supervision — clinically implausible and turinabol is no longer manufactured anyway."

"Zero human data of any kind, sourcing reliability variable, and cleaner same-class options exist (aniracetam has decades of clinical use; TAK-653 has modern human safety data; sunifiram has slightly more in-vitro mechanism characterization). The '1000× more potent than piracetam' claim is a rodent passive-avoidance dose ratio that has never been validated in humans. Unifiram offers no clear advantage over sunifiram in the published animal record. Would upgrade to WATCH-LIST only if (a) a human dose-finding study appeared, (b) a vendor with verified COAs emerged, and (c) a published comparison demonstrated unifiram-specific advantage over sunifiram."

"Bent 2006 and subsequent meta-analyses show modest subjective sleep-quality benefit driven by placebo-prone questionnaires; objective polysomnography (Taibi 2009) is consistently null. For a 20yo MMA athlete already running magnesium glycinate + apigenin + L-theanine + sleep hygiene, valerian adds variability, isovaleric-acid odor, and a real morning-grogginess tail. Better evidence and cleaner subjective profile for every alternative in the V4 stack. SKIP unless the lemon-balm/hops combo becomes a curiosity at travel time."

Khavinson family broad skepticism stands for Vesugen specifically — and the case for Vesugen is even thinner than for pinealon. KED has only one mildly-cited co-result in the 5xFAD-M dendritic spine paper (and even there EDR/Pinealon was the stronger arm), the "vascular bioregulator" claim is essentially monograph-only, and Western replication is zero. For a 20yo MMA athlete with brain-priority (#1) and intact vasculature, there is no compelling mechanism-aligned use case. Would only revisit if (a) independent (non-Khavinson) replication of any vascular endpoint published, (b) a user in this archetype develops vascular pathology requiring a peptide-level intervention, or (c) bloodwork (~June 2026) flags endothelial / vascular markers that no first-line option addresses better.

"Real mechanism (cerebral vasodilation + IKK-β inhibition) with respectable evidence in elderly cognitive decline and post-stroke recovery — but irrelevant to a 20-year-old with already-optimal cerebral perfusion. Bioavailability is poor (~7% oral). Regulatory friction (FDA 2016 tentative ruling kicking it out of dietary supplement category; 2019 warning to women of childbearing age over miscarriage signal) means sourcing quality is unreliable. The compound is mainly indicated for age-related vascular cognitive decline, not for healthy young athletes seeking cognitive enhancement. dc community side-effect cluster (headache 14, brain-fog 13, fatigue 12, tolerance 11) further argues against."

"Supplementation in non-deficient adults has failed every major prevention trial (HOPE, GISSI, Women's Health Study, Physicians' Health Study II, SELECT) and the Miller 2005 meta-analysis (PMID 15537682) flagged a dose-dependent all-cause mortality signal at ≥400 IU/day all-rac-α-tocopherol. ATBC + CARET + SELECT raised cancer concerns specifically. The user is a 20yo MMA athlete eating an animal-protein-rich diet (likely already replete in α-tocopherol from olive oil, almonds, spinach, sunflower seeds, fish oil). V4 fish oil softgels already contain mixed tocopherols as antioxidant preservatives. Genuine clinical-grade vitamin E indications are (a) severe deficiency syndromes (AVED, abetalipoproteinemia, fat malabsorption) — not relevant; (b) biopsy-proven non-diabetic NASH per PIVENS — not relevant absent NAFLD diagnosis. Mixed-tocotrienol products (especially annatto-derived γ-/δ-tocotrienol) sit on the WATCH-LIST: distinct mechanism from tocopherols (HMG-CoA reductase, NF-κB, ceramide), small RCT signals in NAFLD and lipids, but underpowered evidence and α-tocopherol displacement concerns. Verdict moves to OPTIONAL-ADD only if (1) genetic AVED is identified, (2) NAFLD is diagnosed on imaging/biopsy, or (3) a clean modern RCT of mixed tocotrienols establishes specific benefit for the user's training/longevity goals."

Cleanest amphetamine PK on the market and lower IV/intranasal abuse liability than IR Adderall, but oral abuse profile is similar to dexamphetamine and the brain-development concern at age 20(PFC dopamine axon misrouting in male adolescent rodents — replicated 2023-2025) applies equally. 12-14hr duration also collides with this user's late-chronotype migration (evening anxiety + sleep onset push). Verdict flips to STRONG-CANDIDATE only with formal ADHD or BED diagnosis warranting Rx.

For a 20-year-old MMA athlete + business owner with peak endogenous testosterone, brain-priority + longevity orientation, and combat-sport training load, this is SKIP-AT-20 with HIGH confidence — and the tendon/ligament mechanism makes the verdict stronger than for most other AAS in this archetype. Stanozolol carries (1) the worst hepatotoxicity profile in the common 17α-aa class (multiple fatal cholestatic case reports — PMID 28856252, 37948000, 40040852, 40909442); (2) one of the worst lipid profiles of any AAS (HDL crash -33-53% per Thompson 1989 PMID 2915439; HTGL upregulation per Haffner 1983 PMID 6413814); (3) substantial SHBG suppression with downstream HPG suppression (Small 1984 PMID 6430603 — 55% testosterone reduction at 10mg/day x 14 days); (4) a coherent set of tendon/ligament/cartilage signals — reduced collagen synthesis enzymes in tendon (Karpakka 1992 PMID 1636855), stiffer + less-compliant tendons that fail at less elongation (Inhofe 1995 PMID 7778710), MMP downregulation impairing tendon remodeling (Marqueti 2006 PMID 16636352), 22% tendon rupture incidence in long-term AAS users vs 6% controls (Kanayama 2015 PMID 26362436); (5) "dry joints" community report consistently observed during cycles; (6) WADA S1.1 banned with detection windows up to 28 days oral / 2 months injectable. For an MMA athlete whose career rides on tendon, ligament, and joint integrity under high-velocity rotational and impact load, the tendon-rupture signal alone is verdict-determining — a torn pec, biceps, quadriceps, or Achilles ends a fight career. Verdict reverses ONLY for documented HAE prophylaxis (clinically vanishingly rare and would use newer C1-INH-targeted therapies instead) under specialist supervision.

ZERO human RCTs (more thinly studied than even RAD-140 which at least has a halted Phase 2 breast cancer program); evidence base is in vitro / cell-line / one rat hippocampus study. 17α-methyl group puts YK-11 in the "structurally hepatotoxic" class alongside oral 17α-alkylated AAS (anadrol, dianabol, winstrol, methyltestosterone) — community reports and the SARM hepatotoxicity literature consistently flag YK-11 as the most liver-aggressive SARM. HPG suppression is reported as severe (more aggressive than RAD-140 in community bloodwork). Class is genuinely contested in the published literature — some pharmacologists call this a steroid, not a SARM. Sourcing reliability is among the worst in the SARM class because YK-11 is harder to synthesize than the non-steroidal SARMs and the JAMA-2017-style label-accuracy data have not been replicated for YK-11 specifically; assume product identity is unverifiable. WADA-banned, FDA-prohibited, untested in humans, structurally hepatotoxic, severely suppressive — the user is a 20yo MMA athlete with peak natural HPG axis and a brain-priority #1 stack; YK-11 attacks every priority. Verdict would not change pre-25 absent unforeseen indication; would not change post-25 either without (a) a published Phase 1 human safety study, (b) verified COA-tested pharmaceutical-grade source, and (c) clear anabolic deficit not addressed by less-aggressive options. None of those conditions are foreseeable.

Effective for postpartum depression (CORAL, SKYLARK, ROBIN trials). FDA rejected the broader MDD indication in 2023, leaving zuranolone as PPD-specific. Single 14-day course is a novel paradigm in psychiatry. For Dylan, no PPD indication; for any future MDD use, off-label only and probably inferior choice vs Auvelity. Important to know as the first allopregnanolone-class antidepressant.

Real recreational + occasional psychotherapeutic use, but for Dylan at 20 no clinical indication and Schedule I status. Adulteration in street MDMA-pressed-as-2C-B (and vice-versa) is the dominant practical risk. SKIP-PERMANENT — same logic as MDMA: no biohacking case, real harm vectors.

Same risk profile as ketamine + DCK. Marketed online as ketamine-like with "cleaner" qualities; bladder toxicity concern applies to entire NMDA-antagonist class with chronic use. No clinical research. No biohacking case.

Most consistently associated with negative outcomes of the modern dissociative RCs — psychosis, extended dissociation, violent behavior, redose-loop episodes lasting days. No therapeutic case. SKIP-PERMANENT.

Profound clinical signal in depression (GH Research GHP-101 Phase 2 — 87% remission at 1 week, single dose) but the experience is overwhelmingly intense and screening for vulnerability is critical. Toad-sourced material has secondary alkaloids + variable potency; synthetic is cleaner but Schedule I. For a 20yo with no depression indication, no current case + serious risk of psychiatric destabilization in unscreened use. Cardiac risk (transient severe hypertension during peak) is real. SKIP-PERMANENT outside structured clinical context.

This is where the "kratom is just a mild plant" framing breaks down. Isolated 7-OH-mitragynine extracts are functionally equivalent to mid-potency synthetic opioids and carry equivalent overdose + dependence risk. Multiple US deaths attributed to commercial 7-OH-enhanced kratom products. Vivid example: 7-OH "tablets" sold OTC at smoke shops as of 2025 have triggered DEA + state AG action. SKIP-PERMANENT.

"For this user (lean 20yo MMA athlete, 6'0-6'1 / 185-190 lb, no obesity, no body-composition problem) — **fully NOT-RELEVANT**. Adipotide is a fat-vasculature-destruction agent designed for severely obese populations; in a lean athlete it would either do nothing (insufficient WAT to ablate) or cause net harm (off-target nephrotoxicity with no benefit). Independent of this user-fit, the molecule itself is **SKIP-PERMANENT for almost all profiles** because: (a) ZERO human clinical trial data in 14+ years since the 2011 rhesus monkey publication despite intense media attention — this absence is the data; (b) confirmed dose-dependent renal toxicity in the monkey study (kidney PHB1 off-target); (c) FDA never approved a human IND despite the Arap-Pasqualini lab's prominence; (d) gray-market research-chem versions have no quality control and the molecule is structurally complex (cyclic disulfide + D-amino-acid effector) — high probability of vendor-supplied material being misidentified, degraded, or counterfeit; (e) GLP-1/GIP agonists (semaglutide, tirzepatide, retatrutide) now dominate obesity pharmacotherapy with vastly superior evidence + safety. SKIP-PERMANENT (not SKIP-FOR-NOW) because no plausible future scenario rehabilitates adipotide for users in this archetype or for any user with reasonable alternatives — the drug is functionally abandoned and dominated. MEDIUM confidence: monkey data is real and the molecular biology is interesting (verdict isn't HIGH-confidence-SKIP because the underlying science is genuine), but the regulatory + commercial trajectory + safety flag combination is unambiguous."

Modafinil is now $0.50-1.50/pill via Indian pharmacy and bypasses the hepatic prodrug step entirely. Adrafinil is strictly worse on every metric (slower onset, 3-4× higher mg, hepatotoxicity signal that withdrew it from the French market in 2011) with no compensating benefit. Verdict would only change if modafinil sourcing globally collapsed AND adrafinil access remained — currently inverted.

"For a 20-year-old in this archetype — lean MMA athlete with no obesity, no weight-loss indication, no body-composition problem. AOD-9604 was specifically developed for obese adults, failed its pivotal Phase IIb weight-loss trial in that population (n=536, OPTIONS trial 2006), and shows no demonstrated body-composition effect in lean / athletic users at all. Even in obese populations the peptide community's subjective fat-loss reports contrast sharply with the negative phase 2 (failed primary endpoint at 12 and 24 weeks). For lean populations, no clinical trial has ever shown meaningful effect. SKIP-PERMANENT (not SKIP-FOR-NOW) because there is no future biomarker / age threshold that would change verdict for users in this archetype — he is not the target population now, and aging would not move him into it. What would change verdict: development of clinically significant obesity (unlikely given his profile) AND emergence of head-to-head data showing AOD-9604 superior to GLP-1s / better-evidenced alternatives (also unlikely given the molecule's commercial history). MEDIUM confidence (not HIGH) because (a) the Phase IIb negative result was a 24-week trial with intensive diet + exercise that may have masked modest peptide effects, (b) safety profile is genuinely clean across ~900 trial subjects, (c) intra-articular cartilage-repair signal is interesting (Kwon & Park 2015 rabbit data) but irrelevant to the user's elbow thread (BPC-157 + TB-500 are far better-evidenced for his use case)."

Chronic daily use is contraindicated for every relevant-to-archetype goal (cognition, brain preservation, MMA reaction time, sleep architecture, longevity) — the A-tier evidence for tolerance, dependence, severe and sometimes life-threatening withdrawal (seizures, delirium), persistent cognitive impairment, fall/MVA risk, opioid-overdose synergy, and protracted withdrawal syndrome (BIND, 6–18+ months) all converge on chronic-use-bad. Acute single-dose / true emergency PRN use under a prescriber (status epilepticus, pre-procedural anxiolysis, one-off catastrophic panic) is medically appropriate and not what this verdict targets — but for a 20yo nootropic-stack user with no diagnosed anxiety disorder, no seizure history, and a brain-priority goal set, this class is a permanent skip. Nothing about chronic recreational/cognitive/sleep use would change this verdict; the verdict is class-wide because the abuse, dependence, withdrawal, and cognitive-impairment hazards are mechanistically pan-class even though potency, half-life, and subjective profile vary by molecule.

For a 20yo male with intact HPG, this would cause systemic feminization (breast tissue, libido loss, sexual dysfunction, ED) at hair-loss-effective dose — wrong tool entirely. Even for severe MPB cases, topical 5% bicalutamide is occasionally compounded but data is sparse. The legitimate use cases are prostate cancer + transgender feminization. Hepatotoxicity is the dominant safety signal (hepatocellular damage in 1-3% of cancer-dose users, occasional fatal cases) — even at low dose. SKIP-PERMANENT for the male MPB use case; OPTIONAL for the indicated populations (which are out of scope).

Same class as EPO + darbepoetin. CERA was the doping vector in Tour de France 2008 (Schumacher, Kohl, Piepoli, Astana team) before WADA had a validated assay — that gap is now closed. For a tested combat athlete: SKIP-PERMANENT, same thrombosis risk as EPO at supraphysiologic hematocrit, longer washout makes it harder to clear from system before testing. No biohacking case.

For a drug-tested combat athlete, clostebol is one of the worst possible compounds to be exposed to even accidentally — even trace contamination via shared towels, EU pharmacy creams, or topical wound care has produced WADA failures (Sinner 2024 was the marquee case). Has no biohacking case: weaker than testosterone, harder to source legitimately in US, and combat-sport drug-testing is a hard contraindication. Verdict SKIP-PERMANENT means: never useful here.

Parent compound pemoline was withdrawn from US market in 2005 because of fatal hepatotoxicity. Cyclazodone shares the oxazolidinone scaffold and has zero clinical safety data. Multiple anecdotal forum reports of liver enzyme elevation with chronic cyclazodone use. SKIP-PERMANENT — pharmaceutical stimulants (Adderall, Vyvanse, methylphenidate) are vastly safer if a prescription path is appropriate.

Same risk profile as ketamine RC analogs broadly — bladder toxicity at chronic use (ketamine cystitis is the canonical concern), cognitive impairment with frequent use, dissociation-related risk of impulsive behavior. Longer duration than ketamine makes single-session-overshoot harder to recover from. No clinical research program. No biohacking case for Dylan.

For this user and essentially every non-clinical user, Desoxyn sits one full tier above Adderall/Dexedrine on tolerance/abuse/neurotoxicity trajectory with no compensating cognitive advantage that survives the cost-benefit. It is FDA-approved (ADHD + obesity) and pharmaceutically real, but in modern US practice essentially never prescribed — the prescriber DEA exposure, the cost, and the clean availability of Vyvanse/Adderall make it a non-starter clinically. Even granting clinical legitimacy, the brain-development concern at 20 + dopaminergic terminal toxicity signal + appetite suppression severity + faster abuse trajectory all point the same direction. Verdict would not flip even with an ADHD diagnosis — Vyvanse or Adderall would be the appropriate first-line.

Classic endurance-sport doping agent. Real performance benefit (3-10% in TT performance in trained cyclists per Lundby reviews). Real permanent-harm potential: at unsupervised doses pushing hematocrit >55%, thrombosis risk rises sharply (DVT, PE, stroke, MI). Multiple endurance-cyclist deaths in the late 1980s-1990s "EPO era" attributed to nocturnal cardiac events at supraphysiologic hematocrit. Strict WADA M1.1 ban with sensitive isoform-discriminating tests (urinary IEF for rhEPO vs endogenous; biological passport for hematocrit/reticulocyte tracking). For Dylan: not a biohacking tool, not a fit, hard-block on drug-tested status.

Same risk profile as alprazolam class (tolerance, physical dependence, life-threatening withdrawal) + the additional risk of research-chem sourcing (concentration variability, occasional adulteration with novel benzo analogs like clonazolam or flubromazolam that have killed users via respiratory depression at "normal" doses). The community use case is most often "self-medicating anxiety / opioid withdrawal" — a path with poor outcomes. SKIP-PERMANENT.

Phenibut already has documented severe withdrawal syndrome (seizures, psychosis, prolonged dysautonomia lasting weeks-months). F-phenibut's higher potency makes accidental dependence + severe withdrawal more likely at typical use patterns. Several published case reports of F-phenibut-specific dependence + withdrawal. SKIP-PERMANENT.

Hepatotoxicity is among the worst of any oral AAS, the aggression-promoting profile actively conflicts with brain priorities, and zero brain or longevity upside justifies the liver/CV/neurobehavioral risk — no plausible bloodwork or genetic finding flips this verdict.

For a 20yo combat athlete this is one of the worst possible compounds — banned strictly by WADA, can cause severe electrolyte derangement leading to arrhythmia/death (multiple bodybuilder deaths documented), and the masking-agent use is now detectable. No biohacking case. Even for legitimate edema, this would be specialist-managed cardiology/nephrology and not relevant to this archetype.

Decades of pharmacology show oral GABA does not cross the BBB at meaningful concentrations, and the proposed alternative pathway (ENS → vagus → CNS) — while real and now reasonably well-characterized in 2024-2025 microbiota literature — is mechanistically weaker than every other tool already in this archetype's typical stack for the same goal. L-theanine, magnesium glycinate, glycine, taurine, tryptophan, and (PRN) picamilon all do the "calm" job either through actual BBB-crossing molecules or through better-evidenced peripheral mechanisms. There is no relevant-to-archetype niche where oral GABA is the right tool. Verdict would change only if a Western-grade RCT demonstrated unambiguous central GABA-A engagement after oral dosing (MR-spectroscopy brain GABA increase + matched subjective effect), which would invalidate ~60 years of BBB pharmacology — extraordinarily unlikely. Picamilon already covers the "BBB-crossing GABA prodrug" niche.

For nootropic / cognitive-enhancement use in this user, gabapentin is structurally wrong (the name implies GABAergic anxiolysis it cannot deliver), produces dose-dependent cognitive blunting (attention, processing speed, working memory in healthy crossover RCTs), carries a real and increasingly-recognized 2018+ dependence/abuse signal (15-22% misuse prevalence in opioid-using populations, 1% general population, ~5,000 US deaths/year involving gabapentin since 2020), and offers zero cognitive enhancement. The legitimate indications (post-herpetic neuralgia, diabetic peripheral neuropathy, focal epilepsy adjunct, restless legs, alcohol withdrawal taper) are all medical Rx contexts that don't apply to him. Verdict would only flip to OPTIONAL if a user in this archetype develops a documented neuropathic pain syndrome (e.g., the cubital tunnel ulnar neuropathy progresses to chronic neuropathic pain unresponsive to peripheral interventions and BPC-157/TB-500 protocol), at which point it becomes a tool for that specific medical problem, not a cognitive enhancer. Nothing about cognitive-enhancement framing changes the verdict.

GHB has the narrowest therapeutic window of any commonly-encountered psychoactive — recreational-to-unconscious gap is roughly 1.5-3 g vs 3-5 g (literally one extra "capful" of GBL or one mis-measured shot), and recreational-to-respiratory-arrest is 5-15× the active dose. Mixed with alcohol (multiplicative respiratory depression, no specific reversal agent), it is one of the highest case-fatality-rate club drugs in Western Europe (10.6% of acute drug toxicity presentations + 27% of critical-care admissions in Euro-DEN 2019 hospitals). Withdrawal from chronic use is among the most severe in clinical addiction medicine — fulminant autonomic crisis + delirium in >50% of untreated cases, ICU admission ~20-31% in observational cohorts, benzodiazepine-resistant in many cases (different receptor target — GHB acts at GHBR + GABA-B, BZDs at GABA-A), often requiring pharmaceutical GHB re-administration to abort. Sodium oxybate (Xyrem/Xywav/Lumryz) under REMS supervision IS A-tier evidence for narcolepsy/cataplexy/idiopathic-hypersomnia — but the safety envelope depends on the REMS architecture (single dispensing pharmacy, dose titration, monitoring, prohibition of alcohol/CNS-depressants, $177-212K/yr), none of which transfer to biohacker self-dosing. SKIP-PERMANENT applies to ALL non-narcoleptic archetypes; OPTIONAL only for diagnosed narcolepsy/cataplexy/IH under REMS. Verdict would change only if (a) a non-tolerizing GHB analog were discovered, or (b) a user in this archetype develops narcolepsy with cataplexy and exhausts non-oxybate options — neither plausible.

The most cardiotoxic psychedelic in clinical use. ~1 in 300-400 ibogaine sessions in field clinics ends in death, dominantly via QTc prolongation → torsades → sudden cardiac death. Pre-screening (EKG, electrolytes, no CYP2D6-inducing meds, no other QT-prolonging drugs) reduces but does not eliminate the risk. The legitimate clinical case is opioid use disorder with full medical monitoring — there is real published signal there (Mash 2018, Brown 2018, Davis 2017). For a 20yo with no OUD indication, this is gambling permanent cardiac harm against a recreational psychedelic experience. SKIP-PERMANENT means: not used in this archetype. Even the experimental 18-MC (designed to retain anti-addictive effect without hERG block) is still in early human trials and not available. Flips to OPTIONAL only inside a licensed-clinic + cardiology-cleared + OUD-indication context.

Imuracetam (developmental code UCB-G218) is a UCB Pharma 1970s-era racetam candidate that was never marketed and has no published human clinical trials, no commercial form, no available reference standard for research-chem synthesis, and no community sourcing pathway. PubMed returns zero direct results (only auto-correction to the unrelated compound dimiracetam). It is effectively vaporware in the user/biohacker sense — there is no actionable compound to source, dose, or stack. The user should consult the documented, available racetams instead (piracetam, aniracetam, oxiracetam, phenylpiracetam, etc.).

"Genuine opioid pharmacology with documented physical dependence, withdrawal syndrome, and rising overdose case reports. State-level scheduling is expanding rapidly. Can trigger opioid-positive drug screens — career-ending risk for a competitive MMA athlete subject to USADA/state athletic commission testing. The recreational + cognitive upside is far below the risk floor for this archetype."

This is the bipolar disorder mood stabilizer at therapeutic dose. For a 20yo with no bipolar diagnosis there is no indication, and the side-effect profile (thyroid suppression, renal damage at chronic use, tremor, weight gain, GI distress, narrow therapeutic window) makes any "biohacking" use case unacceptable. Different from lithium-orotate (5-20 mg elemental, sold OTC) which achieves serum levels orders of magnitude below pharmacological — that has its own file. Verdict SKIP-PERMANENT here means: pharmaceutical-dose lithium is not a biohacking tool, it is psychiatric treatment.

Same neurotoxicity concerns as MDMA (cumulative serotonergic damage in primate models) + more dopaminergic stress + the same supply-chain adulteration / mis-identification problem. No clinical program. SKIP-PERMANENT.

Real clinical signal in PTSD (MAPP1, MAPP2 Phase 3) — but FDA rejected the NDA in 2024, replication trials underway. For a 20yo with no PTSD indication, this is recreational use with measurable cumulative serotonergic neurotoxicity. Cumulative dose tracks with persistent serotonergic damage in primates (Ricaurte 2002 retraction notwithstanding, multiple replication groups have shown SERT density reduction proportional to lifetime dose). HPPD, persistent depression, and "Suicide Tuesday" post-acute crashes are well-documented even at single doses. Verdict SKIP-PERMANENT means: no biohacking case for healthy use. Flips to OPTIONAL only inside a clinical-trial or licensed-clinic PTSD context with a documented indication. Cardiac risk + hyperthermia risk add hard contraindications for combat-sport context where vasoconstrictor + heat-stress loads are already high.

Among oral anabolics methyltestosterone is strictly dominated — it has the worst hepatotoxicity profile of any clinically used 17αAA, weaker anabolic effect than oxandrolone/oxymetholone/methandrostenolone, and aromatizes to a methylestradiol that is itself harder for the liver to clear. Anyone wanting oral androgen has better tools (oxandrolone for mild, methandrostenolone for mass with cycled liver hits); anyone wanting testosterone has injectable T-enanthate/cypionate at 1/100th the hepatic load. Verdict would only change if a novel hepatoprotective derivative emerged — currently none exists.

Methyltrienolone stacks 17α-methyl hepatotoxicity (worst-class oral) on top of trenbolone-class psychiatric/CV/HPG damage — it sits in the "essentially universally bad idea" tier of AAS, with no human-medical use case in 60+ years and no plausible bloodwork or genetics result that could flip this for any user, let alone a 20yo brain-priority MMA athlete.

One of the most acutely cardiotoxic + hepatotoxic AAS in the underground catalog, used historically by powerlifters + bare-knuckle boxers for the acute aggression boost. Modern bodybuilding has largely abandoned it because the risk/benefit is poor — too many documented cardiac events, hepatic strain, and behavioral disinhibition incidents. For a 20yo combat athlete: hard-no. SKIP-PERMANENT regardless of context. Mentioned here for encyclopedia completeness because it shows up in old powerlifting + boxing forum discussions.

Despite its founding marketing claim, MXE produces bladder + hepatic + cognitive damage similar to ketamine. Multiple fatalities reported (frequently in combination with other depressants). No clinical research. SKIP-PERMANENT.

Most potent broad-spectrum senolytic in preclinical work — but the BCL-xL inhibition causes severe dose-dependent thrombocytopenia in humans (CTCAE grade 3-4 in 30-50% of oncology trial participants). Aging-focused dosing strategies (intermittent low-dose, sister compound A-1331852 with different selectivity) are research-frontier but not ready. For a healthy 20yo: hard skip-permanent. The lower-risk senolytic experiments use D+Q (dasatinib + quercetin), fisetin protocols, or spermidine — all already in the encyclopedia.

Off-label bodybuilding use carries acute lethal hypoglycemia risk for any non-diabetic. a user in this archetype is 20, lean, insulin-sensitive, untested AAS-naive — there is no scenario where exogenous insulin makes sense. Would change only if a user in this archetype develops type 1 diabetes (medically necessary) — which is unrelated to biohacker use.

Buying O-DSMT bypasses the natural CYP2D6 metabolic gate that makes tramadol relatively safe in CYP2D6 normal/poor metabolizers (~7% of European-descent population have ultrarapid CYP2D6 and convert too much tramadol → opioid toxicity; conversely poor metabolizers convert too little → poor analgesia). Isolated M1 gives the ultrarapid-metabolizer dose to everyone. Respiratory depression + dependence risk equivalent to other moderate-strength opioids. SKIP-PERMANENT.

Genuine A-tier efficacy for neuropathic pain, fibromyalgia, and GAD — but Schedule V scheduling, rapid tolerance, severe withdrawal, weight gain, sedation, and a real abuse signal make it strictly worse than the alternatives this user already has access to (L-theanine, propranolol PRN, magnesium, sleep optimization). For nootropic use, no scenario flips this. For specific Rx indications (post-injury neuropathic pain, intractable GAD that fails SSRIs/buspirone) — OPTIONAL under physician supervision only.

For a tested combat athlete, this is strictly a masking-agent context — banned, detectable, no legitimate biohacking case for the archetype. Even for the gout indication, allopurinol or febuxostat are first-line. SKIP-PERMANENT.

For this user specifically — at 6'0-6'1, 185-190 lb, ~10+ hr/wk MMA training, brain-priority — retatrutide is medically wrong-fit, not bad. Strong appetite suppression + glucagon-driven energy redirection actively undermines the protein/calorie surplus and cardiovascular workload his sport demands; lean-mass loss risk with class drugs is well-documented; cognitive priority is unaffected. Verdict is HIGH-confidence SKIP-PERMANENT for HIM. The drug itself is best-in-class for obesity / metabolic syndrome — verdict for that population is STRONG-CANDIDATE pending FDA approval. File entry exists for wiki completeness, not for this archetype's typical stack.

UCB Pharma discontinued seletracetam development circa 2008-2009 in favor of brivaracetam, which advanced to FDA approval (2016). Seletracetam never reached Phase 3, has zero post-2009 publications, no human nootropic data, and no commercial or gray-market sourcing path. The molecule is functionally vaporware. Verdict will not change unless UCB or a successor sponsor revives the asset (no signal of this in 16 years). For any SV2A-based use case, brivaracetam is the only viable option — and even that has minimal nootropic evidence in healthy adults.

a user in this archetype is 20 with peak BMD intact and no osteoporosis indication; teriparatide is a fracture-prevention drug for severe low BMD populations and offers nothing for a young athlete. Would change only if a serious fracture-prone osteoporotic state emerged decades from now.

Functionally an opioid antidepressant masquerading as a "nootropic" — at biohacker doses (250-4000+ mg/day vs 37.5 mg therapeutic) it is opioid-class abuse with full dependence, withdrawal, respiratory depression, and death; non-opioid alternatives exist for every plausible use case. Nothing realistic would change this.

Stacked HIGH-risk profile (brain-development + psychiatric + cardiovascular + HPG) for a 20yo athlete with brain as #1 priority makes Tren a categorical no — there is no plausible future blood/genetics result that flips this verdict.

Tren E is trenbolone's pharmacology with a longer ester — same brain/CV/HPG damage profile as parent trenbolone, with worse "stuck-with-side-effects" risk because the long ester takes weeks to clear if the user wants to abort. For a 20yo brain-priority MMA athlete the compound is categorically wrong; the long ester actively makes it worse than the acetate version.

Severe HPG-axis shutdown in a developing 20yo endocrine system + WADA-banned + gray-market only + zero brain-priority benefit + Population Council designed it specifically AS a male contraceptive (the suppression is the desired clinical effect). No pathway to "yes" for users in this archetype.

Real cardiac substrate-shifting drug with measurable angina relief in clinical trials. The athletic-performance signal is mostly inferential — there's no clean placebo-controlled human trial showing endurance benefit in healthy athletes, but mechanism is plausible and the WADA ban came after a string of cycling + skating positives. For a drug-tested combat athlete: SKIP-PERMANENT. For a non-tested user without angina: no clean evidence of benefit, real CNS side effects (Parkinsonism, restless legs, tremor — multiple EMA black-box-style restrictions added 2012), permanent movement-disorder cases documented in elderly post-marketing data. Risk/benefit is poor in healthy athletes.

For chronic use the pharmacology is fundamentally suboptimal — they impose GABAergic sedation on the brain rather than removing wake drive, suppress N3/REM architecture in some studies, carry a 2019 FDA Boxed Warning for fatal complex sleep behaviors (sleep driving, sleep eating, sleep cooking, ingestion of unsafe substances), produce anterograde amnesia, build tolerance + dependence + rebound insomnia within weeks, and a 2021 case-control study found 79% greater dementia risk in older adults using Z-hypnotics >28 days per quarter. Daridorexant and seltorexant achieve sleep without GABAergic sedation, preserve sleep architecture, have no rebound or dependence through 12 months, and preserve next-day cognition. There is no reason for a brain-priority 20-year-old to ever touch this class chronically. OPTIONAL only for very acute, prescriber-supervised, short-course (≤2 weeks) insomnia where DORAs are unavailable. Verdict will not change — pharmacology is the problem.

Documented for completeness alongside teriparatide.md. Abaloparatide is a fracture-prevention drug for severe postmenopausal osteoporosis; a user in this archetype is 20 with peak BMD and no osteoporosis indication. Not relevant. Verdict would only change in a remote future scenario of severe low BMD.

Anastrozole exists for one class of problem — pathologically elevated estradiol — across four indication clusters (HR+ breast cancer, AAS-induced E2 elevation, TRT E2 management, idiopathic precocious puberty / pubertal gynecomastia). a 20-year-old in this archetype has none of these. He has an intact HPG axis, no anabolic steroid use, no exogenous testosterone, no breast cancer, and no documented gynecomastia. There is zero indication for an aromatase inhibitor, and crashing E2 in a young eugonadal male is actively harmful — low E2 in men produces joint pain, libido collapse, lipid disruption, mood blunting, and accelerated bone loss within months. Verdict shifts to WATCH-LIST only if June 2026 bloodwork shows symptomatic E2 >50 pg/mL with an identifiable cause; shifts to STRONG-CANDIDATE only in the contingency that he initiates TRT or AAS use (not on roadmap) and develops symptomatic high-E2 phenotype.

For this user at 6'0-6'1 / 185-190 lb / 10+ hr/wk MMA / no metabolic disease, bioglutide has zero indication. Even with the "muscle-sparing" advantage being real (Phase 2 clinical signal with 0% lean loss vs. class-typical 25-40%), the drug remains an aggressive multi-receptor metabolic intervention designed for obesity and T2D — populations a user in this archetype is not in. The IGF-1R activation arm (the differentiating feature) creates additional uncertainty for an athlete with normal endogenous IGF-1, including theoretical concerns about supraphysiological IGF-1 signaling, off-target growth effects, and unclear long-term cancer risk profile (IGF-1 axis is implicated in oncogenesis at sustained high levels). For a young lean athlete with no metabolic indication, this profile is downside-only — caloric deficit + appetite suppression + glucagon-driven energy depletion oppose MMA fueling and cardio capacity, while the supposed "upside" of IGF-1R activation creates additional unknown risk vector. Investigational status (Phase 2b/3, no FDA approval, gray-market sourcing only) compounds the no-go. Verdict only re-opens with substantial physiology change AND post-approval safety data at multi-year horizons.

Surgical-only osteoinductive protein. a user in this archetype has no fracture, no spinal pathology, no bone defect. Cancer signal in surgical literature reinforces avoid for non-indicated use. Would change only if a documented non-union fracture occurred.

"Brivaracetam is a third-generation anticonvulsant designed exclusively for partial-onset (focal) seizures in patients with epilepsy. a user in this archetype has no seizure diagnosis, no documented epileptiform EEG findings, no head injury severe enough to require seizure prophylaxis, and no other indication for SV2A modulation. The healthy-adult cognitive-enhancement evidence base for brivaracetam is **literally zero** — no published trials, no n>1 case reports, no meaningful subjective dose reports. Levetiracetam (the parent compound) has equally thin nootropic data and a worse psychiatric AE profile, and brivaracetam was not designed to improve on that gap — it was designed to keep epilepsy efficacy while reducing psychiatric AEs. Sourcing is also a real friction: brivaracetam is still mostly under brand-protected pricing in the US (~$300+/month cash) with limited Indian generic availability emerging in 2024-2025. Verdict shifts to NOT-RELEVANT-but-flagged only if a bona fide post-traumatic seizure indication arises (e.g., a serious MMA head injury producing focal seizures), at which point it becomes a medical Rx decision with neurology, not a self-curated nootropic tool. The HIGH confidence here is dual-tracked: LOW confidence that brivaracetam does anything cognitively interesting in healthy adults (no data either way), HIGH confidence that \"this isn't a nootropic\" — the molecule's design brief, evidence base, and clinical positioning all point in the opposite direction from cognitive enhancement."

"For this user specifically — at 6'0-6'1, 185-190 lb, no metabolic disease, no obesity, no T2DM, active MMA career — there is no indication for amylin agonism. Mechanism is appetite suppression + delayed gastric emptying + ~22% weight loss in combination, all of which directly oppose MMA fueling and lean-mass preservation needs. Not yet FDA-approved standalone (CagriSema submission pending). MEDIUM-HIGH (not HIGH) confidence because Phase 3 evidence is mature and well-replicated but the drug isn't approved yet — verdict is on mechanism + indication mismatch, which is robust regardless of approval timing. Distinct from semaglutide's SKIP-FOR-NOW because cagrilintide won't be available standalone; relevant population question is \"would CagriSema be relevant if this user ever had obesity + T2DM?\" — answer: STRONG-CANDIDATE for that population, NOT-RELEVANT for current this user. **WATCH-LIST for the broader obesity-treatment landscape**: REDEFINE-1/2 readouts position CagriSema to potentially displace semaglutide as 2027 first-line for obesity + T2D combined endpoint; tracking it matters for the field even if not for this user's stack. File entry exists for wiki completeness, not for this archetype's typical stack."

"For this user (20yo MMA athlete, no cardiac pathology, intact myocardium): the entire claimed use case — cardiac tissue support, post-MI recovery, age-related cardiomyopathy adjunct — does not exist in this profile. Khavinson family broad skepticism applies (zero Western replication, single-source evidence, contested mechanism). Even if every Khavinson claim were true, Cardiogen would have nothing to act on in a 20-year-old healthy athlete's heart. NOT-RELEVANT (rather than SKIP-FOR-NOW) reflects that this isn't a \"weigh evidence vs. risk\" question — it's a \"no indication exists\" question. Confidence is LOW because the underlying compound's evidence base is itself low-confidence; we're certain it's irrelevant for users in this archetype, less certain it does anything for anyone."

"Daytrana is a niche pediatric ADHD delivery system whose entire value proposition is solving problems a user in this archetype does not have — kids who can't swallow pills, kids who hide pills, families needing flexible afternoon-cutoff control. For a 20yo MMA athlete, the patch is **mechanically defeated by this user's daily reality**: BJJ sparring tears patches off, prolonged sweating disrupts adhesion and flux, and skin contact during grappling rubs the patch onto a training partner (a Schedule II transfer event). Add the >30% incidence of application-site erythema, the 2015 FDA warning on **chemical leukoderma (permanent skin lightening)**, and ~$400-600/month retail cost for what is functionally Ritalin in a less convenient package — there is no scenario in which Daytrana beats every oral methylphenidate option. Verdict would shift only if (a) this user stopped grappling AND (b) developed an oral methylphenidate-class indication AND (c) had specific issues with oral delivery (rare swallowing problem, severe GI absorption issue) — none plausible."

No indication for users in this archetype. Better-tolerated than venlafaxine but similar emotional/sexual side effects. Pain dual-indication (DPN, fibromyalgia, chronic LBP) is unique value but a user in this archetype has no pain syndrome.

a user in this archetype is 20yo with no HF, no post-MI history, no resistant HTN, and no primary aldosteronism — eplerenone has no current indication. The single niche where it could plausibly become relevant is topical eplerenone for male-pattern baldness if minoxidil monotherapy fails and he wants to avoid oral 5α-reductase inhibitors; that is WATCH-LIST experimental with weak evidence, not standard care. Verdict would shift to STRONG-CANDIDATE only on a heart-failure or post-MI diagnosis (vanishingly unlikely at 20), or to OPTIONAL-ADD as on-cycle water-retention control if he ever runs AAS. Documented here for completeness and the MPB-topical exploratory question.

Cleanest SSRI profile (least drug interactions, fewest off-target effects) but still NOT-RELEVANT for users in this archetype absent clinical anxiety/depression. First-line if SSRI ever indicated.

Ezetimibe is a clean, well-tolerated, A-tier evidence-base lipid-lowering drug with proven CV outcome benefit (IMPROVE-IT 2015, RACING 2022). At 20yo with no known dyslipidemia and no bloodwork yet, it is NOT-RELEVANT. Verdict would upgrade to STRONG-CANDIDATE if June 2026 bloodwork shows ApoB >100 mg/dL or LDL-C >130 mg/dL with a "lean reactor" / hyperabsorber phenotype, or to PRIMARY-PICK if FH (familial hypercholesterolemia) is detected via 23andMe or pedigree. Verdict would stay NOT-RELEVANT if lipids are normal.

Designed for overweight/obese populations needing modest fat-loss support alongside diet/exercise; a user in this archetype is a lean MMA athlete with no fat-loss goal, no B-vitamin deficiency, and no liver dysfunction. Would only become relevant on bulk-cut cycle if he ever entered an obesity-band BMI — vanishingly unlikely.

Disease-specific therapy for achondroplasia/skeletal dysplasia driven by FGFR3 G380R gain-of-function mutation. a user in this archetype has normal stature (6'0-6'1) and no FGFR3 pathology. Would change only if a pediatric/adolescent FGFR3-mutation patient needed it (not this user).

No clinical indication for users in this archetype. Longest half-life of SSRI class (less withdrawal but slower clearance) doesn't change the basic mismatch — emotional blunting + sexual dysfunction not justified absent diagnosis.

Sparse Russian-only data + unreliable gray-market sourcing + Selank already covers this user's anxiolytic role with a multi-mechanism profile and a 17-year clinical track record. GB-115 is mechanistically interesting (CCK-B antagonism is the panic-disorder axis) but offers this user no incremental benefit over what Selank delivers. Verdict would upgrade to WATCH-LIST if (a) Western RCT data emerged, (b) a user in this archetype develops panic-disorder-flavored anxiety that Selank's GABA/enkephalinase axis fails to address, or (c) sourcing stabilizes with verified COA.

"hCG is a Leydig-cell stimulator used in three clinical contexts — TRT testicular preservation, post-AAS PCT, and male infertility. a user in this archetype has none of these conditions: no AAS use, no TRT, intact HPG axis at peak natural function, no fertility concerns. Compound is documented for completeness; no scenario in 2026 makes it relevant absent a major change in clinical status. The \"hCG diet\" (Simeons protocol) is empirically debunked — multiple placebo-controlled trials show weight loss tracks caloric restriction, not hCG."

HCTZ is a first-line antihypertensive — useful for documented hypertension, mild heart failure, kidney stones. a user in this archetype has no hypertension, no heart failure, normal renal function. Bodybuilding "cutting" use carries severe electrolyte risks. Would change only if a user in this archetype develops sustained HTN (unlikely at 20).

Anticonvulsant with no healthy-adult cognitive-enhancement signal — most of the cognitive literature in healthy subjects shows neutral-to-blunting effects on attention, processing speed, and verbal fluency, plus a real ~10-20% rate of "Keppra rage" psychiatric AEs (irritability, anxiety, depression, suicidality) that disqualifies it as a daily nootropic for a 20yo with no seizure indication. The Bakker 2012 / Vossel 2021 LIFT-AD low-dose (125 mg BID) hippocampal-hyperactivity-suppression line is genuinely interesting for amyloid-positive MCI/early-AD older adults and lands the compound on the WATCH-LIST for that archetype — but it does not generalize to healthy young brains, where there is no hippocampal hyperactivity to suppress and the AE profile is the only thing left. Verdict would change only if (a) a user in this archetype develops a seizure indication (becomes a clinical Rx decision, not a nootropic decision), or (b) this user ages into amyloid-positive MCI status and a future LIFT-AD-style trial replicates with hard endpoints, at which point the WATCH-LIST → consideration pathway opens for older-this user, not 20-year-old this user.

Component evidence is decent (each ingredient has independent literature); zero RCTs of the actual Lipo-C blend for weight loss; oral bioavailability of all components is sufficient at supplementation doses; a user in this archetype is a 20yo lean MMA athlete with no fat-loss target, no liver disease, no choline deficiency, eats whole-food diet, and already has B-complex/choline coverage in V4 stack. Verdict would change to OPTIONAL placebo+ only for the older obese / metabolic-syndrome user where motivation and clinic-engagement value compete with negligible direct biochemical benefit.

LL-37 is a high-leverage tool when you have a chronic infection, biofilm-driven indication, mold-biotoxin (CIRS) pattern, refractory chronic rhinosinusitis, or chronic Lyme — none of which a user in this archetype has. The peptide is the "L" in the KLOW combat-recovery stack (KPV + LL-37 + GHK-Cu + BPC-157 + TB-500), but for users in this archetype the antimicrobial slot in that stack is unjustified — his V4 stack is targeted at cognitive/recovery/sleep/skin-irritation issues without an underlying infection driver. Confidence MEDIUM (not HIGH on the SKIP) because (a) there's a theoretical "broad-spectrum prophylaxis" rationale during heavy training blocks where mucosal immunity gets stressed, (b) this user's perioral dermatitis MIGHT have a low-grade staph or Demodex colonization component for which LL-37 topical could matter, and (c) the dual-nature immunomodulation makes this peptide one of the most context-dependent in the catalog — wrong context = wrong outcome. Verdict for users in this archetype stays NOT-RELEVANT because he has no chronic infection indication and his existing V4 + planned BPC-157 protocol covers his actual problems. Would upgrade to OPTIONAL if (a) chronic refractory sinus infection emerges, (b) recurrent skin infections from mat exposure (impetigo, folliculitis, MRSA colonization) become a clinical issue, or (c) bloodwork in June 2026 shows mold-biotoxin / CIRS markers (C4a, TGF-β1, MMP-9 elevated). Would upgrade to STRONG-CANDIDATE only with diagnosed chronic Lyme, CIRS, or biofilm infection.

For this user specifically — at 6'0-6'1, 185-190 lb, 10+ hr/wk MMA training, no metabolic indication — mazdutide is medically wrong-fit, not bad. No indication exists; appetite suppression undermines training fueling; glucagon-driven catabolic + thermogenic skew opposes anabolic recovery in a way that is even more pronounced than tirzepatide's GIP-arm profile; lean-mass-loss class issue applies; no cognitive upside; not US-approved so sourcing would be gray-market for a drug he doesn't need. Verdict for users in this archetype is HIGH-confidence NOT-RELEVANT and is robust to any plausible new data given his current physiology. The drug itself is best-in-Chinese-evidence for obesity + T2D — verdict for that population (when approval lands) is STRONG-CANDIDATE. File entry exists for wiki completeness.

Mechanism is plausible but the entire human evidence base is Russian-only — Voronina / Seredenin / Zakusov Institute lineage — with no Western RCTs, no Western case series, no English-language pharmacology beyond translated abstracts. For this-archetype the compound would be mechanism-redundant on top of Semax + Adamax + Bromantane (planned) + modafinil + the V4 base; sourcing is harder than noopept (less common at RUPharma/CosmicNootropic), data is sparser than noopept, and the marginal contribution is unclear. Verdict would upgrade to WATCH-LIST only if (i) a Russian-language literature dive surfaces meaningful signal beyond the Zakusov ecosystem, or (ii) Adamax/Semax/Bromantane fail to deliver and a different glutamate-axis compound is wanted that noopept cannot fill.

For this user at 6'0-6'1 / 185-190 lb / 10+ hr/wk MMA / no metabolic disease, orforglipron has zero indication. Class-typical GLP-1 effects (appetite suppression, ~25-40% lean-mass-loss fraction, GI burden) directly oppose MMA fueling, recovery, and protein needs; no cognitive upside; no CV/renal/OSA indication exists. Distinct verdict from semaglutide's SKIP-FOR-NOW because orforglipron is even less weight-effective at top dose (~11% vs. semaglutide's ~15% vs. tirzepatide's ~20%) — there's no scenario where orforglipron beats the existing class for a non-this user profile that ALSO applies to him. Wiki-completeness entry. The drug's distinctive feature — needle-free oral dosing — is exactly the feature that doesn't matter for users in this archetype since he has no indication regardless of administration route.

Interesting bench-science peptide for bone formation + hematopoiesis but human clinical data is essentially zero. a user in this archetype has no bone deficit, no marrow suppression, no fracture. Would change only if a small clinical trial showed safety + efficacy AND this user had a bone indication.

Real, mechanistically distinctive anticancer peptide with ~25 years of preclinical work and a clean selectivity story (membrane HDM-2 expressed only on cancer cells). But ZERO verified human clinical trials, FDA warning citing bacterial contamination in marketed product, and a user in this archetype has no cancer indication. Not a candidate compound — listed only for encyclopedic completeness and so the cancer-adjunct case is properly framed if it ever becomes relevant. WATCH-LIST experimental ONLY under oncologist supervision for someone with active malignancy.

Prostate-tissue bioregulator with no use case in a 20yo MMA athlete with intact urogenital function. Khavinson family broad skepticism stands. Prostamax has zero Western RCTs, single-source Russian preclinical data, and no profile-aligned indication for users in this archetype. Verdict reflects "not in scope at all" rather than active rejection of the compound for someone with a prostate indication.

Quillivant XR is an FDA-approved liquid suspension formulation of extended-release methylphenidate designed for **pediatric patients (ages 6-17) who cannot swallow pills** — dysphagia, autism with oral aversion, very young children, feeding tubes. Pharmacokinetically near-equivalent to Concerta XR (12-hour duration, ascending plasma curve, same active drug) but at **5-10x the cost** (~$300-450/month brand-only retail vs. $30-60/month for generic Concerta) with **zero adult use case advantage**. For this user (20yo, can swallow, no ADHD diagnosis, methylphenidate-class already SKIP-FOR-NOW due to chronotype + lane already owned by modafinil), Quillivant offers no benefit any other methylphenidate formulation doesn't — it is strictly a niche pediatric product. Verdict would change only if this user developed dysphagia or feeding-tube dependence AND had clinical ADHD diagnosis AND could not access cheaper liquid alternatives like Methylin oral solution (IR, BID) or compounded MPH suspensions.

Raloxifene's three indication clusters (postmenopausal osteoporosis, breast cancer chemoprevention in postmenopausal women, male AAS-induced/pubertal gynecomastia, and schizophrenia adjunct in postmenopausal women) all require a phenotype a user in this archetype does not have. He is a 20yo male with no anabolic steroid exposure, no documented gynecomastia, no schizophrenia, and intact endogenous testosterone production. There is no conceivable indication for raloxifene in his current profile, and the VTE/DVT/PE risk + libido suppression in eugonadal men make off-label exploration actively harmful. Verdict shifts to STRONG-CANDIDATE only if he develops moderate-severe gynecomastia from any cause (idiopathic, AAS use he doesn't currently do, or rare prolactinoma) and tamoxifen is contraindicated — a multi-step contingency that is essentially zero probability.

"Mechanism is real (SNARE-competitive inhibition is well-characterized in vitro), but topical penetration to neuromuscular junctions is the bottleneck — clinical effect is ~10-20% of injectable Botox and only on dynamic (movement-induced) fine lines, not static wrinkles or deep folds. For this user (20yo, no wrinkles, no cosmetic-aging indication): NOT-RELEVANT — there is nothing to treat. For 35+ users with starting-to-form expression lines, it's a low-risk, low-cost cosmetic add-on with modest evidence. Verdict would change for users in this archetype only if he develops bothersome forehead/eye lines (decade+ from now) or if a delivery-vehicle innovation closes the penetration gap to make topical SNARE-inhibitors actually competitive with injectable BoNT."

For this user specifically — at 6'0-6'1, 185-190 lb, 10+ hr/wk MMA training, no metabolic indication — survodutide is medically wrong-fit, not bad. Strong appetite suppression directly opposes MMA fueling needs; class-typical lean-mass loss + glucagon-driven catabolic skew opposes muscle preservation; no cognitive upside; no indication exists; investigational status means no Rx pathway anyway. Verdict robust. The drug itself is STRONG-CANDIDATE (when approved) for severe obesity + MASH given Phase 2 results (~19% weight loss at 4.8 mg / 46 wk; 62% MASH resolution at 4.8 mg). File entry exists for wiki completeness, not for this archetype's typical stack.

a user in this archetype has no documented thyroid dysfunction; T3 in a euthyroid 20yo is a CV-strain compound with no upside. Revisit only if June 2026 bloodwork shows hypothyroidism (TSH high, fT4/fT3 low) — then OPTIONAL-ADD under endocrinologist.

a user in this archetype is 20yo male with intact HPG axis at peak natural function, no AAS exposure, no documented or symptomatic gynecomastia, no breast cancer / no BRCA mutation, no fertility concern requiring SERM-driven HPG amplification. There is no indication for tamoxifen in his current profile. Off-label exploration would impose endometrial-irrelevant-but-VTE-real risk, libido suppression, vision risk, and CYP2D6-genotype-dependent unpredictable exposure — with zero compensating benefit. Verdict shifts to STRONG-CANDIDATE only if he develops AAS-induced or severe idiopathic gynecomastia, or pursues an AAS cycle requiring PCT (not on roadmap). Documented here for AAS/PCT context and because users searching "SERM" reach this file.

a user in this archetype is 20yo with no hypertension and no current AAS use; an antihypertensive ARB has no primary indication and the PPARγ insulin-sensitization edge is too weak to justify a daily Rx in someone with already-good metabolic markers. Verdict would change to STRONG-CANDIDATE the moment he runs an AAS cycle (telmisartan is the preferred ARB for cycle BP control), develops HTN (>130/85 sustained), or shows worsening insulin/lipid markers in bloodwork. Documented here for those future contexts, not for current use.

Khavinson family broad skepticism stands. Testagen specifically is pitched as an endocrine bioregulator, with the most concrete mechanism story being TSH→thyroid→testosterone (a 3-link inferential chain) plus monograph-only direct testicular claims. a user in this archetype is 20yo with an intact HPG axis, no clinical hypothyroidism, no documented low-T — there is no profile-aligned use case. Verdict would only flip if (a) bloodwork (~June 2026) flags low-normal T or sub-clinical hypothyroidism that no first-line option addresses better, (b) independent (non-Khavinson) replication of any pituitary or testicular endpoint published, or (c) this user ever runs an AAS cycle and wants experimental post-cycle adjuncts (in which case enclomiphene / hCG dominate on evidence).

For this user specifically — at 6'0-6'1, 185-190 lb, 10+ hr/wk MMA training, no metabolic indication — tirzepatide is medically wrong-fit, not bad. Strong appetite suppression directly counters MMA fueling needs; class-average ~25-40% lean-mass-loss fraction is incompatible with combat sport requiring muscle preservation; no cognitive upside; no indication exists. Distinct from semaglutide's SKIP-FOR-NOW because tirzepatide is even more potent (superior in head-to-head SURMOUNT-5), making lean-mass risk arithmetically larger per kg lost. The drug itself is best-in-class for T2D + obesity and now leads on OSA — verdict for those populations is STRONG-CANDIDATE. File entry exists for wiki completeness, not for this archetype's typical stack.

No indication for users in this archetype. Notorious withdrawal syndrome (worst of the SNRIs). Effective drug for severe MDD/GAD but high discontinuation burden + side-effect profile not justified absent diagnosis.

"NOT-RELEVANT for users in this archetype with MEDIUM confidence (not HIGH) because: (a) a user in this archetype has no CIRS, no autoimmune disease, no pulmonary HTN, no chronic inflammation pattern — the indications where VIP has even B-tier evidence are absent; (b) VIP is mechanism-rich but its evidence base is concentrated in disease-state correction (CIRS, autoimmune flare reduction, pulmonary failure rescue), not healthy-baseline enhancement — there is no defensible benefit for a healthy young athlete; (c) the cost ($300-500/month compounded intranasal) is high relative to no expected benefit; (d) the CIRS Shoemaker protocol is itself controversial within mainstream medicine (see Controversies section). Confidence is MEDIUM rather than HIGH because (i) VIP's circadian-SCN role is genuinely mechanistic-interesting and a hypothetical case for sleep/circadian use in healthy populations exists in theory but has no human RCT support; (ii) intranasal CNS delivery means VIP is one of relatively few peptides with credible brain-penetration mechanism, which keeps it on the watch list for future indications; (iii) Aviptadil's COVID-ARDS Phase 2b/3 data (Youssef 2022) is genuinely positive for the mechanically ventilated subgroup, validating that VIP is bioactive in humans even if irrelevant for users in this archetype. Verdict would shift to WATCH-LIST or OPTIONAL-ADD only if a user in this archetype develops (a) confirmed CIRS from biotoxin / mold exposure following Shoemaker's full diagnostic protocol; (b) chronic autoimmune diagnosis with refractory inflammation; (c) chronic pulmonary disease; or (d) is in a position to participate in research-grade circadian-disorder protocol. Verdict would NOT shift on the basis of \"general immune support\" or \"anti-inflammatory\" claims — those are mechanism-extrapolation without healthy-user evidence."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

'"Agmatine sulfate" is the standard salt form sold as a supplement — virtually all commercial agmatine is the sulfate salt. The pharmacology, dosing, evidence, and this user verdict are identical to the parent agmatine.md entry. This file exists as a name-search stub.'

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 20 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 76 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 25 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 40 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 51 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 17 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 3 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"Oral L-arginine has poor bioavailability (~20-30% in adults) due to extensive first-pass hepatic + intestinal arginase metabolism — most never reaches systemic circulation to support eNOS. L-citrulline (especially citrulline-malate) bypasses this and produces higher plasma arginine AUC than equimolar arginine itself. Unless using IV arginine for clinical NO testing or specific cardiovascular indications, citrulline-malate is the strictly superior fork for an MMA athlete targeting blood flow / pump / endurance. Skip arginine; redirect to citrulline-malate."

"AUTO-STUB seeded from dopamine.club. 11 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 64 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 11 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 32 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

This is a peptide-protocol consumable, not a therapeutic. The verdict question "should I take bacteriostatic water" is malformed — you don't take it, you mix peptides with it. The relevant questions are (a) is BAC water the right diluent for a given peptide (almost always yes for biohacker-tier peptides — BPC-157, TB-500, CJC-1295, ipamorelin, sermorelin, melanotan, GHRPs, semaglutide-compounded), (b) where to source it cleanly (pharmacy or licensed compounder, not gray-market peptide vendor add-ons), and (c) when it is contraindicated (newborns/neonates — gasping syndrome from benzyl alcohol; total benzyl alcohol exposure >99 mg/kg/day at chronic dosing; manufacturer-specified incompatibility). HIGH confidence on the resource designation because (1) FDA-approved labeling and 40+ years of clinical use establish the safety profile completely, (2) the gasping-syndrome contraindication is well-defined and irrelevant to adult biohackers running 0.5-5 mL/day, and (3) the alternatives (SWFI, saline) have clear and narrow use cases. Anyone running an injectable peptide protocol needs this consumable; the only meaningful failure mode is poor sourcing or contamination from poor injection technique, not the diluent itself.

"AUTO-STUB seeded from dopamine.club. 41 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 33 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 27 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 50 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 17 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 105 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 8 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 11 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 9 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 3 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 88 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 8 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 65 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 13 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 21 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 141 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 3 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 5 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 16 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 53 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

'"Citicoline" and "CDP-choline" are the same molecule under two naming conventions (citicoline = INN/USAN; CDP-choline = chemistry literature). The pharmacology, dosing, evidence, and this user verdict (CONFIRMED-IN-USE in V4) are identical. This file exists as a name-search stub for users who know the compound by either name.'

"AUTO-STUB seeded from dopamine.club. 110 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 8 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 6 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 15 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 3 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 72 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 76 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 14 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 69 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 7 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 49 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 41 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 4 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 37 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 5 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 6 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 25 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 13 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 76 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 73 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 84 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

'"Elvanse" is the EU/UK trade name for the same molecule sold in the US/CA/AU as Vyvanse — both are lisdexamfetamine dimesylate manufactured by Takeda (originally Shire). Pharmacology, dosing, evidence, scheduling rationale, and this user verdict (SKIP-FOR-NOW MEDIUM, with conditional flip to STRONG-CANDIDATE on formal ADHD or BED diagnosis) are identical. This file exists as a name-search stub for users who know the compound by the EU brand.'

"AUTO-STUB seeded from dopamine.club. 22 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 48 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 4 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 4 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

Ezetrol is the international (EU, Canada, Australia, etc.) brand name for the same active drug as Zetia in the US — ezetimibe, a selective NPC1L1 inhibitor for cholesterol absorption blockade. All research, dosing, and clinical content already documented in `ezetimibe.md`.

"AUTO-STUB seeded from dopamine.club. 9 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 25 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 13 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"MANUAL-STUB. French-developed nootropic (Therabel) used in dementia trials in the 80s-90s. Withdrawn from market in 1995 after rare-but-severe hepatotoxicity / Stevens-Johnson reports. Has a small primary-lit footprint on memory + alertness in aged subjects but the safety signal is the dominant fact."

"AUTO-STUB seeded from dopamine.club. 8 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 66 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 23 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 23 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 54 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 17 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 113 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 5 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 23 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"MANUAL-STUB. Ana Aslan's procaine HCl-based formulation developed in 1950s Romania, marketed as a longevity + anti-depressant agent. Claims of MAO inhibition and cognitive benefit; modern controlled studies have not replicated the original claims. Procaine itself has a short half-life and limited oral bioavailability. Treat as historical artifact + clinical curiosity unless re-investigation surfaces. Verdict likely SKIP after research-pass."

"AUTO-STUB seeded from dopamine.club. 42 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 3 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 37 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 45 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"GLP-1 is a class label, not a single compound. See individual member pages: semaglutide (Ozempic/Wegovy/Rybelsus, weekly), tirzepatide (Mounjaro/Zepbound — dual GLP-1/GIP, weekly), liraglutide (Saxenda/Victoza, daily), and retatrutide (investigational triple GIP/GLP-1/GCG agonist). For this archetype (lean 20yo MMA athlete), GLP-1 agonists are not indicated — no obesity/T2DM, muscle preservation concerns, performance/appetite drawbacks. This page exists for context and search."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 68 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 3 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."

"AUTO-STUB seeded from dopamine.club. 0 community reports on dc. Mechanism, verdict, and sourcing-tier still need research."